data_1qgm_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1qgm _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.462 ' HB ' HG23 ' A' ' 9' ' ' ILE . 26.9 m . . . . . 0 N--CA 1.493 1.713 0 CA-C-O 121.278 0.561 . . . . 0.0 110.264 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.463 ' HB ' ' HB3' ' A' ' 10' ' ' CYS . 2.0 mp -87.54 166.32 1.94 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.212 -0.93 . . . . 0.0 110.276 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.424 ' N ' ' CG2' ' A' ' 2' ' ' ILE . 9.5 m-70 -141.75 161.01 39.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.221 -0.924 . . . . 0.0 110.3 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 26.8 p -161.05 -36.74 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.206 -0.934 . . . . 0.0 110.254 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.559 ' OD1' ' CE2' ' A' ' 24' ' ' TRP . 13.5 m-20 -93.91 -78.93 0.42 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.225 -0.922 . . . . 0.0 110.19 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.449 ' CB ' ' O ' ' A' ' 5' ' ' ASP . . . 171.72 -31.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.282 -0.886 . . . . 0.0 110.144 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.65 -61.49 1.7 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.311 -0.868 . . . . 0.0 110.175 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.8 m -55.22 150.45 11.0 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.246 -0.909 . . . . 0.0 110.14 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.462 HG23 ' HB ' ' A' ' 1' ' ' VAL . 8.4 mt -119.84 172.3 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -0.927 . . . . 0.0 110.245 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.463 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 19.3 t -131.51 136.64 28.89 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.248 -0.907 . . . . 0.0 110.18 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.403 ' O ' HD11 ' A' ' 2' ' ' ILE . 42.9 Cg_endo -72.46 -161.1 0.1 OUTLIER 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.978 1.514 . . . . 0.0 110.569 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.412 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 0.9 OUTLIER -96.0 150.17 20.77 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.23 -0.919 . . . . 0.0 110.414 -179.745 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 64.81 53.29 35.42 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -159.39 170.67 21.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.203 -1.175 . . . . 0.0 110.378 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.409 ' C ' ' SG ' ' A' ' 26' ' ' CYS . 12.2 t -130.88 131.9 44.82 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.346 -0.846 . . . . 0.0 110.235 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.2 132.76 43.97 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.292 -0.88 . . . . 0.0 110.302 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -152.12 157.88 42.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 110.245 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.434 HD21 ' N ' ' A' ' 19' ' ' SER . 0.2 OUTLIER -105.87 136.22 45.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.313 -0.867 . . . . 0.0 110.288 -179.944 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.5 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.9 OUTLIER -78.31 165.37 50.67 Favored Pre-proline 0 N--CA 1.488 1.446 0 O-C-N 121.24 -0.912 . . . . 0.0 110.213 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.573 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.9 Cg_endo -69.39 -11.61 31.72 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 O-C-N 124.038 1.546 . . . . 0.0 110.04 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.573 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.7 m-85 -101.54 5.2 41.69 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.476 -0.765 . . . . 0.0 109.553 178.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.74 21.16 51.82 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.5 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 60.6 t -93.9 123.08 45.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.32 -1.106 . . . . 0.0 110.281 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.559 ' CE2' ' OD1' ' A' ' 5' ' ' ASP . 1.3 m95 -81.09 130.71 35.14 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.243 -0.911 . . . . 0.0 110.21 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.1 p90 -165.42 173.08 11.45 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.207 -0.933 . . . . 0.0 110.331 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.409 ' SG ' ' C ' ' A' ' 15' ' ' THR . 0.1 OUTLIER -109.19 137.22 47.41 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -0.924 . . . . 0.0 110.24 179.705 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.9 t -108.4 147.44 35.67 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.263 -0.898 . . . . 0.0 110.338 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.6 114.14 3.96 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.029 1.541 . . . . 0.0 110.476 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.48 ' CD1' ' C ' ' A' ' 29' ' ' PHE . 20.9 p90 . . . . . 0 N--CA 1.492 1.657 0 O-C-N 121.253 -0.905 . . . . 0.0 110.295 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.523 HG22 ' CG2' ' A' ' 9' ' ' ILE . 30.5 m . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 121.138 0.494 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 31.9 mm -105.3 157.17 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.251 -0.906 . . . . 0.0 110.572 -179.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 12.4 m-70 -134.53 125.75 27.95 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.277 -0.889 . . . . 0.0 110.061 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -113.41 -50.65 2.85 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 0.0 110.501 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -90.86 -70.01 0.7 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.261 -0.899 . . . . 0.0 110.479 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 175.17 -46.55 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.195 -0.941 . . . . 0.0 110.36 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -100.14 -20.07 16.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.204 -0.935 . . . . 0.0 110.342 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.7 m -82.84 140.72 32.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.303 -0.873 . . . . 0.0 110.266 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.523 ' CG2' HG22 ' A' ' 1' ' ' VAL . 4.3 mt -125.91 166.38 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.193 -0.942 . . . . 0.0 110.293 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 1' ' ' VAL . 10.0 m -147.3 155.6 46.32 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.265 -0.897 . . . . 0.0 109.958 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.96 -166.29 0.28 Allowed 'Trans proline' 0 C--N 1.303 -1.817 0 O-C-N 123.942 1.496 . . . . 0.0 110.373 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -95.56 152.26 18.59 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.266 -0.896 . . . . 0.0 110.313 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.2 12.07 84.95 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -124.3 170.14 11.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -1.141 . . . . 0.0 110.396 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.472 ' CG2' ' HB3' ' A' ' 27' ' ' SER . 11.8 t -129.86 139.09 51.25 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.879 . . . . 0.0 110.249 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.3 p -62.69 134.61 56.56 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.275 -0.891 . . . . 0.0 110.353 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 4.7 m -153.91 133.71 13.03 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.299 -0.875 . . . . 0.0 110.21 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.464 HD22 ' HA ' ' A' ' 24' ' ' TRP . 0.4 OUTLIER -91.97 143.8 26.11 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -0.927 . . . . 0.0 110.301 -179.796 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.516 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -79.41 172.71 9.17 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.278 -0.888 . . . . 0.0 110.332 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.597 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.9 Cg_endo -69.87 -7.17 20.43 Favored 'Trans proline' 0 C--N 1.302 -1.885 0 O-C-N 124.167 1.614 . . . . 0.0 110.174 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.597 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 4.2 m-85 -109.51 -0.17 18.96 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.393 -0.817 . . . . 0.0 109.623 178.816 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.56 17.86 37.52 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.516 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 48.0 t -87.53 108.9 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.27 -1.135 . . . . 0.0 110.438 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.544 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -65.25 124.34 21.92 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.229 -0.919 . . . . 0.0 110.416 179.982 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.49 ' C ' ' CD1' ' A' ' 25' ' ' TYR . 15.5 p90 -148.25 171.66 15.6 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.165 -0.959 . . . . 0.0 110.162 179.397 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 4.3 m -106.35 118.02 35.55 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.177 -0.952 . . . . 0.0 110.257 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.472 ' HB3' ' CG2' ' A' ' 15' ' ' THR . 23.3 t -84.82 139.22 37.42 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.265 -0.897 . . . . 0.0 110.318 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -77.17 120.68 5.45 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 124.063 1.56 . . . . 0.0 110.397 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.489 ' C ' ' CD1' ' A' ' 29' ' ' PHE . 14.4 p90 . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.183 -0.948 . . . . 0.0 110.223 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.473 ' HB ' HG23 ' A' ' 9' ' ' ILE . 29.8 m . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 121.202 0.525 . . . . 0.0 110.348 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.439 ' N ' ' O ' ' A' ' 10' ' ' CYS . 45.4 mm -93.17 143.13 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 110.2 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -122.81 109.63 14.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 110.119 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -149.17 22.9 0.95 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.362 -0.836 . . . . 0.0 110.215 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.495 ' OD1' ' CH2' ' A' ' 24' ' ' TRP . 75.0 m-20 -137.32 -166.18 1.89 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.206 -0.934 . . . . 0.0 110.173 179.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.51 -59.38 2.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 110.276 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -136.33 -46.33 0.63 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 110.26 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.444 ' CB ' ' HB3' ' A' ' 24' ' ' TRP . 19.1 m -45.27 112.05 0.4 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.172 -0.955 . . . . 0.0 110.1 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.504 HD11 HG22 ' A' ' 9' ' ' ILE . 12.3 mt -85.82 167.53 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.292 -0.88 . . . . 0.0 110.235 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.439 ' O ' ' N ' ' A' ' 2' ' ' ILE . 31.0 m -129.84 141.83 43.23 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.249 -0.907 . . . . 0.0 110.324 -179.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.51 -166.6 0.34 Allowed 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.957 1.504 . . . . 0.0 110.267 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.9 148.69 22.03 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.237 -0.914 . . . . 0.0 110.348 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.98 0.94 89.81 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.2 p -117.58 170.24 8.91 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.137 -1.213 . . . . 0.0 110.399 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.8 t -134.32 144.69 48.44 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.159 -0.963 . . . . 0.0 110.503 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -52.4 140.62 21.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.308 -0.87 . . . . 0.0 110.402 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.523 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 9.0 t -160.23 124.39 3.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.262 -0.899 . . . . 0.0 110.235 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.438 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.1 OUTLIER -100.85 117.95 35.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.224 -0.922 . . . . 0.0 110.425 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.473 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -56.07 162.13 3.16 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.246 -0.909 . . . . 0.0 110.139 179.637 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.593 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.2 Cg_endo -69.35 -6.82 19.32 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 124.009 1.531 . . . . 0.0 110.116 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.593 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.4 m-85 -100.31 -5.97 26.61 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.423 -0.798 . . . . 0.0 109.688 179.001 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 99.21 17.44 27.13 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.473 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 67.4 t -89.97 115.36 29.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.266 -1.138 . . . . 0.0 110.298 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.533 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -74.08 125.79 29.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.357 -0.84 . . . . 0.0 110.37 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.523 ' CE1' ' HB3' ' A' ' 17' ' ' SER . 8.8 p90 -154.47 174.52 14.79 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 110.282 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.9 m -115.54 116.68 28.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.262 -0.899 . . . . 0.0 110.132 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 3.3 t -84.86 134.59 41.32 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.274 -0.891 . . . . 0.0 110.402 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -74.48 118.08 5.21 Favored 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.003 1.528 . . . . 0.0 110.423 179.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 24.5 p90 . . . . . 0 N--CA 1.492 1.654 0 O-C-N 121.186 -0.946 . . . . 0.0 110.24 179.844 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 30.1 m . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.29 0.567 . . . . 0.0 110.259 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.528 ' N ' ' O ' ' A' ' 10' ' ' CYS . 40.5 mm -45.38 155.69 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.203 -0.936 . . . . 0.0 110.054 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.466 ' O ' ' N ' ' A' ' 5' ' ' ASP . 1.8 m-70 -130.64 -60.59 0.98 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.115 -0.991 . . . . 0.0 110.575 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.464 ' CB ' ' O ' ' A' ' 3' ' ' HIS . 0.5 OUTLIER 66.75 -67.97 0.15 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.234 -0.916 . . . . 0.0 110.268 -179.776 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.502 ' OD2' ' N ' ' A' ' 8' ' ' THR . 9.9 p-10 -80.88 -138.83 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 0.0 110.1 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -128.56 -6.21 5.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.953 . . . . 0.0 110.392 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.446 ' N ' ' OD2' ' A' ' 5' ' ' ASP . . . -137.13 -65.54 0.54 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.213 -0.929 . . . . 0.0 110.203 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.502 ' N ' ' OD2' ' A' ' 5' ' ' ASP . 5.1 m -48.7 111.95 0.54 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.234 -0.917 . . . . 0.0 110.272 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 6.0 mt -90.83 151.74 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.21 -0.931 . . . . 0.0 110.128 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.528 ' O ' ' N ' ' A' ' 2' ' ' ILE . 23.7 m -127.13 139.68 35.77 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.17 -0.956 . . . . 0.0 110.298 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -74.91 -161.18 0.12 Allowed 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 124.02 1.537 . . . . 0.0 110.362 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -95.5 150.61 20.12 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.284 -0.885 . . . . 0.0 110.304 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.1 12.95 80.17 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.468 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 1.2 p -121.63 169.39 10.75 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.199 -1.177 . . . . 0.0 110.447 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.578 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 12.6 t -131.93 157.09 44.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.28 -0.888 . . . . 0.0 110.288 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.4 m -58.3 127.82 34.05 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.287 -0.883 . . . . 0.0 109.861 179.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.57 ' OG ' ' CZ ' ' A' ' 25' ' ' TYR . 1.3 t -141.72 124.26 15.85 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.939 . . . . 0.0 110.684 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.576 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.1 OUTLIER -109.03 126.99 53.72 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.385 -0.822 . . . . 0.0 110.051 179.201 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.508 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -67.9 163.33 50.99 Favored Pre-proline 0 C--N 1.301 -1.513 0 O-C-N 121.217 -0.927 . . . . 0.0 110.284 180.0 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.595 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.0 Cg_endo -69.08 -8.59 24.01 Favored 'Trans proline' 0 C--N 1.302 -1.879 0 O-C-N 124.111 1.585 . . . . 0.0 110.126 179.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.595 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.6 m-85 -100.68 -1.04 36.23 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.372 -0.83 . . . . 0.0 109.746 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.3 17.44 39.77 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.508 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 94.0 t -91.03 112.47 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.408 -1.054 . . . . 0.0 110.172 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.576 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 2.7 m95 -71.46 142.31 50.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.259 -0.901 . . . . 0.0 110.273 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.57 ' CZ ' ' OG ' ' A' ' 17' ' ' SER . 24.6 p90 -170.23 174.12 5.49 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.277 -0.889 . . . . 0.0 110.267 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.468 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 2.6 m -106.81 141.81 37.45 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.247 -0.908 . . . . 0.0 110.285 -179.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.515 ' HB3' ' CB ' ' A' ' 17' ' ' SER . 0.9 OUTLIER -118.91 141.95 31.03 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.217 -0.927 . . . . 0.0 110.208 179.784 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -74.61 104.3 1.85 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 124.081 1.569 . . . . 0.0 110.531 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.578 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 8.2 p90 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.212 -0.93 . . . . 0.0 110.294 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.433 ' HB ' HG23 ' A' ' 9' ' ' ILE . 30.8 m . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.323 0.582 . . . . 0.0 110.216 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.493 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 36.4 mm -83.55 148.18 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.219 -0.925 . . . . 0.0 110.307 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.402 ' CE1' HG12 ' A' ' 9' ' ' ILE . 9.9 m-70 -118.79 126.41 51.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.175 -0.953 . . . . 0.0 110.398 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 26.9 m -80.28 -68.94 0.63 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.297 -0.877 . . . . 0.0 110.275 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -104.63 -90.27 0.4 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.278 -0.889 . . . . 0.0 110.163 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -146.66 10.28 1.06 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.289 -0.882 . . . . 0.0 110.393 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.435 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -140.11 -76.27 0.33 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.206 -0.934 . . . . 0.0 110.318 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.453 HG23 ' HB3' ' A' ' 24' ' ' TRP . 8.6 m -41.63 147.84 0.17 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.31 -0.869 . . . . 0.0 110.364 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.433 HG23 ' HB ' ' A' ' 1' ' ' VAL . 15.2 mt -131.71 169.61 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.279 -0.888 . . . . 0.0 110.129 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.493 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 63.2 m -145.67 146.27 28.69 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.156 -0.965 . . . . 0.0 110.327 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -73.02 -175.02 1.74 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.012 1.532 . . . . 0.0 110.472 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -84.83 156.87 21.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.239 -0.913 . . . . 0.0 110.226 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.15 3.52 90.54 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.0 p -127.1 170.27 12.53 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.238 -1.154 . . . . 0.0 110.213 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.5 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 9.0 t -128.2 156.0 43.62 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.218 -0.926 . . . . 0.0 110.349 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.3 m -73.29 128.83 36.6 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.278 -0.888 . . . . 0.0 110.176 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.445 ' OG ' ' CZ ' ' A' ' 25' ' ' TYR . 32.9 t -137.19 130.2 30.69 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.28 -0.887 . . . . 0.0 110.243 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.588 ' HG ' ' CE2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -105.19 106.38 16.85 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.186 -0.946 . . . . 0.0 110.294 179.815 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.491 ' HB3' ' HB ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -46.18 157.81 0.4 Allowed Pre-proline 0 C--N 1.301 -1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 110.218 179.718 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.595 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.0 Cg_endo -68.69 -11.66 32.49 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 124.041 1.548 . . . . 0.0 110.026 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.595 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.0 m-85 -93.24 -8.71 41.49 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.456 -0.777 . . . . 0.0 109.641 178.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 100.8 19.9 16.14 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.491 ' HB ' ' HB3' ' A' ' 19' ' ' SER . 61.2 t -94.97 115.91 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.236 -1.155 . . . . 0.0 110.123 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.588 ' CE2' ' HG ' ' A' ' 18' ' ' LEU . 0.2 OUTLIER -77.84 126.78 31.37 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.335 -0.853 . . . . 0.0 110.503 -179.525 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.445 ' CZ ' ' OG ' ' A' ' 17' ' ' SER . 28.0 p90 -154.72 171.69 19.14 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.917 . . . . 0.0 110.125 179.304 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.3 m -106.45 135.6 47.67 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.216 -0.927 . . . . 0.0 110.068 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.456 ' O ' HG23 ' A' ' 15' ' ' THR . 12.0 t -115.4 143.71 30.97 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.204 -0.935 . . . . 0.0 110.324 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.73 125.02 9.68 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 124.034 1.544 . . . . 0.0 110.4 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.5 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 14.8 p90 . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.305 -0.872 . . . . 0.0 110.219 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.528 ' CB ' ' O ' ' A' ' 10' ' ' CYS . 23.6 m . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.252 0.549 . . . . 0.0 110.308 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.484 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 34.2 mm -88.46 143.17 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.166 -0.959 . . . . 0.0 110.114 179.552 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.463 ' NE2' HG22 ' A' ' 9' ' ' ILE . 7.3 m-70 -129.17 119.51 24.21 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.193 -0.942 . . . . 0.0 110.598 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 87.1 m -124.3 11.76 8.76 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.986 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -150.29 -90.23 0.07 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.392 -0.818 . . . . 0.0 110.207 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -176.09 -32.39 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.16 -0.963 . . . . 0.0 110.244 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.482 ' O ' ' CG1' ' A' ' 9' ' ' ILE . . . -105.38 -75.5 0.63 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.2 -0.938 . . . . 0.0 110.258 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 42.8 m -43.47 139.74 1.95 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.24 -0.913 . . . . 0.0 110.394 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.482 ' CG1' ' O ' ' A' ' 7' ' ' ALA . 4.4 mt -135.85 147.69 28.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 0.0 110.217 179.788 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.528 ' O ' ' CB ' ' A' ' 1' ' ' VAL . 98.1 m -111.34 148.69 39.29 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.305 -0.872 . . . . 0.0 109.982 179.726 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.43 ' O ' ' CG ' ' A' ' 12' ' ' ASP . 45.4 Cg_endo -74.7 -90.34 0.01 OUTLIER 'Trans proline' 0 C--N 1.302 -1.869 0 O-C-N 123.846 1.445 . . . . 0.0 110.335 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.43 ' CG ' ' O ' ' A' ' 11' ' ' PRO . 21.1 m-20 -158.86 164.28 35.86 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.371 -0.831 . . . . 0.0 110.181 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.32 13.26 48.92 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.442 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 1.3 p -124.07 169.74 11.37 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.217 -1.166 . . . . 0.0 110.308 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.445 HG23 ' O ' ' A' ' 27' ' ' SER . 8.9 t -129.59 153.81 47.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.141 -0.974 . . . . 0.0 110.494 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.441 ' SG ' HG23 ' A' ' 2' ' ' ILE . 60.2 m -63.86 127.47 31.52 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.262 -0.899 . . . . 0.0 110.147 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.509 ' HB3' ' CE2' ' A' ' 25' ' ' TYR . 10.7 t -138.9 133.99 32.63 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 110.265 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.446 HD21 ' N ' ' A' ' 19' ' ' SER . 0.2 OUTLIER -99.34 135.89 40.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.169 -0.957 . . . . 0.0 110.316 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.499 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.4 OUTLIER -79.06 166.13 44.16 Favored Pre-proline 0 C--N 1.303 -1.415 0 O-C-N 121.325 -0.859 . . . . 0.0 110.243 -179.992 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.567 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.9 Cg_endo -69.39 -10.73 29.63 Favored 'Trans proline' 0 C--N 1.301 -1.951 0 O-C-N 124.057 1.556 . . . . 0.0 110.022 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.567 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -104.06 -0.51 28.65 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.429 -0.794 . . . . 0.0 109.667 179.007 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.11 15.32 48.72 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.499 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 92.3 t -87.0 119.15 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.292 -1.122 . . . . 0.0 110.191 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.513 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 0.6 OUTLIER -77.75 128.16 33.59 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 110.458 -179.747 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.509 ' CE2' ' HB3' ' A' ' 17' ' ' SER . 37.1 p90 -152.74 172.52 16.56 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.27 -0.894 . . . . 0.0 110.086 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.442 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 4.0 m -101.92 141.42 34.79 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.209 -0.932 . . . . 0.0 110.193 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.445 ' O ' HG23 ' A' ' 15' ' ' THR . 3.4 t -116.16 141.7 28.17 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.173 -0.954 . . . . 0.0 110.389 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -75.38 129.27 11.86 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.061 1.558 . . . . 0.0 110.488 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 43.6 p90 . . . . . 0 N--CA 1.492 1.65 0 O-C-N 121.223 -0.923 . . . . 0.0 110.214 -179.886 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.523 HG22 ' CG2' ' A' ' 9' ' ' ILE . 28.6 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.224 0.535 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.464 HD13 ' HA ' ' A' ' 12' ' ' ASP . 2.5 mp -50.89 160.6 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.242 -0.911 . . . . 0.0 110.147 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.48 ' NE2' HG22 ' A' ' 9' ' ' ILE . 4.4 m-70 -148.12 89.43 1.73 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.195 -0.941 . . . . 0.0 110.354 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 63.9 m -92.59 -41.39 10.25 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.265 -0.897 . . . . 0.0 110.091 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.49 ' O ' ' CB ' ' A' ' 6' ' ' ALA . 8.3 t70 -85.14 -86.57 0.13 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.269 -0.894 . . . . 0.0 110.217 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.49 ' CB ' ' O ' ' A' ' 5' ' ' ASP . . . 170.31 -27.66 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.188 -0.945 . . . . 0.0 110.354 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.439 ' O ' ' CG1' ' A' ' 9' ' ' ILE . . . -105.01 -81.51 0.53 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.174 -0.954 . . . . 0.0 110.335 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.485 ' C ' ' CG1' ' A' ' 9' ' ' ILE . 89.5 m -41.18 155.4 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.292 -0.88 . . . . 0.0 110.458 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.523 ' CG2' HG22 ' A' ' 1' ' ' VAL . 6.1 mt -150.11 145.78 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.212 -0.93 . . . . 0.0 110.181 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.583 ' CB ' ' CD ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -130.08 -170.2 0.21 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 110.22 179.591 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.583 ' CD ' ' CB ' ' A' ' 10' ' ' CYS . 45.8 Cg_endo -87.27 175.4 4.77 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.822 1.433 . . . . 0.0 110.75 -178.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.464 ' HA ' HD13 ' A' ' 2' ' ' ILE . 5.7 m-20 -91.63 151.37 20.72 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.296 -0.878 . . . . 0.0 110.3 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.85 -6.09 51.42 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 4.6 p -114.39 171.68 7.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.192 -1.181 . . . . 0.0 110.25 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.507 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 14.7 t -115.94 134.33 55.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.312 -0.867 . . . . 0.0 110.311 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.2 m -45.05 147.02 0.74 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.244 -0.91 . . . . 0.0 110.367 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.55 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 29.0 m -161.69 135.02 6.34 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.306 -0.871 . . . . 0.0 110.337 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.532 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -106.64 142.39 36.36 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.225 -0.922 . . . . 0.0 110.211 179.996 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.493 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -84.14 168.02 24.11 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.168 -0.957 . . . . 0.0 110.291 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.566 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.5 Cg_endo -69.61 -8.83 24.62 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 124.098 1.578 . . . . 0.0 110.176 -179.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.566 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -103.63 0.95 31.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.432 -0.792 . . . . 0.0 109.627 179.173 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.98 16.88 49.74 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.254 -1.538 . . . . 0.0 109.254 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.493 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 97.2 t -86.59 115.52 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.359 -1.083 . . . . 0.0 110.295 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.532 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 1.0 OUTLIER -75.61 135.41 40.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.294 -0.879 . . . . 0.0 110.325 179.973 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.55 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 24.8 p90 -163.8 176.56 9.4 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.252 -0.905 . . . . 0.0 110.35 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.462 ' SG ' ' HD2' ' A' ' 11' ' ' PRO . 11.1 p -114.38 130.06 56.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.344 -0.847 . . . . 0.0 110.26 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.414 ' O ' HG21 ' A' ' 15' ' ' THR . 1.1 p -99.94 146.03 31.2 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 0.0 110.253 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -73.13 104.43 1.78 Allowed 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 123.999 1.526 . . . . 0.0 110.411 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.507 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 0.5 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 O-C-N 121.314 -0.866 . . . . 0.0 110.406 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.515 HG22 ' CG2' ' A' ' 9' ' ' ILE . 6.5 m . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 121.281 0.562 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.48 ' O ' ' HB2' ' A' ' 10' ' ' CYS . 2.6 mp -90.06 154.8 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.279 -0.888 . . . . 0.0 110.274 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.423 ' N ' HG21 ' A' ' 2' ' ' ILE . 15.0 m-70 -129.42 114.86 16.68 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.188 -0.945 . . . . 0.0 110.198 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 30.0 m -71.51 -39.6 70.68 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 110.318 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.457 ' O ' ' CB ' ' A' ' 6' ' ' ALA . 23.7 t0 -125.18 -59.75 1.38 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.221 -0.924 . . . . 0.0 110.406 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.457 ' CB ' ' O ' ' A' ' 5' ' ' ASP . . . 170.6 -25.37 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.174 -0.954 . . . . 0.0 110.43 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -100.05 -51.31 3.72 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 44.5 m -70.09 128.15 35.28 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.308 -0.87 . . . . 0.0 110.397 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.515 ' CG2' HG22 ' A' ' 1' ' ' VAL . 4.1 mt -97.64 176.7 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.209 -0.932 . . . . 0.0 110.07 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.48 ' HB2' ' O ' ' A' ' 2' ' ' ILE . 30.3 m -152.85 139.41 12.42 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.288 -0.882 . . . . 0.0 110.637 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.37 177.82 8.3 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 O-C-N 124.126 1.593 . . . . 0.0 110.433 179.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 12' ' ' ASP . 0.9 OUTLIER -85.19 147.85 26.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.167 -0.958 . . . . 0.0 110.311 179.779 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 92.93 -7.29 76.77 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.406 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 4.1 p -109.83 169.58 8.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.228 -1.16 . . . . 0.0 110.308 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.468 ' O ' ' HA ' ' A' ' 26' ' ' CYS . 15.4 t -125.83 151.1 47.26 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.228 -0.92 . . . . 0.0 110.359 -179.777 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.474 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 1.1 m -66.56 148.76 51.44 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.336 -0.852 . . . . 0.0 110.525 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.507 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 0.2 OUTLIER -170.31 137.26 1.45 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.35 -0.844 . . . . 0.0 110.223 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.458 ' HG ' ' CE3' ' A' ' 24' ' ' TRP . 0.3 OUTLIER -96.46 141.11 30.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 110.277 -179.982 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.534 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.6 OUTLIER -78.78 169.86 18.77 Favored Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.324 -0.86 . . . . 0.0 110.244 -179.918 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.552 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.7 Cg_endo -69.46 -16.5 38.84 Favored 'Trans proline' 0 C--N 1.301 -1.97 0 O-C-N 124.075 1.566 . . . . 0.0 109.939 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.552 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 2.9 m-85 -98.74 1.99 46.59 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.516 -0.74 . . . . 0.0 109.593 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.95 23.22 33.32 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.534 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 23.8 t -92.3 112.77 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.284 -1.127 . . . . 0.0 110.304 -179.757 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.458 ' CE3' ' HG ' ' A' ' 18' ' ' LEU . 1.6 m95 -65.98 126.43 28.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.274 -0.891 . . . . 0.0 110.271 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.507 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 6.3 p90 -157.19 177.37 11.55 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.079 -1.013 . . . . 0.0 110.388 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.474 ' SG ' ' HA ' ' A' ' 16' ' ' CYS . 1.9 m -126.5 138.61 53.52 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.425 -0.797 . . . . 0.0 110.098 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.41 139.25 21.81 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.202 -0.936 . . . . 0.0 110.576 -179.474 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -74.62 118.49 5.34 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.076 1.566 . . . . 0.0 110.331 179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' A' ' 29' ' ' PHE . 40.2 p90 . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.204 -0.935 . . . . 0.0 110.303 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.48 ' CG2' ' O ' ' A' ' 1' ' ' VAL . 3.4 m . . . . . 0 N--CA 1.494 1.741 0 CA-C-O 121.295 0.569 . . . . 0.0 110.417 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.452 ' N ' ' O ' ' A' ' 10' ' ' CYS . 5.2 mm -58.71 161.73 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.265 -0.897 . . . . 0.0 110.061 179.464 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.408 ' CD2' HG22 ' A' ' 1' ' ' VAL . 1.9 m-70 -149.01 125.92 11.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.257 -0.902 . . . . 0.0 110.507 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 28.3 p -126.44 21.52 7.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.336 -0.853 . . . . 0.0 110.111 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.461 ' N ' ' OD1' ' A' ' 5' ' ' ASP . 23.3 p-10 -167.65 -128.95 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.369 -0.832 . . . . 0.0 110.008 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.1 11.54 2.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.065 -1.022 . . . . 0.0 110.284 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.444 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -139.93 -85.1 0.23 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.227 -0.921 . . . . 0.0 110.459 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.444 ' C ' ' O ' ' A' ' 7' ' ' ALA . 55.9 m -40.81 141.6 0.56 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.23 -0.919 . . . . 0.0 110.524 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.488 HD11 HG22 ' A' ' 9' ' ' ILE . 7.8 mt -128.47 146.74 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.23 -0.919 . . . . 0.0 110.008 179.529 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.474 ' O ' ' CA ' ' A' ' 1' ' ' VAL . 46.0 m -122.26 145.38 44.13 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.199 -0.938 . . . . 0.0 110.408 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.32 -173.53 1.32 Allowed 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 124.097 1.577 . . . . 0.0 110.258 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.498 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 2.5 m-20 -86.64 151.16 23.67 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.231 -0.918 . . . . 0.0 110.422 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.81 8.4 73.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 5.4 p -133.58 167.88 19.68 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.267 -1.137 . . . . 0.0 110.313 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.484 HG23 ' O ' ' A' ' 27' ' ' SER . 10.4 t -128.49 141.41 51.39 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 0.0 110.203 179.686 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.75 138.16 57.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.226 -0.921 . . . . 0.0 110.139 -179.883 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.522 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 2.4 t -148.64 138.33 22.08 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.214 -0.929 . . . . 0.0 110.289 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.514 HD21 ' N ' ' A' ' 19' ' ' SER . 0.0 OUTLIER -95.94 131.06 42.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.384 -0.823 . . . . 0.0 110.037 179.692 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.561 ' OG ' ' HB ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -78.41 169.79 19.18 Favored Pre-proline 0 C--N 1.3 -1.561 0 O-C-N 121.346 -0.846 . . . . 0.0 110.52 -179.817 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.613 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 37.6 Cg_endo -69.07 -13.62 36.74 Favored 'Trans proline' 0 C--N 1.301 -1.959 0 O-C-N 124.208 1.636 . . . . 0.0 109.996 179.588 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.613 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 2.1 m-85 -92.03 -11.44 35.94 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.444 -0.785 . . . . 0.0 109.445 178.67 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.48 24.04 14.98 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.561 ' HB ' ' OG ' ' A' ' 19' ' ' SER . 39.9 t -102.04 125.47 56.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.17 -1.194 . . . . 0.0 110.2 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.459 ' CH2' ' HB2' ' A' ' 18' ' ' LEU . 1.7 m95 -81.09 119.09 23.12 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.284 -0.885 . . . . 0.0 110.27 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.522 ' CE1' ' HB3' ' A' ' 17' ' ' SER . 30.8 p90 -140.14 168.1 20.59 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.067 -1.021 . . . . 0.0 110.503 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 10.2 m -94.82 111.32 23.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.302 -0.874 . . . . 0.0 110.271 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.484 ' O ' HG23 ' A' ' 15' ' ' THR . 0.2 OUTLIER -96.05 147.47 33.02 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.348 -0.845 . . . . 0.0 110.396 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -77.39 125.26 7.59 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 124.059 1.557 . . . . 0.0 110.455 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' A' ' 29' ' ' PHE . 36.6 p90 . . . . . 0 N--CA 1.492 1.647 0 O-C-N 121.186 -0.946 . . . . 0.0 110.207 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.41 ' O ' HG21 ' A' ' 1' ' ' VAL . 20.5 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.279 0.561 . . . . 0.0 110.261 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.481 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 26.5 mm -55.9 148.21 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.918 . . . . 0.0 110.143 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.508 ' CE1' HG12 ' A' ' 9' ' ' ILE . 1.9 m-70 -130.85 129.45 42.34 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.228 -0.92 . . . . 0.0 110.455 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.474 ' O ' ' N ' ' A' ' 6' ' ' ALA . 58.0 m -142.01 -175.2 4.32 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.285 -0.885 . . . . 0.0 110.036 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.489 ' HB2' ' CE2' ' A' ' 24' ' ' TRP . 4.5 t70 54.75 -88.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.168 -0.958 . . . . 0.0 110.218 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.474 ' N ' ' O ' ' A' ' 4' ' ' CYS . . . -171.9 -40.2 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.254 -0.904 . . . . 0.0 110.326 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.406 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -119.82 -59.22 1.83 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.2 -0.937 . . . . 0.0 110.308 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.406 ' C ' ' O ' ' A' ' 7' ' ' ALA . 6.9 m -43.77 151.81 0.19 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.195 -0.941 . . . . 0.0 110.318 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.508 HG12 ' CE1' ' A' ' 3' ' ' HIS . 12.8 mt -131.23 167.37 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.209 -0.932 . . . . 0.0 110.279 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.481 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 55.7 m -133.87 147.5 64.49 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.2 -0.938 . . . . 0.0 110.205 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.55 -177.02 3.07 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.055 1.555 . . . . 0.0 110.607 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -84.72 151.94 24.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.268 -0.895 . . . . 0.0 110.237 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.45 28.47 57.6 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.547 ' C ' ' CE2' ' A' ' 29' ' ' PHE . 5.3 p -149.41 166.89 27.73 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.28 -1.13 . . . . 0.0 110.38 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.607 ' HB ' ' CE1' ' A' ' 29' ' ' PHE . 13.1 t -121.92 155.47 35.41 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.337 -0.852 . . . . 0.0 110.295 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 74.0 m -82.22 144.6 30.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.924 . . . . 0.0 110.124 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.462 ' HB2' ' CZ ' ' A' ' 25' ' ' TYR . 62.6 m -154.37 160.75 41.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 110.416 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.582 ' HG ' ' CZ3' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -114.81 134.13 55.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.875 . . . . 0.0 110.179 179.585 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.523 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -74.07 172.56 8.25 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.304 -0.872 . . . . 0.0 110.382 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.592 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.5 Cg_endo -69.87 -11.48 30.79 Favored 'Trans proline' 0 C--N 1.302 -1.879 0 O-C-N 123.976 1.514 . . . . 0.0 110.023 -179.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.592 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.4 m-85 -103.51 0.82 31.52 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.433 -0.792 . . . . 0.0 109.643 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . 0.419 ' C ' HD23 ' A' ' 18' ' ' LEU . . . 90.17 27.84 19.57 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.564 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.523 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 34.2 t -94.96 123.71 47.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.309 -1.112 . . . . 0.0 110.304 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.582 ' CZ3' ' HG ' ' A' ' 18' ' ' LEU . 2.7 m95 -78.6 114.92 17.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.205 -0.934 . . . . 0.0 110.202 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.462 ' CZ ' ' HB2' ' A' ' 17' ' ' SER . 29.1 p90 -136.08 172.53 12.88 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.189 -0.945 . . . . 0.0 110.161 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 8.0 m -114.98 117.38 30.44 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.273 -0.892 . . . . 0.0 110.276 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.4 p -96.47 161.63 26.17 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.308 -0.87 . . . . 0.0 110.162 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -74.79 170.59 20.02 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.889 1.468 . . . . 0.0 110.527 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.607 ' CE1' ' HB ' ' A' ' 15' ' ' THR . 17.4 m-85 . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.281 -0.887 . . . . 0.0 110.169 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.455 ' O ' HG22 ' A' ' 1' ' ' VAL . 21.1 m . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 121.157 0.504 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.516 ' CG2' ' SG ' ' A' ' 16' ' ' CYS . 18.5 mm -54.28 164.84 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.231 -0.918 . . . . 0.0 109.996 179.776 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.514 ' O ' ' N ' ' A' ' 5' ' ' ASP . 5.5 m-70 -126.03 -19.47 4.78 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.121 -0.987 . . . . 0.0 110.734 -179.477 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.505 ' HB2' ' O ' ' A' ' 3' ' ' HIS . 9.3 m 66.07 -61.28 0.28 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.232 -0.917 . . . . 0.0 110.289 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.514 ' N ' ' O ' ' A' ' 3' ' ' HIS . 23.0 t0 -126.32 -56.44 1.42 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.218 -0.926 . . . . 0.0 110.279 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 176.34 -32.48 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.304 -0.872 . . . . 0.0 110.22 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.42 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -100.07 -77.97 0.52 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.227 -0.921 . . . . 0.0 110.244 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.476 HG22 ' O ' ' A' ' 24' ' ' TRP . 3.1 m -43.36 116.35 0.91 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.218 -0.926 . . . . 0.0 110.213 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 9.7 mt -97.28 145.4 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.227 -0.921 . . . . 0.0 110.206 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.486 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 7.4 m -124.51 149.89 63.08 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.238 -0.914 . . . . 0.0 110.108 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.473 ' O ' ' OG1' ' A' ' 14' ' ' THR . 43.4 Cg_endo -73.0 176.62 8.83 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 123.977 1.514 . . . . 0.0 110.493 -179.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -84.35 165.71 18.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.252 -0.905 . . . . 0.0 110.315 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.59 11.8 65.97 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.473 ' OG1' ' O ' ' A' ' 11' ' ' PRO . 9.1 p -127.47 172.59 10.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.28 -1.129 . . . . 0.0 110.265 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.5 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 12.4 t -125.94 152.79 45.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.275 -0.891 . . . . 0.0 110.283 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.516 ' SG ' ' CG2' ' A' ' 2' ' ' ILE . 98.0 m -82.11 136.0 35.23 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.303 -0.873 . . . . 0.0 110.24 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.549 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 1.0 OUTLIER -142.45 148.51 37.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -0.93 . . . . 0.0 110.27 179.996 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.52 ' HG ' ' CH2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -104.41 140.78 37.43 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.351 -0.843 . . . . 0.0 110.431 -179.864 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.51 ' N ' HD21 ' A' ' 18' ' ' LEU . 1.0 OUTLIER -86.38 171.98 9.25 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.325 -0.859 . . . . 0.0 110.454 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.569 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.5 Cg_endo -69.57 -14.67 37.04 Favored 'Trans proline' 0 C--N 1.3 -1.975 0 O-C-N 124.05 1.553 . . . . 0.0 109.905 179.444 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.569 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.1 m-85 -98.59 0.12 44.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.352 -0.842 . . . . 0.0 109.774 179.056 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.74 30.8 17.11 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 68.4 t -100.65 123.99 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.227 -1.16 . . . . 0.0 110.223 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.52 ' CH2' ' HG ' ' A' ' 18' ' ' LEU . 3.5 m95 -83.36 114.07 21.17 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.28 -0.887 . . . . 0.0 110.036 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.549 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 42.1 p90 -132.65 172.01 13.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 110.337 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.4 m -102.47 132.7 48.33 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.349 -0.845 . . . . 0.0 110.112 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.43 ' O ' HG23 ' A' ' 15' ' ' THR . 0.3 OUTLIER -109.75 137.63 20.46 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.13 -0.981 . . . . 0.0 110.097 179.802 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -72.92 109.39 2.8 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 124.009 1.531 . . . . 0.0 110.555 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.567 ' O ' ' CG ' ' A' ' 29' ' ' PHE . 2.9 p90 . . . . . 0 N--CA 1.491 1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 110.371 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.526 HG22 ' CG2' ' A' ' 9' ' ' ILE . 34.9 m . . . . . 0 N--CA 1.496 1.832 0 CA-C-O 121.246 0.546 . . . . 0.0 110.346 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 13.1 mm -50.53 158.13 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.146 -0.972 . . . . 0.0 109.75 179.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.545 ' O ' ' N ' ' A' ' 5' ' ' ASP . 1.1 m-70 -136.7 -48.03 0.62 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.09 -1.006 . . . . 0.0 110.536 -179.446 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.495 ' HB2' ' O ' ' A' ' 3' ' ' HIS . 81.0 m 59.0 -77.11 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.304 -0.872 . . . . 0.0 110.1 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 3' ' ' HIS . 3.0 t70 -78.74 -135.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.231 -0.918 . . . . 0.0 110.013 179.468 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.14 8.37 4.37 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.127 -0.983 . . . . 0.0 110.367 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.429 ' O ' ' CG1' ' A' ' 9' ' ' ILE . . . -139.91 -84.72 0.23 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.225 -0.922 . . . . 0.0 110.49 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.447 HG23 ' HB3' ' A' ' 24' ' ' TRP . 7.1 m -40.89 100.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.336 -0.852 . . . . 0.0 110.511 -179.573 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.535 HG12 ' CE1' ' A' ' 3' ' ' HIS . 6.9 mt -89.42 169.56 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.343 -0.848 . . . . 0.0 110.211 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.464 ' O ' ' HB ' ' A' ' 1' ' ' VAL . 3.0 m -143.15 162.64 41.99 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.213 -0.929 . . . . 0.0 110.399 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -80.0 -159.59 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.037 1.546 . . . . 0.0 110.464 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.467 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 5.6 m-20 -107.13 150.1 26.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.204 -0.935 . . . . 0.0 110.286 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 86.12 29.12 26.32 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.472 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 0.9 OUTLIER -144.12 170.53 15.77 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -1.164 . . . . 0.0 110.312 179.871 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.453 ' O ' HG21 ' A' ' 15' ' ' THR . 9.5 t -125.61 142.48 51.49 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.209 -0.932 . . . . 0.0 110.367 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 3.3 m -65.26 142.62 58.22 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.325 -0.859 . . . . 0.0 110.271 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 14.3 m -158.84 130.43 6.45 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.275 -0.891 . . . . 0.0 110.056 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.523 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -94.45 136.78 34.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 110.45 -179.796 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.485 ' N ' HD21 ' A' ' 18' ' ' LEU . 1.1 p -79.81 169.54 19.67 Favored Pre-proline 0 N--CA 1.487 1.412 0 O-C-N 121.275 -0.891 . . . . 0.0 110.256 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.573 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 40.3 Cg_endo -69.67 -6.76 19.33 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 O-C-N 124.056 1.556 . . . . 0.0 110.183 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.573 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.7 m-85 -106.2 -3.0 21.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.331 -0.856 . . . . 0.0 109.965 179.295 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.18 13.74 47.87 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.2 113.82 24.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.137 -1.213 . . . . 0.0 110.012 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.523 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 0.0 OUTLIER -76.98 116.92 18.07 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.336 -0.853 . . . . 0.0 110.324 -179.726 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 8.1 p90 -143.39 176.11 9.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.274 -0.891 . . . . 0.0 110.241 179.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.472 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 58.0 m -124.47 138.11 54.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 110.193 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.2 t -107.89 150.39 40.25 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.24 -0.913 . . . . 0.0 110.705 -179.107 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -77.29 121.03 5.52 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 124.13 1.595 . . . . 0.0 110.405 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 42.3 p90 . . . . . 0 N--CA 1.493 1.697 0 O-C-N 121.157 -0.964 . . . . 0.0 110.314 179.843 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.443 ' HB ' HG23 ' A' ' 9' ' ' ILE . 19.5 m . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.317 0.58 . . . . 0.0 110.249 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.538 ' N ' ' O ' ' A' ' 10' ' ' CYS . 37.4 mm -85.22 156.98 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.25 -0.907 . . . . 0.0 110.134 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.412 ' CE1' HG12 ' A' ' 9' ' ' ILE . 4.0 m-70 -139.48 118.94 12.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.281 -0.887 . . . . 0.0 110.24 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 13.5 m -133.86 10.64 3.95 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.259 -0.901 . . . . 0.0 110.385 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.46 ' OD1' ' N ' ' A' ' 6' ' ' ALA . 0.7 OUTLIER -130.96 -101.12 0.3 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.184 -0.948 . . . . 0.0 110.191 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.46 ' N ' ' OD1' ' A' ' 5' ' ' ASP . . . -162.8 -43.15 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.061 -1.024 . . . . 0.0 110.065 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.72 -51.51 2.83 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 110.088 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 52.5 m -57.59 161.77 3.39 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.333 -0.854 . . . . 0.0 110.223 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.475 HD11 HG22 ' A' ' 9' ' ' ILE . 12.7 mt -140.7 172.71 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.259 -0.901 . . . . 0.0 110.055 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.538 ' O ' ' N ' ' A' ' 2' ' ' ILE . 56.8 m -143.22 137.87 15.13 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.182 -0.949 . . . . 0.0 110.521 -179.706 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.28 -166.08 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.939 1.494 . . . . 0.0 110.267 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 52.2 m-20 -90.08 147.93 23.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.198 -0.939 . . . . 0.0 110.199 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.45 18.63 60.05 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.41 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 0.6 OUTLIER -136.06 171.26 14.74 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.245 -1.15 . . . . 0.0 110.306 179.967 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.456 HG21 ' O ' ' A' ' 27' ' ' SER . 15.3 t -132.55 140.88 48.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.236 -0.915 . . . . 0.0 110.261 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 29.3 m -65.26 131.72 47.23 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.267 -0.895 . . . . 0.0 110.136 179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -156.54 138.2 14.15 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.098 -1.001 . . . . 0.0 110.46 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.426 HD22 ' C ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -88.72 143.49 26.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.324 -0.86 . . . . 0.0 110.287 179.726 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.455 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -82.24 169.54 17.99 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.318 -0.864 . . . . 0.0 110.478 -179.699 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.562 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.3 Cg_endo -69.02 -14.43 38.43 Favored 'Trans proline' 0 C--N 1.302 -1.909 0 O-C-N 124.135 1.597 . . . . 0.0 110.166 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.562 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 2.5 m-85 -100.19 1.62 42.15 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.379 -0.826 . . . . 0.0 109.614 178.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.77 29.45 15.84 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.455 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 76.5 t -103.75 123.49 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.246 -1.149 . . . . 0.0 110.445 -179.667 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.471 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.9 OUTLIER -76.86 118.74 19.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.249 -0.907 . . . . 0.0 110.312 179.906 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.524 ' CE2' ' OG ' ' A' ' 27' ' ' SER . 40.7 p90 -144.28 168.6 19.69 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.084 -1.01 . . . . 0.0 110.681 179.574 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.41 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 3.4 m -106.09 117.93 35.31 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.446 -0.784 . . . . 0.0 109.649 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.524 ' OG ' ' CE2' ' A' ' 25' ' ' TYR . 0.7 OUTLIER -93.81 142.65 25.36 Favored Pre-proline 0 C--N 1.303 -1.455 0 O-C-N 121.174 -0.954 . . . . 0.0 110.716 -178.943 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -75.69 126.19 9.36 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 124.135 1.597 . . . . 0.0 110.46 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.542 ' CG ' ' O ' ' A' ' 29' ' ' PHE . 34.6 p90 . . . . . 0 N--CA 1.493 1.688 0 O-C-N 121.242 -0.911 . . . . 0.0 110.268 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.458 HG22 HG22 ' A' ' 9' ' ' ILE . 29.1 m . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 121.266 0.555 . . . . 0.0 110.192 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.485 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 32.7 mm -77.67 146.49 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.213 -0.929 . . . . 0.0 110.312 -179.849 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.58 ' CE1' HG12 ' A' ' 9' ' ' ILE . 3.9 m-70 -138.04 83.29 1.97 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.315 -0.866 . . . . 0.0 110.089 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -72.32 -32.01 66.17 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.301 -0.874 . . . . 0.0 110.441 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.488 ' OD2' ' NE1' ' A' ' 24' ' ' TRP . 0.6 OUTLIER -116.34 -89.64 0.57 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.18 -0.95 . . . . 0.0 110.357 -179.849 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -171.89 -32.84 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.162 -0.962 . . . . 0.0 110.354 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -99.31 -83.63 0.42 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 110.234 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.449 HG22 ' O ' ' A' ' 24' ' ' TRP . 62.9 m -52.17 106.55 0.15 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.225 -0.922 . . . . 0.0 110.158 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.58 HG12 ' CE1' ' A' ' 3' ' ' HIS . 6.2 mt -90.65 165.02 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.191 -0.943 . . . . 0.0 110.335 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.485 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 99.4 m -133.73 140.74 37.57 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.267 -0.896 . . . . 0.0 110.057 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.0 173.81 13.43 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.901 1.474 . . . . 0.0 110.424 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.474 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 1.1 m-20 -77.12 152.5 34.91 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.281 -0.887 . . . . 0.0 110.472 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' A' ' 29' ' ' PHE . . . 90.55 -8.27 80.07 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.0 p -116.95 166.52 12.07 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.183 -1.186 . . . . 0.0 110.151 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.501 ' O ' ' CG2' ' A' ' 15' ' ' THR . 14.8 t -123.54 119.36 29.7 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.333 -0.854 . . . . 0.0 110.375 179.683 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . 0.457 ' O ' ' OG ' ' A' ' 17' ' ' SER . 20.6 p -50.34 158.36 0.59 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.214 -0.929 . . . . 0.0 110.18 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.574 ' HB2' ' CZ ' ' A' ' 25' ' ' TYR . 42.4 m -167.44 146.64 5.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.198 -0.938 . . . . 0.0 110.022 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.56 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -108.6 134.73 50.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 110.485 -179.654 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.468 ' HB3' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -78.53 167.79 32.45 Favored Pre-proline 0 C--N 1.304 -1.399 0 O-C-N 121.34 -0.85 . . . . 0.0 109.989 179.543 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.584 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 37.9 Cg_endo -69.56 -11.92 32.15 Favored 'Trans proline' 0 C--N 1.3 -2.009 0 O-C-N 124.022 1.538 . . . . 0.0 109.942 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.584 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.2 m-85 -97.79 -2.31 41.32 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.399 -0.813 . . . . 0.0 109.75 178.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.85 21.17 29.07 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.468 ' HB ' ' HB3' ' A' ' 19' ' ' SER . 75.6 t -91.54 119.58 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.273 -1.133 . . . . 0.0 110.38 -179.744 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.56 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 0.6 OUTLIER -84.01 126.66 33.26 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.266 -0.896 . . . . 0.0 110.181 179.765 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.574 ' CZ ' ' HB2' ' A' ' 17' ' ' SER . 32.6 p90 -147.75 174.82 11.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.215 -0.928 . . . . 0.0 110.246 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 4.0 m -114.18 107.65 15.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.261 -0.9 . . . . 0.0 110.223 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.476 ' HB3' ' CG2' ' A' ' 15' ' ' THR . 9.8 t -70.59 144.01 90.78 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.192 -0.943 . . . . 0.0 109.897 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -76.17 170.61 19.7 Favored 'Trans proline' 0 C--N 1.299 -2.053 0 O-C-N 123.817 1.43 . . . . 0.0 110.918 -179.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 13' ' ' GLY . 2.4 m-85 . . . . . 0 N--CA 1.494 1.774 0 O-C-N 121.459 -0.776 . . . . 0.0 110.201 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' VAL . . . . . 0.447 HG21 ' O ' ' A' ' 1' ' ' VAL . 5.9 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.233 0.539 . . . . 0.0 110.331 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.462 ' O ' ' N ' ' A' ' 10' ' ' CYS . 30.1 mm -44.1 152.87 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.273 -0.892 . . . . 0.0 110.223 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.565 ' O ' ' N ' ' A' ' 5' ' ' ASP . 4.0 m-70 -120.38 -64.69 1.22 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.184 -0.947 . . . . 0.0 110.336 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' CYS . . . . . 0.52 ' HB3' ' O ' ' A' ' 3' ' ' HIS . 1.7 t 59.65 -72.29 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.511 -0.743 . . . . 0.0 110.386 179.753 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.565 ' N ' ' O ' ' A' ' 3' ' ' HIS . 81.1 m-20 -54.75 -163.67 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.178 -0.951 . . . . 0.0 110.297 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -103.92 -19.93 14.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.12 -0.988 . . . . 0.0 110.547 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . 0.426 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -135.72 -79.69 0.42 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.257 -0.902 . . . . 0.0 110.557 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 7' ' ' ALA . 97.5 m -41.24 132.13 2.61 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.344 -0.847 . . . . 0.0 110.387 -179.636 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ILE . . . . . 0.531 HG12 ' CE1' ' A' ' 3' ' ' HIS . 0.9 OUTLIER -98.46 175.78 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.265 -0.897 . . . . 0.0 110.048 179.972 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . 0.462 ' N ' ' O ' ' A' ' 2' ' ' ILE . 1.5 m -130.0 132.9 24.42 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 110.329 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . 0.495 ' O ' ' O ' ' A' ' 12' ' ' ASP . 48.5 Cg_endo -77.78 154.42 30.3 Favored 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.009 1.531 . . . . 0.0 110.02 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.495 ' O ' ' O ' ' A' ' 11' ' ' PRO . 7.3 m-20 48.66 179.22 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.164 -0.96 . . . . 0.0 110.139 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' A' ' 14' ' ' THR . . . -55.42 -64.19 4.6 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 179.699 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.52 ' O ' ' O ' ' A' ' 13' ' ' GLY . 0.8 OUTLIER 44.39 -179.24 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.545 -0.973 . . . . 0.0 110.963 179.294 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' THR . . . . . 0.514 ' CG2' ' O ' ' A' ' 27' ' ' SER . 9.9 t -136.41 155.58 49.82 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.292 -0.88 . . . . 0.0 110.195 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -69.8 127.85 34.35 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.269 -0.894 . . . . 0.0 110.225 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.584 ' O ' ' CD1' ' A' ' 25' ' ' TYR . 8.2 m -142.61 125.09 15.69 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.213 -0.929 . . . . 0.0 110.19 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.564 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -101.66 137.59 39.77 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.199 -0.938 . . . . 0.0 110.192 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.489 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.2 p -79.18 167.13 37.01 Favored Pre-proline 0 C--N 1.303 -1.454 0 O-C-N 121.315 -0.866 . . . . 0.0 110.423 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.575 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 39.0 Cg_endo -69.61 -7.93 22.29 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 O-C-N 124.041 1.548 . . . . 0.0 110.118 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' TYR . . . . . 0.575 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -103.89 -2.54 26.06 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.476 -0.765 . . . . 0.0 109.639 178.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.9 24.97 15.77 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.489 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 72.2 t -95.29 114.85 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.263 -1.139 . . . . 0.0 110.402 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' TRP . . . . . 0.564 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -76.62 123.46 26.14 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.327 -0.858 . . . . 0.0 110.379 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' TYR . . . . . 0.584 ' CD1' ' O ' ' A' ' 17' ' ' SER . 22.9 p90 -147.58 173.35 12.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.143 -0.973 . . . . 0.0 110.29 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' CYS . . . . . 0.443 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 3.4 m -106.11 147.05 29.42 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.374 -0.829 . . . . 0.0 110.221 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.514 ' O ' ' CG2' ' A' ' 15' ' ' THR . 0.9 OUTLIER -130.71 149.26 73.08 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.9 . . . . 0.0 110.346 179.951 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -74.06 127.67 11.58 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 O-C-N 124.098 1.578 . . . . 0.0 110.312 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 14.4 p90 . . . . . 0 N--CA 1.492 1.648 0 O-C-N 121.2 -0.938 . . . . 0.0 110.324 -179.781 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.462 ' HB ' HG23 ' A' ' 9' ' ' ILE . 26.9 m . . . . . 0 N--CA 1.493 1.713 0 CA-C-O 121.278 0.561 . . . . 0.0 110.264 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.463 ' HB ' ' HB3' ' A' ' 10' ' ' CYS . 2.0 mp -87.54 166.32 1.94 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.212 -0.93 . . . . 0.0 110.276 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.424 ' N ' ' CG2' ' A' ' 2' ' ' ILE . 9.5 m-70 -141.75 161.01 39.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.221 -0.924 . . . . 0.0 110.3 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 26.8 p -161.05 -36.74 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.206 -0.934 . . . . 0.0 110.254 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.559 ' OD1' ' CE2' ' A' ' 24' ' ' TRP . 13.5 m-20 -93.91 -78.93 0.42 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.225 -0.922 . . . . 0.0 110.19 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.449 ' CB ' ' O ' ' A' ' 5' ' ' ASP . . . 171.72 -31.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.282 -0.886 . . . . 0.0 110.144 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.65 -61.49 1.7 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.311 -0.868 . . . . 0.0 110.175 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.8 m -55.22 150.45 11.0 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.246 -0.909 . . . . 0.0 110.14 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.462 HG23 ' HB ' ' A' ' 1' ' ' VAL . 8.4 mt -119.84 172.3 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -0.927 . . . . 0.0 110.245 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.463 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 19.3 t -131.51 136.64 28.89 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.248 -0.907 . . . . 0.0 110.18 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.403 ' O ' HD11 ' A' ' 2' ' ' ILE . 42.9 Cg_endo -72.46 -161.1 0.1 OUTLIER 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.978 1.514 . . . . 0.0 110.569 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.412 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 0.9 OUTLIER -96.0 150.17 20.77 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.23 -0.919 . . . . 0.0 110.414 -179.745 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 64.81 53.29 35.42 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -159.39 170.67 21.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.203 -1.175 . . . . 0.0 110.378 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.409 ' C ' ' SG ' ' A' ' 26' ' ' CYS . 12.2 t -130.88 131.9 44.82 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.346 -0.846 . . . . 0.0 110.235 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.2 132.76 43.97 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.292 -0.88 . . . . 0.0 110.302 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -152.12 157.88 42.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 110.245 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.434 HD21 ' N ' ' A' ' 19' ' ' SER . 0.2 OUTLIER -105.87 136.22 45.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.313 -0.867 . . . . 0.0 110.288 -179.944 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.5 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.9 OUTLIER -78.31 165.37 50.67 Favored Pre-proline 0 N--CA 1.488 1.446 0 O-C-N 121.24 -0.912 . . . . 0.0 110.213 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.573 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.9 Cg_endo -69.39 -11.61 31.72 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 O-C-N 124.038 1.546 . . . . 0.0 110.04 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.573 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.7 m-85 -101.54 5.2 41.69 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.476 -0.765 . . . . 0.0 109.553 178.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.74 21.16 51.82 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.5 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 60.6 t -93.9 123.08 45.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.32 -1.106 . . . . 0.0 110.281 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.559 ' CE2' ' OD1' ' A' ' 5' ' ' ASP . 1.3 m95 -81.09 130.71 35.14 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.243 -0.911 . . . . 0.0 110.21 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.1 p90 -165.42 173.08 11.45 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.207 -0.933 . . . . 0.0 110.331 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.409 ' SG ' ' C ' ' A' ' 15' ' ' THR . 0.1 OUTLIER -109.19 137.22 47.41 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -0.924 . . . . 0.0 110.24 179.705 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.9 t -108.4 147.44 35.67 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.263 -0.898 . . . . 0.0 110.338 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.6 114.14 3.96 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.029 1.541 . . . . 0.0 110.476 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.48 ' CD1' ' C ' ' A' ' 29' ' ' PHE . 20.9 p90 -102.51 169.25 8.78 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.253 -0.905 . . . . 0.0 110.295 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.1 t . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.325 -179.995 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.523 HG22 ' CG2' ' A' ' 9' ' ' ILE . 30.5 m . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 121.138 0.494 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 31.9 mm -105.3 157.17 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.251 -0.906 . . . . 0.0 110.572 -179.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 12.4 m-70 -134.53 125.75 27.95 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.277 -0.889 . . . . 0.0 110.061 179.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -113.41 -50.65 2.85 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 0.0 110.501 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -90.86 -70.01 0.7 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.261 -0.899 . . . . 0.0 110.479 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 175.17 -46.55 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.195 -0.941 . . . . 0.0 110.36 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -100.14 -20.07 16.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.204 -0.935 . . . . 0.0 110.342 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.7 m -82.84 140.72 32.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.303 -0.873 . . . . 0.0 110.266 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.523 ' CG2' HG22 ' A' ' 1' ' ' VAL . 4.3 mt -125.91 166.38 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.193 -0.942 . . . . 0.0 110.293 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 1' ' ' VAL . 10.0 m -147.3 155.6 46.32 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.265 -0.897 . . . . 0.0 109.958 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.96 -166.29 0.28 Allowed 'Trans proline' 0 C--N 1.303 -1.817 0 O-C-N 123.942 1.496 . . . . 0.0 110.373 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -95.56 152.26 18.59 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.266 -0.896 . . . . 0.0 110.313 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.2 12.07 84.95 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -124.3 170.14 11.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -1.141 . . . . 0.0 110.396 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.472 ' CG2' ' HB3' ' A' ' 27' ' ' SER . 11.8 t -129.86 139.09 51.25 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.879 . . . . 0.0 110.249 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.3 p -62.69 134.61 56.56 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.275 -0.891 . . . . 0.0 110.353 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 4.7 m -153.91 133.71 13.03 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.299 -0.875 . . . . 0.0 110.21 179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.464 HD22 ' HA ' ' A' ' 24' ' ' TRP . 0.4 OUTLIER -91.97 143.8 26.11 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -0.927 . . . . 0.0 110.301 -179.796 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.516 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -79.41 172.71 9.17 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.278 -0.888 . . . . 0.0 110.332 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.597 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.9 Cg_endo -69.87 -7.17 20.43 Favored 'Trans proline' 0 C--N 1.302 -1.885 0 O-C-N 124.167 1.614 . . . . 0.0 110.174 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.597 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 4.2 m-85 -109.51 -0.17 18.96 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.393 -0.817 . . . . 0.0 109.623 178.816 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.56 17.86 37.52 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.516 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 48.0 t -87.53 108.9 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.27 -1.135 . . . . 0.0 110.438 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.544 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -65.25 124.34 21.92 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.229 -0.919 . . . . 0.0 110.416 179.982 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.49 ' C ' ' CD1' ' A' ' 25' ' ' TYR . 15.5 p90 -148.25 171.66 15.6 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.165 -0.959 . . . . 0.0 110.162 179.397 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 4.3 m -106.35 118.02 35.55 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.177 -0.952 . . . . 0.0 110.257 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.472 ' HB3' ' CG2' ' A' ' 15' ' ' THR . 23.3 t -84.82 139.22 37.42 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.265 -0.897 . . . . 0.0 110.318 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -77.17 120.68 5.45 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 124.063 1.56 . . . . 0.0 110.397 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.489 ' C ' ' CD1' ' A' ' 29' ' ' PHE . 14.4 p90 -119.38 158.33 26.39 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.183 -0.948 . . . . 0.0 110.223 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 28.7 t . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.321 179.912 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.473 ' HB ' HG23 ' A' ' 9' ' ' ILE . 29.8 m . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 121.202 0.525 . . . . 0.0 110.348 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.439 ' N ' ' O ' ' A' ' 10' ' ' CYS . 45.4 mm -93.17 143.13 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 110.2 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -122.81 109.63 14.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 110.119 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -149.17 22.9 0.95 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.362 -0.836 . . . . 0.0 110.215 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.495 ' OD1' ' CH2' ' A' ' 24' ' ' TRP . 75.0 m-20 -137.32 -166.18 1.89 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.206 -0.934 . . . . 0.0 110.173 179.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.51 -59.38 2.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 110.276 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -136.33 -46.33 0.63 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 110.26 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.444 ' CB ' ' HB3' ' A' ' 24' ' ' TRP . 19.1 m -45.27 112.05 0.4 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.172 -0.955 . . . . 0.0 110.1 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.504 HD11 HG22 ' A' ' 9' ' ' ILE . 12.3 mt -85.82 167.53 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.292 -0.88 . . . . 0.0 110.235 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.439 ' O ' ' N ' ' A' ' 2' ' ' ILE . 31.0 m -129.84 141.83 43.23 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.249 -0.907 . . . . 0.0 110.324 -179.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.51 -166.6 0.34 Allowed 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.957 1.504 . . . . 0.0 110.267 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.9 148.69 22.03 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.237 -0.914 . . . . 0.0 110.348 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.98 0.94 89.81 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.2 p -117.58 170.24 8.91 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.137 -1.213 . . . . 0.0 110.399 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 14.8 t -134.32 144.69 48.44 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.159 -0.963 . . . . 0.0 110.503 -179.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -52.4 140.62 21.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.308 -0.87 . . . . 0.0 110.402 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.523 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 9.0 t -160.23 124.39 3.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.262 -0.899 . . . . 0.0 110.235 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.438 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.1 OUTLIER -100.85 117.95 35.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.224 -0.922 . . . . 0.0 110.425 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.473 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -56.07 162.13 3.16 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.246 -0.909 . . . . 0.0 110.139 179.637 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.593 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.2 Cg_endo -69.35 -6.82 19.32 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 124.009 1.531 . . . . 0.0 110.116 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.593 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.4 m-85 -100.31 -5.97 26.61 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.423 -0.798 . . . . 0.0 109.688 179.001 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 99.21 17.44 27.13 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.473 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 67.4 t -89.97 115.36 29.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.266 -1.138 . . . . 0.0 110.298 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.533 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -74.08 125.79 29.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.357 -0.84 . . . . 0.0 110.37 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.523 ' CE1' ' HB3' ' A' ' 17' ' ' SER . 8.8 p90 -154.47 174.52 14.79 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 110.282 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.9 m -115.54 116.68 28.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.262 -0.899 . . . . 0.0 110.132 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 3.3 t -84.86 134.59 41.32 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.274 -0.891 . . . . 0.0 110.402 -179.572 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -74.48 118.08 5.21 Favored 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.003 1.528 . . . . 0.0 110.423 179.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.419 ' O ' ' OG ' ' A' ' 30' ' ' SER . 24.5 p90 -121.25 158.13 28.79 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.186 -0.946 . . . . 0.0 110.24 179.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.419 ' OG ' ' O ' ' A' ' 29' ' ' PHE . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.295 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 30.1 m . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.29 0.567 . . . . 0.0 110.259 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.528 ' N ' ' O ' ' A' ' 10' ' ' CYS . 40.5 mm -45.38 155.69 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.203 -0.936 . . . . 0.0 110.054 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.466 ' O ' ' N ' ' A' ' 5' ' ' ASP . 1.8 m-70 -130.64 -60.59 0.98 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.115 -0.991 . . . . 0.0 110.575 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.464 ' CB ' ' O ' ' A' ' 3' ' ' HIS . 0.5 OUTLIER 66.75 -67.97 0.15 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.234 -0.916 . . . . 0.0 110.268 -179.776 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.502 ' OD2' ' N ' ' A' ' 8' ' ' THR . 9.9 p-10 -80.88 -138.83 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 0.0 110.1 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -128.56 -6.21 5.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.953 . . . . 0.0 110.392 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.446 ' N ' ' OD2' ' A' ' 5' ' ' ASP . . . -137.13 -65.54 0.54 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.213 -0.929 . . . . 0.0 110.203 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.502 ' N ' ' OD2' ' A' ' 5' ' ' ASP . 5.1 m -48.7 111.95 0.54 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.234 -0.917 . . . . 0.0 110.272 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 6.0 mt -90.83 151.74 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.21 -0.931 . . . . 0.0 110.128 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.528 ' O ' ' N ' ' A' ' 2' ' ' ILE . 23.7 m -127.13 139.68 35.77 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.17 -0.956 . . . . 0.0 110.298 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -74.91 -161.18 0.12 Allowed 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 124.02 1.537 . . . . 0.0 110.362 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -95.5 150.61 20.12 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.284 -0.885 . . . . 0.0 110.304 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.1 12.95 80.17 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.468 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 1.2 p -121.63 169.39 10.75 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.199 -1.177 . . . . 0.0 110.447 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.578 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 12.6 t -131.93 157.09 44.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.28 -0.888 . . . . 0.0 110.288 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.4 m -58.3 127.82 34.05 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.287 -0.883 . . . . 0.0 109.861 179.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.57 ' OG ' ' CZ ' ' A' ' 25' ' ' TYR . 1.3 t -141.72 124.26 15.85 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.939 . . . . 0.0 110.684 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.576 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.1 OUTLIER -109.03 126.99 53.72 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.385 -0.822 . . . . 0.0 110.051 179.201 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.508 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -67.9 163.33 50.99 Favored Pre-proline 0 C--N 1.301 -1.513 0 O-C-N 121.217 -0.927 . . . . 0.0 110.284 180.0 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.595 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.0 Cg_endo -69.08 -8.59 24.01 Favored 'Trans proline' 0 C--N 1.302 -1.879 0 O-C-N 124.111 1.585 . . . . 0.0 110.126 179.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.595 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.6 m-85 -100.68 -1.04 36.23 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.372 -0.83 . . . . 0.0 109.746 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.3 17.44 39.77 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.508 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 94.0 t -91.03 112.47 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.408 -1.054 . . . . 0.0 110.172 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.576 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 2.7 m95 -71.46 142.31 50.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.259 -0.901 . . . . 0.0 110.273 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.57 ' CZ ' ' OG ' ' A' ' 17' ' ' SER . 24.6 p90 -170.23 174.12 5.49 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.277 -0.889 . . . . 0.0 110.267 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.468 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 2.6 m -106.81 141.81 37.45 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.247 -0.908 . . . . 0.0 110.285 -179.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.515 ' HB3' ' CB ' ' A' ' 17' ' ' SER . 0.9 OUTLIER -118.91 141.95 31.03 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.217 -0.927 . . . . 0.0 110.208 179.784 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -74.61 104.3 1.85 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 124.081 1.569 . . . . 0.0 110.531 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.578 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 8.2 p90 -111.51 150.58 29.73 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.212 -0.93 . . . . 0.0 110.294 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.263 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.433 ' HB ' HG23 ' A' ' 9' ' ' ILE . 30.8 m . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.323 0.582 . . . . 0.0 110.216 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.493 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 36.4 mm -83.55 148.18 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.219 -0.925 . . . . 0.0 110.307 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.402 ' CE1' HG12 ' A' ' 9' ' ' ILE . 9.9 m-70 -118.79 126.41 51.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.175 -0.953 . . . . 0.0 110.398 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 26.9 m -80.28 -68.94 0.63 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.297 -0.877 . . . . 0.0 110.275 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -104.63 -90.27 0.4 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.278 -0.889 . . . . 0.0 110.163 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -146.66 10.28 1.06 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.289 -0.882 . . . . 0.0 110.393 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.435 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -140.11 -76.27 0.33 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.206 -0.934 . . . . 0.0 110.318 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.453 HG23 ' HB3' ' A' ' 24' ' ' TRP . 8.6 m -41.63 147.84 0.17 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.31 -0.869 . . . . 0.0 110.364 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.433 HG23 ' HB ' ' A' ' 1' ' ' VAL . 15.2 mt -131.71 169.61 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.279 -0.888 . . . . 0.0 110.129 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.493 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 63.2 m -145.67 146.27 28.69 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.156 -0.965 . . . . 0.0 110.327 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -73.02 -175.02 1.74 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.012 1.532 . . . . 0.0 110.472 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -84.83 156.87 21.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.239 -0.913 . . . . 0.0 110.226 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.15 3.52 90.54 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.0 p -127.1 170.27 12.53 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.238 -1.154 . . . . 0.0 110.213 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.5 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 9.0 t -128.2 156.0 43.62 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.218 -0.926 . . . . 0.0 110.349 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.3 m -73.29 128.83 36.6 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.278 -0.888 . . . . 0.0 110.176 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.445 ' OG ' ' CZ ' ' A' ' 25' ' ' TYR . 32.9 t -137.19 130.2 30.69 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.28 -0.887 . . . . 0.0 110.243 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.588 ' HG ' ' CE2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -105.19 106.38 16.85 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.186 -0.946 . . . . 0.0 110.294 179.815 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.491 ' HB3' ' HB ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -46.18 157.81 0.4 Allowed Pre-proline 0 C--N 1.301 -1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 110.218 179.718 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.595 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.0 Cg_endo -68.69 -11.66 32.49 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 124.041 1.548 . . . . 0.0 110.026 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.595 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.0 m-85 -93.24 -8.71 41.49 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.456 -0.777 . . . . 0.0 109.641 178.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 100.8 19.9 16.14 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.491 ' HB ' ' HB3' ' A' ' 19' ' ' SER . 61.2 t -94.97 115.91 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.236 -1.155 . . . . 0.0 110.123 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.588 ' CE2' ' HG ' ' A' ' 18' ' ' LEU . 0.2 OUTLIER -77.84 126.78 31.37 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.335 -0.853 . . . . 0.0 110.503 -179.525 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.445 ' CZ ' ' OG ' ' A' ' 17' ' ' SER . 28.0 p90 -154.72 171.69 19.14 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.917 . . . . 0.0 110.125 179.304 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.3 m -106.45 135.6 47.67 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.216 -0.927 . . . . 0.0 110.068 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.456 ' O ' HG23 ' A' ' 15' ' ' THR . 12.0 t -115.4 143.71 30.97 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.204 -0.935 . . . . 0.0 110.324 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.73 125.02 9.68 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 124.034 1.544 . . . . 0.0 110.4 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.5 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 14.8 p90 -135.01 172.05 13.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.305 -0.872 . . . . 0.0 110.219 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.227 179.769 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.528 ' CB ' ' O ' ' A' ' 10' ' ' CYS . 23.6 m . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.252 0.549 . . . . 0.0 110.308 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.484 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 34.2 mm -88.46 143.17 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.166 -0.959 . . . . 0.0 110.114 179.552 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.463 ' NE2' HG22 ' A' ' 9' ' ' ILE . 7.3 m-70 -129.17 119.51 24.21 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.193 -0.942 . . . . 0.0 110.598 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 87.1 m -124.3 11.76 8.76 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.986 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -150.29 -90.23 0.07 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.392 -0.818 . . . . 0.0 110.207 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -176.09 -32.39 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.16 -0.963 . . . . 0.0 110.244 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.482 ' O ' ' CG1' ' A' ' 9' ' ' ILE . . . -105.38 -75.5 0.63 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.2 -0.938 . . . . 0.0 110.258 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 42.8 m -43.47 139.74 1.95 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.24 -0.913 . . . . 0.0 110.394 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.482 ' CG1' ' O ' ' A' ' 7' ' ' ALA . 4.4 mt -135.85 147.69 28.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 0.0 110.217 179.788 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.528 ' O ' ' CB ' ' A' ' 1' ' ' VAL . 98.1 m -111.34 148.69 39.29 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.305 -0.872 . . . . 0.0 109.982 179.726 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.43 ' O ' ' CG ' ' A' ' 12' ' ' ASP . 45.4 Cg_endo -74.7 -90.34 0.01 OUTLIER 'Trans proline' 0 C--N 1.302 -1.869 0 O-C-N 123.846 1.445 . . . . 0.0 110.335 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.43 ' CG ' ' O ' ' A' ' 11' ' ' PRO . 21.1 m-20 -158.86 164.28 35.86 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.371 -0.831 . . . . 0.0 110.181 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.32 13.26 48.92 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.442 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 1.3 p -124.07 169.74 11.37 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.217 -1.166 . . . . 0.0 110.308 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.445 HG23 ' O ' ' A' ' 27' ' ' SER . 8.9 t -129.59 153.81 47.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.141 -0.974 . . . . 0.0 110.494 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.441 ' SG ' HG23 ' A' ' 2' ' ' ILE . 60.2 m -63.86 127.47 31.52 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.262 -0.899 . . . . 0.0 110.147 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.509 ' HB3' ' CE2' ' A' ' 25' ' ' TYR . 10.7 t -138.9 133.99 32.63 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 110.265 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.446 HD21 ' N ' ' A' ' 19' ' ' SER . 0.2 OUTLIER -99.34 135.89 40.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.169 -0.957 . . . . 0.0 110.316 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.499 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.4 OUTLIER -79.06 166.13 44.16 Favored Pre-proline 0 C--N 1.303 -1.415 0 O-C-N 121.325 -0.859 . . . . 0.0 110.243 -179.992 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.567 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.9 Cg_endo -69.39 -10.73 29.63 Favored 'Trans proline' 0 C--N 1.301 -1.951 0 O-C-N 124.057 1.556 . . . . 0.0 110.022 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.567 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -104.06 -0.51 28.65 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.429 -0.794 . . . . 0.0 109.667 179.007 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.11 15.32 48.72 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.499 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 92.3 t -87.0 119.15 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.292 -1.122 . . . . 0.0 110.191 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.513 ' CE3' ' HA ' ' A' ' 24' ' ' TRP . 0.6 OUTLIER -77.75 128.16 33.59 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 110.458 -179.747 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.509 ' CE2' ' HB3' ' A' ' 17' ' ' SER . 37.1 p90 -152.74 172.52 16.56 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.27 -0.894 . . . . 0.0 110.086 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.442 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 4.0 m -101.92 141.42 34.79 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.209 -0.932 . . . . 0.0 110.193 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.445 ' O ' HG23 ' A' ' 15' ' ' THR . 3.4 t -116.16 141.7 28.17 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.173 -0.954 . . . . 0.0 110.389 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -75.38 129.27 11.86 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.061 1.558 . . . . 0.0 110.488 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.446 ' O ' ' HB3' ' A' ' 30' ' ' SER . 43.6 p90 -133.14 154.15 50.87 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.223 -0.923 . . . . 0.0 110.214 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.446 ' HB3' ' O ' ' A' ' 29' ' ' PHE . 21.8 t . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.271 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.523 HG22 ' CG2' ' A' ' 9' ' ' ILE . 28.6 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.224 0.535 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.464 HD13 ' HA ' ' A' ' 12' ' ' ASP . 2.5 mp -50.89 160.6 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.242 -0.911 . . . . 0.0 110.147 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.48 ' NE2' HG22 ' A' ' 9' ' ' ILE . 4.4 m-70 -148.12 89.43 1.73 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.195 -0.941 . . . . 0.0 110.354 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 63.9 m -92.59 -41.39 10.25 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.265 -0.897 . . . . 0.0 110.091 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.49 ' O ' ' CB ' ' A' ' 6' ' ' ALA . 8.3 t70 -85.14 -86.57 0.13 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.269 -0.894 . . . . 0.0 110.217 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.49 ' CB ' ' O ' ' A' ' 5' ' ' ASP . . . 170.31 -27.66 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.188 -0.945 . . . . 0.0 110.354 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.439 ' O ' ' CG1' ' A' ' 9' ' ' ILE . . . -105.01 -81.51 0.53 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.174 -0.954 . . . . 0.0 110.335 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.485 ' C ' ' CG1' ' A' ' 9' ' ' ILE . 89.5 m -41.18 155.4 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.292 -0.88 . . . . 0.0 110.458 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.523 ' CG2' HG22 ' A' ' 1' ' ' VAL . 6.1 mt -150.11 145.78 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.212 -0.93 . . . . 0.0 110.181 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.583 ' CB ' ' CD ' ' A' ' 11' ' ' PRO . 0.0 OUTLIER -130.08 -170.2 0.21 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 110.22 179.591 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.583 ' CD ' ' CB ' ' A' ' 10' ' ' CYS . 45.8 Cg_endo -87.27 175.4 4.77 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.822 1.433 . . . . 0.0 110.75 -178.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.464 ' HA ' HD13 ' A' ' 2' ' ' ILE . 5.7 m-20 -91.63 151.37 20.72 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.296 -0.878 . . . . 0.0 110.3 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.85 -6.09 51.42 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 4.6 p -114.39 171.68 7.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.192 -1.181 . . . . 0.0 110.25 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.507 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 14.7 t -115.94 134.33 55.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.312 -0.867 . . . . 0.0 110.311 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.2 m -45.05 147.02 0.74 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.244 -0.91 . . . . 0.0 110.367 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.55 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 29.0 m -161.69 135.02 6.34 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.306 -0.871 . . . . 0.0 110.337 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.532 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -106.64 142.39 36.36 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.225 -0.922 . . . . 0.0 110.211 179.996 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.493 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -84.14 168.02 24.11 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.168 -0.957 . . . . 0.0 110.291 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.566 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.5 Cg_endo -69.61 -8.83 24.62 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 124.098 1.578 . . . . 0.0 110.176 -179.726 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.566 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -103.63 0.95 31.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.432 -0.792 . . . . 0.0 109.627 179.173 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.98 16.88 49.74 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.254 -1.538 . . . . 0.0 109.254 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.493 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 97.2 t -86.59 115.52 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.359 -1.083 . . . . 0.0 110.295 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.532 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 1.0 OUTLIER -75.61 135.41 40.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.294 -0.879 . . . . 0.0 110.325 179.973 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.55 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 24.8 p90 -163.8 176.56 9.4 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.252 -0.905 . . . . 0.0 110.35 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.462 ' SG ' ' HD2' ' A' ' 11' ' ' PRO . 11.1 p -114.38 130.06 56.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.344 -0.847 . . . . 0.0 110.26 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.414 ' O ' HG21 ' A' ' 15' ' ' THR . 1.1 p -99.94 146.03 31.2 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 0.0 110.253 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -73.13 104.43 1.78 Allowed 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 123.999 1.526 . . . . 0.0 110.411 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.507 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 0.5 OUTLIER -120.54 160.63 22.79 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.314 -0.866 . . . . 0.0 110.406 -179.848 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.9 t . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.232 179.844 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.515 HG22 ' CG2' ' A' ' 9' ' ' ILE . 6.5 m . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 121.281 0.562 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.48 ' O ' ' HB2' ' A' ' 10' ' ' CYS . 2.6 mp -90.06 154.8 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.279 -0.888 . . . . 0.0 110.274 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.423 ' N ' HG21 ' A' ' 2' ' ' ILE . 15.0 m-70 -129.42 114.86 16.68 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.188 -0.945 . . . . 0.0 110.198 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 30.0 m -71.51 -39.6 70.68 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 110.318 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.457 ' O ' ' CB ' ' A' ' 6' ' ' ALA . 23.7 t0 -125.18 -59.75 1.38 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.221 -0.924 . . . . 0.0 110.406 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.457 ' CB ' ' O ' ' A' ' 5' ' ' ASP . . . 170.6 -25.37 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.174 -0.954 . . . . 0.0 110.43 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -100.05 -51.31 3.72 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 44.5 m -70.09 128.15 35.28 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.308 -0.87 . . . . 0.0 110.397 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.515 ' CG2' HG22 ' A' ' 1' ' ' VAL . 4.1 mt -97.64 176.7 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.209 -0.932 . . . . 0.0 110.07 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.48 ' HB2' ' O ' ' A' ' 2' ' ' ILE . 30.3 m -152.85 139.41 12.42 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.288 -0.882 . . . . 0.0 110.637 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.37 177.82 8.3 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 O-C-N 124.126 1.593 . . . . 0.0 110.433 179.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 12' ' ' ASP . 0.9 OUTLIER -85.19 147.85 26.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.167 -0.958 . . . . 0.0 110.311 179.779 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 92.93 -7.29 76.77 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.406 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 4.1 p -109.83 169.58 8.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.228 -1.16 . . . . 0.0 110.308 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.468 ' O ' ' HA ' ' A' ' 26' ' ' CYS . 15.4 t -125.83 151.1 47.26 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.228 -0.92 . . . . 0.0 110.359 -179.777 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.474 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 1.1 m -66.56 148.76 51.44 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.336 -0.852 . . . . 0.0 110.525 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.507 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 0.2 OUTLIER -170.31 137.26 1.45 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.35 -0.844 . . . . 0.0 110.223 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.458 ' HG ' ' CE3' ' A' ' 24' ' ' TRP . 0.3 OUTLIER -96.46 141.11 30.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 110.277 -179.982 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.534 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.6 OUTLIER -78.78 169.86 18.77 Favored Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.324 -0.86 . . . . 0.0 110.244 -179.918 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.552 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.7 Cg_endo -69.46 -16.5 38.84 Favored 'Trans proline' 0 C--N 1.301 -1.97 0 O-C-N 124.075 1.566 . . . . 0.0 109.939 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.552 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 2.9 m-85 -98.74 1.99 46.59 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.516 -0.74 . . . . 0.0 109.593 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.95 23.22 33.32 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.534 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 23.8 t -92.3 112.77 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.284 -1.127 . . . . 0.0 110.304 -179.757 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.458 ' CE3' ' HG ' ' A' ' 18' ' ' LEU . 1.6 m95 -65.98 126.43 28.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.274 -0.891 . . . . 0.0 110.271 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.507 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 6.3 p90 -157.19 177.37 11.55 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.079 -1.013 . . . . 0.0 110.388 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.474 ' SG ' ' HA ' ' A' ' 16' ' ' CYS . 1.9 m -126.5 138.61 53.52 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.425 -0.797 . . . . 0.0 110.098 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.41 139.25 21.81 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.202 -0.936 . . . . 0.0 110.576 -179.474 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -74.62 118.49 5.34 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.076 1.566 . . . . 0.0 110.331 179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' A' ' 29' ' ' PHE . 40.2 p90 -101.0 142.38 32.56 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.204 -0.935 . . . . 0.0 110.303 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 29' ' ' PHE . 75.4 m . . . . . 0 N--CA 1.491 1.576 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.265 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.48 ' CG2' ' O ' ' A' ' 1' ' ' VAL . 3.4 m . . . . . 0 N--CA 1.494 1.741 0 CA-C-O 121.295 0.569 . . . . 0.0 110.417 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.452 ' N ' ' O ' ' A' ' 10' ' ' CYS . 5.2 mm -58.71 161.73 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.265 -0.897 . . . . 0.0 110.061 179.464 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.408 ' CD2' HG22 ' A' ' 1' ' ' VAL . 1.9 m-70 -149.01 125.92 11.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.257 -0.902 . . . . 0.0 110.507 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 28.3 p -126.44 21.52 7.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.336 -0.853 . . . . 0.0 110.111 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.461 ' N ' ' OD1' ' A' ' 5' ' ' ASP . 23.3 p-10 -167.65 -128.95 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.369 -0.832 . . . . 0.0 110.008 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.1 11.54 2.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.065 -1.022 . . . . 0.0 110.284 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.444 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -139.93 -85.1 0.23 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.227 -0.921 . . . . 0.0 110.459 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.444 ' C ' ' O ' ' A' ' 7' ' ' ALA . 55.9 m -40.81 141.6 0.56 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.23 -0.919 . . . . 0.0 110.524 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.488 HD11 HG22 ' A' ' 9' ' ' ILE . 7.8 mt -128.47 146.74 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.23 -0.919 . . . . 0.0 110.008 179.529 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.474 ' O ' ' CA ' ' A' ' 1' ' ' VAL . 46.0 m -122.26 145.38 44.13 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.199 -0.938 . . . . 0.0 110.408 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.32 -173.53 1.32 Allowed 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 124.097 1.577 . . . . 0.0 110.258 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.498 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 2.5 m-20 -86.64 151.16 23.67 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.231 -0.918 . . . . 0.0 110.422 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.81 8.4 73.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 5.4 p -133.58 167.88 19.68 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.267 -1.137 . . . . 0.0 110.313 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.484 HG23 ' O ' ' A' ' 27' ' ' SER . 10.4 t -128.49 141.41 51.39 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 0.0 110.203 179.686 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.75 138.16 57.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.226 -0.921 . . . . 0.0 110.139 -179.883 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.522 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 2.4 t -148.64 138.33 22.08 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.214 -0.929 . . . . 0.0 110.289 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.514 HD21 ' N ' ' A' ' 19' ' ' SER . 0.0 OUTLIER -95.94 131.06 42.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.384 -0.823 . . . . 0.0 110.037 179.692 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.561 ' OG ' ' HB ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -78.41 169.79 19.18 Favored Pre-proline 0 C--N 1.3 -1.561 0 O-C-N 121.346 -0.846 . . . . 0.0 110.52 -179.817 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.613 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 37.6 Cg_endo -69.07 -13.62 36.74 Favored 'Trans proline' 0 C--N 1.301 -1.959 0 O-C-N 124.208 1.636 . . . . 0.0 109.996 179.588 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.613 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 2.1 m-85 -92.03 -11.44 35.94 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.444 -0.785 . . . . 0.0 109.445 178.67 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.48 24.04 14.98 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.561 ' HB ' ' OG ' ' A' ' 19' ' ' SER . 39.9 t -102.04 125.47 56.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.17 -1.194 . . . . 0.0 110.2 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.459 ' CH2' ' HB2' ' A' ' 18' ' ' LEU . 1.7 m95 -81.09 119.09 23.12 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.284 -0.885 . . . . 0.0 110.27 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.522 ' CE1' ' HB3' ' A' ' 17' ' ' SER . 30.8 p90 -140.14 168.1 20.59 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.067 -1.021 . . . . 0.0 110.503 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 10.2 m -94.82 111.32 23.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.302 -0.874 . . . . 0.0 110.271 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.484 ' O ' HG23 ' A' ' 15' ' ' THR . 0.2 OUTLIER -96.05 147.47 33.02 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.348 -0.845 . . . . 0.0 110.396 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -77.39 125.26 7.59 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 124.059 1.557 . . . . 0.0 110.455 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.429 ' O ' ' O ' ' A' ' 30' ' ' SER . 36.6 p90 -104.82 154.38 20.12 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.186 -0.946 . . . . 0.0 110.207 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 29' ' ' PHE . 75.0 m . . . . . 0 N--CA 1.492 1.629 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.305 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.41 ' O ' HG21 ' A' ' 1' ' ' VAL . 20.5 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.279 0.561 . . . . 0.0 110.261 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.481 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 26.5 mm -55.9 148.21 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.918 . . . . 0.0 110.143 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.508 ' CE1' HG12 ' A' ' 9' ' ' ILE . 1.9 m-70 -130.85 129.45 42.34 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.228 -0.92 . . . . 0.0 110.455 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.474 ' O ' ' N ' ' A' ' 6' ' ' ALA . 58.0 m -142.01 -175.2 4.32 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.285 -0.885 . . . . 0.0 110.036 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.489 ' HB2' ' CE2' ' A' ' 24' ' ' TRP . 4.5 t70 54.75 -88.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.168 -0.958 . . . . 0.0 110.218 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.474 ' N ' ' O ' ' A' ' 4' ' ' CYS . . . -171.9 -40.2 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.254 -0.904 . . . . 0.0 110.326 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.406 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -119.82 -59.22 1.83 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.2 -0.937 . . . . 0.0 110.308 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.406 ' C ' ' O ' ' A' ' 7' ' ' ALA . 6.9 m -43.77 151.81 0.19 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.195 -0.941 . . . . 0.0 110.318 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.508 HG12 ' CE1' ' A' ' 3' ' ' HIS . 12.8 mt -131.23 167.37 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.209 -0.932 . . . . 0.0 110.279 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.481 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 55.7 m -133.87 147.5 64.49 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.2 -0.938 . . . . 0.0 110.205 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.55 -177.02 3.07 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.055 1.555 . . . . 0.0 110.607 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -84.72 151.94 24.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.268 -0.895 . . . . 0.0 110.237 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.45 28.47 57.6 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.547 ' C ' ' CE2' ' A' ' 29' ' ' PHE . 5.3 p -149.41 166.89 27.73 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.28 -1.13 . . . . 0.0 110.38 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.607 ' HB ' ' CE1' ' A' ' 29' ' ' PHE . 13.1 t -121.92 155.47 35.41 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.337 -0.852 . . . . 0.0 110.295 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 74.0 m -82.22 144.6 30.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.924 . . . . 0.0 110.124 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.462 ' HB2' ' CZ ' ' A' ' 25' ' ' TYR . 62.6 m -154.37 160.75 41.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 110.416 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.582 ' HG ' ' CZ3' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -114.81 134.13 55.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.875 . . . . 0.0 110.179 179.585 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.523 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -74.07 172.56 8.25 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.304 -0.872 . . . . 0.0 110.382 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.592 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.5 Cg_endo -69.87 -11.48 30.79 Favored 'Trans proline' 0 C--N 1.302 -1.879 0 O-C-N 123.976 1.514 . . . . 0.0 110.023 -179.749 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.592 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.4 m-85 -103.51 0.82 31.52 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.433 -0.792 . . . . 0.0 109.643 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . 0.419 ' C ' HD23 ' A' ' 18' ' ' LEU . . . 90.17 27.84 19.57 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.564 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.523 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 34.2 t -94.96 123.71 47.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.309 -1.112 . . . . 0.0 110.304 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.582 ' CZ3' ' HG ' ' A' ' 18' ' ' LEU . 2.7 m95 -78.6 114.92 17.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.205 -0.934 . . . . 0.0 110.202 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.462 ' CZ ' ' HB2' ' A' ' 17' ' ' SER . 29.1 p90 -136.08 172.53 12.88 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.189 -0.945 . . . . 0.0 110.161 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 8.0 m -114.98 117.38 30.44 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.273 -0.892 . . . . 0.0 110.276 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.4 p -96.47 161.63 26.17 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.308 -0.87 . . . . 0.0 110.162 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -74.79 170.59 20.02 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.889 1.468 . . . . 0.0 110.527 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.607 ' CE1' ' HB ' ' A' ' 15' ' ' THR . 17.4 m-85 -98.47 87.45 3.85 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.281 -0.887 . . . . 0.0 110.169 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.2 p . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.185 179.994 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.455 ' O ' HG22 ' A' ' 1' ' ' VAL . 21.1 m . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 121.157 0.504 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.516 ' CG2' ' SG ' ' A' ' 16' ' ' CYS . 18.5 mm -54.28 164.84 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.231 -0.918 . . . . 0.0 109.996 179.776 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.514 ' O ' ' N ' ' A' ' 5' ' ' ASP . 5.5 m-70 -126.03 -19.47 4.78 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.121 -0.987 . . . . 0.0 110.734 -179.477 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.505 ' HB2' ' O ' ' A' ' 3' ' ' HIS . 9.3 m 66.07 -61.28 0.28 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.232 -0.917 . . . . 0.0 110.289 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.514 ' N ' ' O ' ' A' ' 3' ' ' HIS . 23.0 t0 -126.32 -56.44 1.42 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.218 -0.926 . . . . 0.0 110.279 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . 176.34 -32.48 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.304 -0.872 . . . . 0.0 110.22 179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.42 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -100.07 -77.97 0.52 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.227 -0.921 . . . . 0.0 110.244 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.476 HG22 ' O ' ' A' ' 24' ' ' TRP . 3.1 m -43.36 116.35 0.91 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.218 -0.926 . . . . 0.0 110.213 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 9.7 mt -97.28 145.4 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.227 -0.921 . . . . 0.0 110.206 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.486 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 7.4 m -124.51 149.89 63.08 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.238 -0.914 . . . . 0.0 110.108 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.473 ' O ' ' OG1' ' A' ' 14' ' ' THR . 43.4 Cg_endo -73.0 176.62 8.83 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 123.977 1.514 . . . . 0.0 110.493 -179.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -84.35 165.71 18.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.252 -0.905 . . . . 0.0 110.315 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.59 11.8 65.97 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.473 ' OG1' ' O ' ' A' ' 11' ' ' PRO . 9.1 p -127.47 172.59 10.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.28 -1.129 . . . . 0.0 110.265 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.5 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 12.4 t -125.94 152.79 45.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.275 -0.891 . . . . 0.0 110.283 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.516 ' SG ' ' CG2' ' A' ' 2' ' ' ILE . 98.0 m -82.11 136.0 35.23 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.303 -0.873 . . . . 0.0 110.24 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.549 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 1.0 OUTLIER -142.45 148.51 37.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -0.93 . . . . 0.0 110.27 179.996 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.52 ' HG ' ' CH2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -104.41 140.78 37.43 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.351 -0.843 . . . . 0.0 110.431 -179.864 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.51 ' N ' HD21 ' A' ' 18' ' ' LEU . 1.0 OUTLIER -86.38 171.98 9.25 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.325 -0.859 . . . . 0.0 110.454 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.569 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.5 Cg_endo -69.57 -14.67 37.04 Favored 'Trans proline' 0 C--N 1.3 -1.975 0 O-C-N 124.05 1.553 . . . . 0.0 109.905 179.444 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.569 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.1 m-85 -98.59 0.12 44.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.352 -0.842 . . . . 0.0 109.774 179.056 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.74 30.8 17.11 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 68.4 t -100.65 123.99 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.227 -1.16 . . . . 0.0 110.223 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.52 ' CH2' ' HG ' ' A' ' 18' ' ' LEU . 3.5 m95 -83.36 114.07 21.17 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.28 -0.887 . . . . 0.0 110.036 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.549 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 42.1 p90 -132.65 172.01 13.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 110.337 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.4 m -102.47 132.7 48.33 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.349 -0.845 . . . . 0.0 110.112 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.43 ' O ' HG23 ' A' ' 15' ' ' THR . 0.3 OUTLIER -109.75 137.63 20.46 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.13 -0.981 . . . . 0.0 110.097 179.802 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -72.92 109.39 2.8 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 124.009 1.531 . . . . 0.0 110.555 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.567 ' O ' ' CG ' ' A' ' 29' ' ' PHE . 2.9 p90 -129.31 125.28 36.39 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 110.371 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.259 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.526 HG22 ' CG2' ' A' ' 9' ' ' ILE . 34.9 m . . . . . 0 N--CA 1.496 1.832 0 CA-C-O 121.246 0.546 . . . . 0.0 110.346 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 13.1 mm -50.53 158.13 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.146 -0.972 . . . . 0.0 109.75 179.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.545 ' O ' ' N ' ' A' ' 5' ' ' ASP . 1.1 m-70 -136.7 -48.03 0.62 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.09 -1.006 . . . . 0.0 110.536 -179.446 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.495 ' HB2' ' O ' ' A' ' 3' ' ' HIS . 81.0 m 59.0 -77.11 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.304 -0.872 . . . . 0.0 110.1 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 3' ' ' HIS . 3.0 t70 -78.74 -135.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.231 -0.918 . . . . 0.0 110.013 179.468 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.14 8.37 4.37 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.127 -0.983 . . . . 0.0 110.367 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.429 ' O ' ' CG1' ' A' ' 9' ' ' ILE . . . -139.91 -84.72 0.23 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.225 -0.922 . . . . 0.0 110.49 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.447 HG23 ' HB3' ' A' ' 24' ' ' TRP . 7.1 m -40.89 100.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.336 -0.852 . . . . 0.0 110.511 -179.573 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.535 HG12 ' CE1' ' A' ' 3' ' ' HIS . 6.9 mt -89.42 169.56 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.343 -0.848 . . . . 0.0 110.211 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.464 ' O ' ' HB ' ' A' ' 1' ' ' VAL . 3.0 m -143.15 162.64 41.99 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.213 -0.929 . . . . 0.0 110.399 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -80.0 -159.59 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.037 1.546 . . . . 0.0 110.464 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.467 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 5.6 m-20 -107.13 150.1 26.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.204 -0.935 . . . . 0.0 110.286 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 86.12 29.12 26.32 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.472 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 0.9 OUTLIER -144.12 170.53 15.77 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -1.164 . . . . 0.0 110.312 179.871 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.453 ' O ' HG21 ' A' ' 15' ' ' THR . 9.5 t -125.61 142.48 51.49 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.209 -0.932 . . . . 0.0 110.367 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 3.3 m -65.26 142.62 58.22 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.325 -0.859 . . . . 0.0 110.271 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 14.3 m -158.84 130.43 6.45 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.275 -0.891 . . . . 0.0 110.056 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.523 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -94.45 136.78 34.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 110.45 -179.796 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.485 ' N ' HD21 ' A' ' 18' ' ' LEU . 1.1 p -79.81 169.54 19.67 Favored Pre-proline 0 N--CA 1.487 1.412 0 O-C-N 121.275 -0.891 . . . . 0.0 110.256 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.573 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 40.3 Cg_endo -69.67 -6.76 19.33 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 O-C-N 124.056 1.556 . . . . 0.0 110.183 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.573 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.7 m-85 -106.2 -3.0 21.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.331 -0.856 . . . . 0.0 109.965 179.295 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.18 13.74 47.87 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.2 113.82 24.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.137 -1.213 . . . . 0.0 110.012 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.523 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 0.0 OUTLIER -76.98 116.92 18.07 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.336 -0.853 . . . . 0.0 110.324 -179.726 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 8.1 p90 -143.39 176.11 9.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.274 -0.891 . . . . 0.0 110.241 179.737 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.472 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 58.0 m -124.47 138.11 54.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 110.193 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.2 t -107.89 150.39 40.25 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.24 -0.913 . . . . 0.0 110.705 -179.107 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -77.29 121.03 5.52 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 124.13 1.595 . . . . 0.0 110.405 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.455 ' CD1' ' HB2' ' A' ' 30' ' ' SER . 42.3 p90 -111.95 163.93 13.68 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.157 -0.964 . . . . 0.0 110.314 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' SER . . . . . 0.455 ' HB2' ' CD1' ' A' ' 29' ' ' PHE . 5.0 m . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 118.007 -0.996 . . . . 0.0 110.286 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.443 ' HB ' HG23 ' A' ' 9' ' ' ILE . 19.5 m . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.317 0.58 . . . . 0.0 110.249 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.538 ' N ' ' O ' ' A' ' 10' ' ' CYS . 37.4 mm -85.22 156.98 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.25 -0.907 . . . . 0.0 110.134 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.412 ' CE1' HG12 ' A' ' 9' ' ' ILE . 4.0 m-70 -139.48 118.94 12.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.281 -0.887 . . . . 0.0 110.24 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 13.5 m -133.86 10.64 3.95 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.259 -0.901 . . . . 0.0 110.385 -179.758 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.46 ' OD1' ' N ' ' A' ' 6' ' ' ALA . 0.7 OUTLIER -130.96 -101.12 0.3 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.184 -0.948 . . . . 0.0 110.191 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.46 ' N ' ' OD1' ' A' ' 5' ' ' ASP . . . -162.8 -43.15 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.061 -1.024 . . . . 0.0 110.065 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.72 -51.51 2.83 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 110.088 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 52.5 m -57.59 161.77 3.39 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.333 -0.854 . . . . 0.0 110.223 179.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.475 HD11 HG22 ' A' ' 9' ' ' ILE . 12.7 mt -140.7 172.71 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.259 -0.901 . . . . 0.0 110.055 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.538 ' O ' ' N ' ' A' ' 2' ' ' ILE . 56.8 m -143.22 137.87 15.13 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.182 -0.949 . . . . 0.0 110.521 -179.706 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.28 -166.08 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.939 1.494 . . . . 0.0 110.267 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 52.2 m-20 -90.08 147.93 23.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.198 -0.939 . . . . 0.0 110.199 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.45 18.63 60.05 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.41 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 0.6 OUTLIER -136.06 171.26 14.74 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.245 -1.15 . . . . 0.0 110.306 179.967 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.456 HG21 ' O ' ' A' ' 27' ' ' SER . 15.3 t -132.55 140.88 48.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.236 -0.915 . . . . 0.0 110.261 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 29.3 m -65.26 131.72 47.23 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.267 -0.895 . . . . 0.0 110.136 179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -156.54 138.2 14.15 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.098 -1.001 . . . . 0.0 110.46 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.426 HD22 ' C ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -88.72 143.49 26.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.324 -0.86 . . . . 0.0 110.287 179.726 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.455 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -82.24 169.54 17.99 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.318 -0.864 . . . . 0.0 110.478 -179.699 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.562 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.3 Cg_endo -69.02 -14.43 38.43 Favored 'Trans proline' 0 C--N 1.302 -1.909 0 O-C-N 124.135 1.597 . . . . 0.0 110.166 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.562 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 2.5 m-85 -100.19 1.62 42.15 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.379 -0.826 . . . . 0.0 109.614 178.884 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.77 29.45 15.84 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.455 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 76.5 t -103.75 123.49 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.246 -1.149 . . . . 0.0 110.445 -179.667 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.471 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.9 OUTLIER -76.86 118.74 19.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.249 -0.907 . . . . 0.0 110.312 179.906 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.524 ' CE2' ' OG ' ' A' ' 27' ' ' SER . 40.7 p90 -144.28 168.6 19.69 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.084 -1.01 . . . . 0.0 110.681 179.574 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.41 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 3.4 m -106.09 117.93 35.31 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.446 -0.784 . . . . 0.0 109.649 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.524 ' OG ' ' CE2' ' A' ' 25' ' ' TYR . 0.7 OUTLIER -93.81 142.65 25.36 Favored Pre-proline 0 C--N 1.303 -1.455 0 O-C-N 121.174 -0.954 . . . . 0.0 110.716 -178.943 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -75.69 126.19 9.36 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 124.135 1.597 . . . . 0.0 110.46 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.542 ' CG ' ' O ' ' A' ' 29' ' ' PHE . 34.6 p90 -123.67 118.33 27.01 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.242 -0.911 . . . . 0.0 110.268 179.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.331 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.458 HG22 HG22 ' A' ' 9' ' ' ILE . 29.1 m . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 121.266 0.555 . . . . 0.0 110.192 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.485 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 32.7 mm -77.67 146.49 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.213 -0.929 . . . . 0.0 110.312 -179.849 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.58 ' CE1' HG12 ' A' ' 9' ' ' ILE . 3.9 m-70 -138.04 83.29 1.97 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.315 -0.866 . . . . 0.0 110.089 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -72.32 -32.01 66.17 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.301 -0.874 . . . . 0.0 110.441 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.488 ' OD2' ' NE1' ' A' ' 24' ' ' TRP . 0.6 OUTLIER -116.34 -89.64 0.57 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.18 -0.95 . . . . 0.0 110.357 -179.849 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -171.89 -32.84 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.162 -0.962 . . . . 0.0 110.354 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -99.31 -83.63 0.42 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 110.234 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.449 HG22 ' O ' ' A' ' 24' ' ' TRP . 62.9 m -52.17 106.55 0.15 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.225 -0.922 . . . . 0.0 110.158 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.58 HG12 ' CE1' ' A' ' 3' ' ' HIS . 6.2 mt -90.65 165.02 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.191 -0.943 . . . . 0.0 110.335 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.485 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 99.4 m -133.73 140.74 37.57 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.267 -0.896 . . . . 0.0 110.057 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.0 173.81 13.43 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.901 1.474 . . . . 0.0 110.424 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.474 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 1.1 m-20 -77.12 152.5 34.91 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.281 -0.887 . . . . 0.0 110.472 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' A' ' 29' ' ' PHE . . . 90.55 -8.27 80.07 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.0 p -116.95 166.52 12.07 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.183 -1.186 . . . . 0.0 110.151 179.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.501 ' O ' ' CG2' ' A' ' 15' ' ' THR . 14.8 t -123.54 119.36 29.7 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.333 -0.854 . . . . 0.0 110.375 179.683 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . 0.457 ' O ' ' OG ' ' A' ' 17' ' ' SER . 20.6 p -50.34 158.36 0.59 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.214 -0.929 . . . . 0.0 110.18 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.574 ' HB2' ' CZ ' ' A' ' 25' ' ' TYR . 42.4 m -167.44 146.64 5.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.198 -0.938 . . . . 0.0 110.022 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.56 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -108.6 134.73 50.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 110.485 -179.654 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.468 ' HB3' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -78.53 167.79 32.45 Favored Pre-proline 0 C--N 1.304 -1.399 0 O-C-N 121.34 -0.85 . . . . 0.0 109.989 179.543 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.584 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 37.9 Cg_endo -69.56 -11.92 32.15 Favored 'Trans proline' 0 C--N 1.3 -2.009 0 O-C-N 124.022 1.538 . . . . 0.0 109.942 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.584 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.2 m-85 -97.79 -2.31 41.32 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.399 -0.813 . . . . 0.0 109.75 178.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.85 21.17 29.07 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.468 ' HB ' ' HB3' ' A' ' 19' ' ' SER . 75.6 t -91.54 119.58 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.273 -1.133 . . . . 0.0 110.38 -179.744 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.56 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 0.6 OUTLIER -84.01 126.66 33.26 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.266 -0.896 . . . . 0.0 110.181 179.765 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.574 ' CZ ' ' HB2' ' A' ' 17' ' ' SER . 32.6 p90 -147.75 174.82 11.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.215 -0.928 . . . . 0.0 110.246 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 4.0 m -114.18 107.65 15.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.261 -0.9 . . . . 0.0 110.223 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.476 ' HB3' ' CG2' ' A' ' 15' ' ' THR . 9.8 t -70.59 144.01 90.78 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.192 -0.943 . . . . 0.0 109.897 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -76.17 170.61 19.7 Favored 'Trans proline' 0 C--N 1.299 -2.053 0 O-C-N 123.817 1.43 . . . . 0.0 110.918 -179.363 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 13' ' ' GLY . 2.4 m-85 -97.32 83.59 3.32 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.459 -0.776 . . . . 0.0 110.201 179.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.708 0 CA-C-O 117.999 -1.0 . . . . 0.0 110.248 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' VAL . . . . . 0.447 HG21 ' O ' ' A' ' 1' ' ' VAL . 5.9 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.233 0.539 . . . . 0.0 110.331 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.462 ' O ' ' N ' ' A' ' 10' ' ' CYS . 30.1 mm -44.1 152.87 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.273 -0.892 . . . . 0.0 110.223 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.565 ' O ' ' N ' ' A' ' 5' ' ' ASP . 4.0 m-70 -120.38 -64.69 1.22 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.184 -0.947 . . . . 0.0 110.336 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' CYS . . . . . 0.52 ' HB3' ' O ' ' A' ' 3' ' ' HIS . 1.7 t 59.65 -72.29 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.511 -0.743 . . . . 0.0 110.386 179.753 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.565 ' N ' ' O ' ' A' ' 3' ' ' HIS . 81.1 m-20 -54.75 -163.67 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.178 -0.951 . . . . 0.0 110.297 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -103.92 -19.93 14.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.12 -0.988 . . . . 0.0 110.547 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . 0.426 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -135.72 -79.69 0.42 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.257 -0.902 . . . . 0.0 110.557 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 7' ' ' ALA . 97.5 m -41.24 132.13 2.61 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.344 -0.847 . . . . 0.0 110.387 -179.636 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . 0.531 HG12 ' CE1' ' A' ' 3' ' ' HIS . 0.9 OUTLIER -98.46 175.78 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.265 -0.897 . . . . 0.0 110.048 179.972 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . 0.462 ' N ' ' O ' ' A' ' 2' ' ' ILE . 1.5 m -130.0 132.9 24.42 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 110.329 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . 0.495 ' O ' ' O ' ' A' ' 12' ' ' ASP . 48.5 Cg_endo -77.78 154.42 30.3 Favored 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.009 1.531 . . . . 0.0 110.02 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.495 ' O ' ' O ' ' A' ' 11' ' ' PRO . 7.3 m-20 48.66 179.22 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.164 -0.96 . . . . 0.0 110.139 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' A' ' 14' ' ' THR . . . -55.42 -64.19 4.6 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 179.699 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.52 ' O ' ' O ' ' A' ' 13' ' ' GLY . 0.8 OUTLIER 44.39 -179.24 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.545 -0.973 . . . . 0.0 110.963 179.294 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' THR . . . . . 0.514 ' CG2' ' O ' ' A' ' 27' ' ' SER . 9.9 t -136.41 155.58 49.82 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.292 -0.88 . . . . 0.0 110.195 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -69.8 127.85 34.35 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.269 -0.894 . . . . 0.0 110.225 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.584 ' O ' ' CD1' ' A' ' 25' ' ' TYR . 8.2 m -142.61 125.09 15.69 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.213 -0.929 . . . . 0.0 110.19 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.564 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -101.66 137.59 39.77 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.199 -0.938 . . . . 0.0 110.192 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.489 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.2 p -79.18 167.13 37.01 Favored Pre-proline 0 C--N 1.303 -1.454 0 O-C-N 121.315 -0.866 . . . . 0.0 110.423 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.575 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 39.0 Cg_endo -69.61 -7.93 22.29 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 O-C-N 124.041 1.548 . . . . 0.0 110.118 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' TYR . . . . . 0.575 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -103.89 -2.54 26.06 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.476 -0.765 . . . . 0.0 109.639 178.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.9 24.97 15.77 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.489 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 72.2 t -95.29 114.85 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.263 -1.139 . . . . 0.0 110.402 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' TRP . . . . . 0.564 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -76.62 123.46 26.14 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.327 -0.858 . . . . 0.0 110.379 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' TYR . . . . . 0.584 ' CD1' ' O ' ' A' ' 17' ' ' SER . 22.9 p90 -147.58 173.35 12.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.143 -0.973 . . . . 0.0 110.29 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' CYS . . . . . 0.443 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 3.4 m -106.11 147.05 29.42 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.374 -0.829 . . . . 0.0 110.221 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.514 ' O ' ' CG2' ' A' ' 15' ' ' THR . 0.9 OUTLIER -130.71 149.26 73.08 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.9 . . . . 0.0 110.346 179.951 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -74.06 127.67 11.58 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 O-C-N 124.098 1.578 . . . . 0.0 110.312 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -107.45 171.79 7.19 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.2 -0.938 . . . . 0.0 110.324 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.7 t . . . . . 0 N--CA 1.491 1.576 0 CA-C-O 118.045 -0.978 . . . . 0.0 110.264 -179.88 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.521 ' HB ' HG22 ' A' ' 9' ' ' ILE . 26.9 m . . . . . 0 N--CA 1.493 1.713 0 CA-C-O 121.278 0.561 . . . . 0.0 110.264 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.504 HG22 ' N ' ' A' ' 3' ' ' HIS . 2.0 mp -87.54 166.32 1.94 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.212 -0.93 . . . . 0.0 110.276 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.504 ' N ' HG22 ' A' ' 2' ' ' ILE . 9.5 m-70 -141.75 161.01 39.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.221 -0.924 . . . . 0.0 110.3 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 26.8 p -161.05 -36.74 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.206 -0.934 . . . . 0.0 110.254 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.653 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 13.5 m-20 -93.91 -78.93 0.42 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.225 -0.922 . . . . 0.0 110.19 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.653 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 171.72 -31.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.282 -0.886 . . . . 0.0 110.144 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.65 -61.49 1.7 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.311 -0.868 . . . . 0.0 110.175 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.8 m -55.22 150.45 11.0 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.246 -0.909 . . . . 0.0 110.14 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.521 HG22 ' HB ' ' A' ' 1' ' ' VAL . 8.4 mt -119.84 172.3 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -0.927 . . . . 0.0 110.245 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.467 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 19.3 t -131.51 136.64 28.89 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.248 -0.907 . . . . 0.0 110.18 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -72.46 -161.1 0.1 OUTLIER 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.978 1.514 . . . . 0.0 110.569 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.412 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 0.9 OUTLIER -96.0 150.17 20.77 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.23 -0.919 . . . . 0.0 110.414 -179.745 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.658 ' O ' HG23 ' A' ' 14' ' ' THR . . . 64.81 53.29 35.42 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.658 HG23 ' O ' ' A' ' 13' ' ' GLY . 0.9 OUTLIER -159.39 170.67 21.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.203 -1.175 . . . . 0.0 110.378 179.931 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.481 ' O ' HG23 ' A' ' 15' ' ' THR . 12.2 t -130.88 131.9 44.82 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.346 -0.846 . . . . 0.0 110.235 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.2 132.76 43.97 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.292 -0.88 . . . . 0.0 110.302 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -152.12 157.88 42.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 110.245 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.465 ' HA ' HD23 ' A' ' 18' ' ' LEU . 0.2 OUTLIER -105.87 136.22 45.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.313 -0.867 . . . . 0.0 110.288 -179.944 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.508 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.9 OUTLIER -78.31 165.37 50.67 Favored Pre-proline 0 N--CA 1.488 1.446 0 O-C-N 121.24 -0.912 . . . . 0.0 110.213 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.589 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.9 Cg_endo -69.39 -11.61 31.72 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 O-C-N 124.038 1.546 . . . . 0.0 110.04 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.589 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.7 m-85 -101.54 5.2 41.69 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.476 -0.765 . . . . 0.0 109.553 178.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.74 21.16 51.82 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.508 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 60.6 t -93.9 123.08 45.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.32 -1.106 . . . . 0.0 110.281 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.559 ' CE2' ' OD1' ' A' ' 5' ' ' ASP . 1.3 m95 -81.09 130.71 35.14 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.243 -0.911 . . . . 0.0 110.21 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.1 p90 -165.42 173.08 11.45 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.207 -0.933 . . . . 0.0 110.331 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.409 ' SG ' ' C ' ' A' ' 15' ' ' THR . 0.1 OUTLIER -109.19 137.22 47.41 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -0.924 . . . . 0.0 110.24 179.705 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.9 t -108.4 147.44 35.67 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.263 -0.898 . . . . 0.0 110.338 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.6 114.14 3.96 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.029 1.541 . . . . 0.0 110.476 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.48 ' CD1' ' C ' ' A' ' 29' ' ' PHE . 20.9 p90 . . . . . 0 N--CA 1.492 1.657 0 O-C-N 121.253 -0.905 . . . . 0.0 110.295 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.596 ' HB ' HG22 ' A' ' 9' ' ' ILE . 30.5 m . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 121.138 0.494 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.422 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 31.9 mm -105.3 157.17 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.251 -0.906 . . . . 0.0 110.572 -179.694 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.486 ' NE2' HG23 ' A' ' 9' ' ' ILE . 12.4 m-70 -134.53 125.75 27.95 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.277 -0.889 . . . . 0.0 110.061 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -113.41 -50.65 2.85 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 0.0 110.501 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.605 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 12.8 t70 -90.86 -70.01 0.7 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.261 -0.899 . . . . 0.0 110.479 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.605 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 175.17 -46.55 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.195 -0.941 . . . . 0.0 110.36 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -100.14 -20.07 16.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.204 -0.935 . . . . 0.0 110.342 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.7 m -82.84 140.72 32.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.303 -0.873 . . . . 0.0 110.266 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.596 HG22 ' HB ' ' A' ' 1' ' ' VAL . 4.3 mt -125.91 166.38 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.193 -0.942 . . . . 0.0 110.293 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 1' ' ' VAL . 10.0 m -147.3 155.6 46.32 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.265 -0.897 . . . . 0.0 109.958 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.96 -166.29 0.28 Allowed 'Trans proline' 0 C--N 1.303 -1.817 0 O-C-N 123.942 1.496 . . . . 0.0 110.373 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -95.56 152.26 18.59 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.266 -0.896 . . . . 0.0 110.313 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.2 12.07 84.95 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -124.3 170.14 11.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -1.141 . . . . 0.0 110.396 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 27' ' ' SER . 11.8 t -129.86 139.09 51.25 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.879 . . . . 0.0 110.249 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.3 p -62.69 134.61 56.56 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.275 -0.891 . . . . 0.0 110.353 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.401 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 4.7 m -153.91 133.71 13.03 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.299 -0.875 . . . . 0.0 110.21 179.76 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.476 ' HA ' HD23 ' A' ' 18' ' ' LEU . 0.4 OUTLIER -91.97 143.8 26.11 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -0.927 . . . . 0.0 110.301 -179.796 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.525 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -79.41 172.71 9.17 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.278 -0.888 . . . . 0.0 110.332 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.615 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.9 Cg_endo -69.87 -7.17 20.43 Favored 'Trans proline' 0 C--N 1.302 -1.885 0 O-C-N 124.167 1.614 . . . . 0.0 110.174 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.615 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 4.2 m-85 -109.51 -0.17 18.96 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.393 -0.817 . . . . 0.0 109.623 178.816 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.56 17.86 37.52 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.525 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 48.0 t -87.53 108.9 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.27 -1.135 . . . . 0.0 110.438 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.552 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -65.25 124.34 21.92 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.229 -0.919 . . . . 0.0 110.416 179.982 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.49 ' C ' ' CD1' ' A' ' 25' ' ' TYR . 15.5 p90 -148.25 171.66 15.6 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.165 -0.959 . . . . 0.0 110.162 179.397 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 4.3 m -106.35 118.02 35.55 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.177 -0.952 . . . . 0.0 110.257 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.772 ' O ' HG22 ' A' ' 15' ' ' THR . 23.3 t -84.82 139.22 37.42 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.265 -0.897 . . . . 0.0 110.318 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -77.17 120.68 5.45 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 124.063 1.56 . . . . 0.0 110.397 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.489 ' CD1' ' C ' ' A' ' 29' ' ' PHE . 14.4 p90 . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.183 -0.948 . . . . 0.0 110.223 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.501 HG21 HG21 ' A' ' 9' ' ' ILE . 29.8 m . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 121.202 0.525 . . . . 0.0 110.348 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.505 ' N ' ' O ' ' A' ' 10' ' ' CYS . 45.4 mm -93.17 143.13 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 110.2 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -122.81 109.63 14.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 110.119 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -149.17 22.9 0.95 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.362 -0.836 . . . . 0.0 110.215 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.495 ' OD1' ' CH2' ' A' ' 24' ' ' TRP . 75.0 m-20 -137.32 -166.18 1.89 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.206 -0.934 . . . . 0.0 110.173 179.742 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.51 -59.38 2.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 110.276 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -136.33 -46.33 0.63 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 110.26 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.462 ' CB ' ' HB3' ' A' ' 24' ' ' TRP . 19.1 m -45.27 112.05 0.4 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.172 -0.955 . . . . 0.0 110.1 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.501 HG21 HG21 ' A' ' 1' ' ' VAL . 12.3 mt -85.82 167.53 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.292 -0.88 . . . . 0.0 110.235 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.505 ' O ' ' N ' ' A' ' 2' ' ' ILE . 31.0 m -129.84 141.83 43.23 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.249 -0.907 . . . . 0.0 110.324 -179.754 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.51 -166.6 0.34 Allowed 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.957 1.504 . . . . 0.0 110.267 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.9 148.69 22.03 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.237 -0.914 . . . . 0.0 110.348 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.98 0.94 89.81 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.2 p -117.58 170.24 8.91 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.137 -1.213 . . . . 0.0 110.399 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.802 HG22 ' O ' ' A' ' 27' ' ' SER . 14.8 t -134.32 144.69 48.44 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.159 -0.963 . . . . 0.0 110.503 -179.697 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -52.4 140.62 21.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.308 -0.87 . . . . 0.0 110.402 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.533 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 9.0 t -160.23 124.39 3.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.262 -0.899 . . . . 0.0 110.235 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.462 HD23 ' O ' ' A' ' 23' ' ' VAL . 0.1 OUTLIER -100.85 117.95 35.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.224 -0.922 . . . . 0.0 110.425 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.483 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -56.07 162.13 3.16 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.246 -0.909 . . . . 0.0 110.139 179.637 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.607 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.2 Cg_endo -69.35 -6.82 19.32 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 124.009 1.531 . . . . 0.0 110.116 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.607 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.4 m-85 -100.31 -5.97 26.61 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.423 -0.798 . . . . 0.0 109.688 179.001 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 99.21 17.44 27.13 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.483 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 67.4 t -89.97 115.36 29.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.266 -1.138 . . . . 0.0 110.298 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.534 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -74.08 125.79 29.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.357 -0.84 . . . . 0.0 110.37 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.533 ' CE1' ' HB3' ' A' ' 17' ' ' SER . 8.8 p90 -154.47 174.52 14.79 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 110.282 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.9 m -115.54 116.68 28.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.262 -0.899 . . . . 0.0 110.132 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.802 ' O ' HG22 ' A' ' 15' ' ' THR . 3.3 t -84.86 134.59 41.32 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.274 -0.891 . . . . 0.0 110.402 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -74.48 118.08 5.21 Favored 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.003 1.528 . . . . 0.0 110.423 179.724 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.404 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 24.5 p90 . . . . . 0 N--CA 1.492 1.654 0 O-C-N 121.186 -0.946 . . . . 0.0 110.24 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.533 ' O ' HG23 ' A' ' 1' ' ' VAL . 30.1 m . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.29 0.567 . . . . 0.0 110.259 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.528 ' N ' ' O ' ' A' ' 10' ' ' CYS . 40.5 mm -45.38 155.69 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.203 -0.936 . . . . 0.0 110.054 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.466 ' O ' ' N ' ' A' ' 5' ' ' ASP . 1.8 m-70 -130.64 -60.59 0.98 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.115 -0.991 . . . . 0.0 110.575 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.464 ' CB ' ' O ' ' A' ' 3' ' ' HIS . 0.5 OUTLIER 66.75 -67.97 0.15 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.234 -0.916 . . . . 0.0 110.268 -179.776 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.502 ' OD2' ' N ' ' A' ' 8' ' ' THR . 9.9 p-10 -80.88 -138.83 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 0.0 110.1 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -128.56 -6.21 5.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.953 . . . . 0.0 110.392 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -137.13 -65.54 0.54 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.213 -0.929 . . . . 0.0 110.203 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.502 ' N ' ' OD2' ' A' ' 5' ' ' ASP . 5.1 m -48.7 111.95 0.54 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.234 -0.917 . . . . 0.0 110.272 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.495 HG22 ' HB ' ' A' ' 1' ' ' VAL . 6.0 mt -90.83 151.74 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.21 -0.931 . . . . 0.0 110.128 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.528 ' O ' ' N ' ' A' ' 2' ' ' ILE . 23.7 m -127.13 139.68 35.77 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.17 -0.956 . . . . 0.0 110.298 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -74.91 -161.18 0.12 Allowed 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 124.02 1.537 . . . . 0.0 110.362 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -95.5 150.61 20.12 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.284 -0.885 . . . . 0.0 110.304 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.1 12.95 80.17 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 1.2 p -121.63 169.39 10.75 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.199 -1.177 . . . . 0.0 110.447 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.695 HG22 ' O ' ' A' ' 27' ' ' SER . 12.6 t -131.93 157.09 44.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.28 -0.888 . . . . 0.0 110.288 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.4 m -58.3 127.82 34.05 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.287 -0.883 . . . . 0.0 109.861 179.469 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.573 ' HB3' ' CE2' ' A' ' 25' ' ' TYR . 1.3 t -141.72 124.26 15.85 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.939 . . . . 0.0 110.684 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.586 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.1 OUTLIER -109.03 126.99 53.72 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.385 -0.822 . . . . 0.0 110.051 179.201 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.518 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -67.9 163.33 50.99 Favored Pre-proline 0 C--N 1.301 -1.513 0 O-C-N 121.217 -0.927 . . . . 0.0 110.284 180.0 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.603 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.0 Cg_endo -69.08 -8.59 24.01 Favored 'Trans proline' 0 C--N 1.302 -1.879 0 O-C-N 124.111 1.585 . . . . 0.0 110.126 179.712 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.603 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.6 m-85 -100.68 -1.04 36.23 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.372 -0.83 . . . . 0.0 109.746 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.3 17.44 39.77 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.518 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 94.0 t -91.03 112.47 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.408 -1.054 . . . . 0.0 110.172 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.586 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 2.7 m95 -71.46 142.31 50.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.259 -0.901 . . . . 0.0 110.273 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.573 ' CE2' ' HB3' ' A' ' 17' ' ' SER . 24.6 p90 -170.23 174.12 5.49 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.277 -0.889 . . . . 0.0 110.267 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.497 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 2.6 m -106.81 141.81 37.45 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.247 -0.908 . . . . 0.0 110.285 -179.132 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.695 ' O ' HG22 ' A' ' 15' ' ' THR . 0.9 OUTLIER -118.91 141.95 31.03 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.217 -0.927 . . . . 0.0 110.208 179.784 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -74.61 104.3 1.85 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 124.081 1.569 . . . . 0.0 110.531 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.59 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 8.2 p90 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.212 -0.93 . . . . 0.0 110.294 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.653 ' HB ' HG22 ' A' ' 9' ' ' ILE . 30.8 m . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.323 0.582 . . . . 0.0 110.216 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.526 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 36.4 mm -83.55 148.18 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.219 -0.925 . . . . 0.0 110.307 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.9 m80 -118.79 126.41 51.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.175 -0.953 . . . . 0.0 110.398 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 26.9 m -80.28 -68.94 0.63 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.297 -0.877 . . . . 0.0 110.275 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -104.63 -90.27 0.4 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.278 -0.889 . . . . 0.0 110.163 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -146.66 10.28 1.06 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.289 -0.882 . . . . 0.0 110.393 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.435 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -140.11 -76.27 0.33 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.206 -0.934 . . . . 0.0 110.318 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.689 HG21 ' HB3' ' A' ' 24' ' ' TRP . 8.6 m -41.63 147.84 0.17 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.31 -0.869 . . . . 0.0 110.364 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.653 HG22 ' HB ' ' A' ' 1' ' ' VAL . 15.2 mt -131.71 169.61 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.279 -0.888 . . . . 0.0 110.129 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.526 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 63.2 m -145.67 146.27 28.69 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.156 -0.965 . . . . 0.0 110.327 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -73.02 -175.02 1.74 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.012 1.532 . . . . 0.0 110.472 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -84.83 156.87 21.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.239 -0.913 . . . . 0.0 110.226 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.15 3.52 90.54 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.0 p -127.1 170.27 12.53 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.238 -1.154 . . . . 0.0 110.213 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 27' ' ' SER . 9.0 t -128.2 156.0 43.62 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.218 -0.926 . . . . 0.0 110.349 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.3 m -73.29 128.83 36.6 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.278 -0.888 . . . . 0.0 110.176 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.414 ' OG ' ' CZ ' ' A' ' 25' ' ' TYR . 32.9 t -137.19 130.2 30.69 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.28 -0.887 . . . . 0.0 110.243 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.595 ' HG ' ' CE2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -105.19 106.38 16.85 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.186 -0.946 . . . . 0.0 110.294 179.815 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.508 ' HB3' ' HB ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -46.18 157.81 0.4 Allowed Pre-proline 0 C--N 1.301 -1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 110.218 179.718 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.606 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.0 Cg_endo -68.69 -11.66 32.49 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 124.041 1.548 . . . . 0.0 110.026 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.606 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.0 m-85 -93.24 -8.71 41.49 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.456 -0.777 . . . . 0.0 109.641 178.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 100.8 19.9 16.14 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.508 ' HB ' ' HB3' ' A' ' 19' ' ' SER . 61.2 t -94.97 115.91 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.236 -1.155 . . . . 0.0 110.123 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.689 ' HB3' HG21 ' A' ' 8' ' ' THR . 0.2 OUTLIER -77.84 126.78 31.37 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.335 -0.853 . . . . 0.0 110.503 -179.525 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.414 ' CZ ' ' OG ' ' A' ' 17' ' ' SER . 28.0 p90 -154.72 171.69 19.14 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.917 . . . . 0.0 110.125 179.304 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.3 m -106.45 135.6 47.67 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.216 -0.927 . . . . 0.0 110.068 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.772 ' O ' HG22 ' A' ' 15' ' ' THR . 12.0 t -115.4 143.71 30.97 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.204 -0.935 . . . . 0.0 110.324 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.73 125.02 9.68 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 124.034 1.544 . . . . 0.0 110.4 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.508 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 14.8 p90 . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.305 -0.872 . . . . 0.0 110.219 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.618 ' HB ' HG22 ' A' ' 9' ' ' ILE . 23.6 m . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.252 0.549 . . . . 0.0 110.308 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.502 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 34.2 mm -88.46 143.17 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.166 -0.959 . . . . 0.0 110.114 179.552 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.593 ' NE2' HG23 ' A' ' 9' ' ' ILE . 7.3 m-70 -129.17 119.51 24.21 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.193 -0.942 . . . . 0.0 110.598 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 87.1 m -124.3 11.76 8.76 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.986 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -150.29 -90.23 0.07 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.392 -0.818 . . . . 0.0 110.207 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -176.09 -32.39 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.16 -0.963 . . . . 0.0 110.244 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.482 ' O ' ' CG1' ' A' ' 9' ' ' ILE . . . -105.38 -75.5 0.63 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.2 -0.938 . . . . 0.0 110.258 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 42.8 m -43.47 139.74 1.95 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.24 -0.913 . . . . 0.0 110.394 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.618 HG22 ' HB ' ' A' ' 1' ' ' VAL . 4.4 mt -135.85 147.69 28.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 0.0 110.217 179.788 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.528 ' O ' ' CB ' ' A' ' 1' ' ' VAL . 98.1 m -111.34 148.69 39.29 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.305 -0.872 . . . . 0.0 109.982 179.726 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.43 ' O ' ' CG ' ' A' ' 12' ' ' ASP . 45.4 Cg_endo -74.7 -90.34 0.01 OUTLIER 'Trans proline' 0 C--N 1.302 -1.869 0 O-C-N 123.846 1.445 . . . . 0.0 110.335 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.43 ' CG ' ' O ' ' A' ' 11' ' ' PRO . 21.1 m-20 -158.86 164.28 35.86 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.371 -0.831 . . . . 0.0 110.181 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.32 13.26 48.92 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.472 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 1.3 p -124.07 169.74 11.37 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.217 -1.166 . . . . 0.0 110.308 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.642 HG22 ' O ' ' A' ' 27' ' ' SER . 8.9 t -129.59 153.81 47.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.141 -0.974 . . . . 0.0 110.494 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 60.2 m -63.86 127.47 31.52 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.262 -0.899 . . . . 0.0 110.147 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.514 ' HB3' ' CE2' ' A' ' 25' ' ' TYR . 10.7 t -138.9 133.99 32.63 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 110.265 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.449 HD23 ' HA ' ' A' ' 18' ' ' LEU . 0.2 OUTLIER -99.34 135.89 40.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.169 -0.957 . . . . 0.0 110.316 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.509 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.4 OUTLIER -79.06 166.13 44.16 Favored Pre-proline 0 C--N 1.303 -1.415 0 O-C-N 121.325 -0.859 . . . . 0.0 110.243 -179.992 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.585 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.9 Cg_endo -69.39 -10.73 29.63 Favored 'Trans proline' 0 C--N 1.301 -1.951 0 O-C-N 124.057 1.556 . . . . 0.0 110.022 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.585 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -104.06 -0.51 28.65 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.429 -0.794 . . . . 0.0 109.667 179.007 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.11 15.32 48.72 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.509 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 92.3 t -87.0 119.15 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.292 -1.122 . . . . 0.0 110.191 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.498 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.6 OUTLIER -77.75 128.16 33.59 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 110.458 -179.747 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.514 ' CE2' ' HB3' ' A' ' 17' ' ' SER . 37.1 p90 -152.74 172.52 16.56 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.27 -0.894 . . . . 0.0 110.086 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.472 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 4.0 m -101.92 141.42 34.79 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.209 -0.932 . . . . 0.0 110.193 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.642 ' O ' HG22 ' A' ' 15' ' ' THR . 3.4 t -116.16 141.7 28.17 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.173 -0.954 . . . . 0.0 110.389 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -75.38 129.27 11.86 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.061 1.558 . . . . 0.0 110.488 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 43.6 p90 . . . . . 0 N--CA 1.492 1.65 0 O-C-N 121.223 -0.923 . . . . 0.0 110.214 -179.886 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.696 ' HB ' HG22 ' A' ' 9' ' ' ILE . 28.6 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.224 0.535 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.459 ' H ' HD12 ' A' ' 2' ' ' ILE . 2.5 mp -50.89 160.6 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.242 -0.911 . . . . 0.0 110.147 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.409 ' N ' HG22 ' A' ' 2' ' ' ILE . 4.4 m-70 -148.12 89.43 1.73 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.195 -0.941 . . . . 0.0 110.354 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 63.9 m -92.59 -41.39 10.25 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.265 -0.897 . . . . 0.0 110.091 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.708 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 8.3 t70 -85.14 -86.57 0.13 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.269 -0.894 . . . . 0.0 110.217 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.708 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 170.31 -27.66 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.188 -0.945 . . . . 0.0 110.354 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.439 ' O ' ' CG1' ' A' ' 9' ' ' ILE . . . -105.01 -81.51 0.53 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.174 -0.954 . . . . 0.0 110.335 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.485 ' C ' ' CG1' ' A' ' 9' ' ' ILE . 89.5 m -41.18 155.4 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.292 -0.88 . . . . 0.0 110.458 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.696 HG22 ' HB ' ' A' ' 1' ' ' VAL . 6.1 mt -150.11 145.78 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.212 -0.93 . . . . 0.0 110.181 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.675 ' O ' HG12 ' A' ' 1' ' ' VAL . 0.0 OUTLIER -130.08 -170.2 0.21 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 110.22 179.591 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.583 ' CD ' ' CB ' ' A' ' 10' ' ' CYS . 45.8 Cg_endo -87.27 175.4 4.77 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.822 1.433 . . . . 0.0 110.75 -178.802 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -91.63 151.37 20.72 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.296 -0.878 . . . . 0.0 110.3 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.85 -6.09 51.42 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 4.6 p -114.39 171.68 7.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.192 -1.181 . . . . 0.0 110.25 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.519 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 14.7 t -115.94 134.33 55.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.312 -0.867 . . . . 0.0 110.311 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.2 m -45.05 147.02 0.74 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.244 -0.91 . . . . 0.0 110.367 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.569 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 29.0 m -161.69 135.02 6.34 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.306 -0.871 . . . . 0.0 110.337 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.539 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -106.64 142.39 36.36 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.225 -0.922 . . . . 0.0 110.211 179.996 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.503 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -84.14 168.02 24.11 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.168 -0.957 . . . . 0.0 110.291 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.585 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.5 Cg_endo -69.61 -8.83 24.62 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 124.098 1.578 . . . . 0.0 110.176 -179.726 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.585 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -103.63 0.95 31.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.432 -0.792 . . . . 0.0 109.627 179.173 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.98 16.88 49.74 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.254 -1.538 . . . . 0.0 109.254 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.506 ' O ' HD23 ' A' ' 18' ' ' LEU . 97.2 t -86.59 115.52 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.359 -1.083 . . . . 0.0 110.295 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.539 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 1.0 OUTLIER -75.61 135.41 40.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.294 -0.879 . . . . 0.0 110.325 179.973 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.569 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 24.8 p90 -163.8 176.56 9.4 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.252 -0.905 . . . . 0.0 110.35 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.497 ' SG ' ' HD2' ' A' ' 11' ' ' PRO . 11.1 p -114.38 130.06 56.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.344 -0.847 . . . . 0.0 110.26 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.401 ' O ' HG22 ' A' ' 15' ' ' THR . 1.1 p -99.94 146.03 31.2 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 0.0 110.253 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -73.13 104.43 1.78 Allowed 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 123.999 1.526 . . . . 0.0 110.411 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.519 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 0.5 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 O-C-N 121.314 -0.866 . . . . 0.0 110.406 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.7 ' HB ' HG22 ' A' ' 9' ' ' ILE . 6.5 m . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 121.281 0.562 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.476 ' O ' ' HB2' ' A' ' 10' ' ' CYS . 2.6 mp -90.06 154.8 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.279 -0.888 . . . . 0.0 110.274 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.49 ' NE2' HG23 ' A' ' 9' ' ' ILE . 15.0 m-70 -129.42 114.86 16.68 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.188 -0.945 . . . . 0.0 110.198 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 30.0 m -71.51 -39.6 70.68 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 110.318 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.698 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 23.7 t0 -125.18 -59.75 1.38 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.221 -0.924 . . . . 0.0 110.406 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.698 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 170.6 -25.37 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.174 -0.954 . . . . 0.0 110.43 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -100.05 -51.31 3.72 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 44.5 m -70.09 128.15 35.28 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.308 -0.87 . . . . 0.0 110.397 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.7 HG22 ' HB ' ' A' ' 1' ' ' VAL . 4.1 mt -97.64 176.7 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.209 -0.932 . . . . 0.0 110.07 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.488 ' O ' ' HA ' ' A' ' 1' ' ' VAL . 30.3 m -152.85 139.41 12.42 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.288 -0.882 . . . . 0.0 110.637 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.37 177.82 8.3 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 O-C-N 124.126 1.593 . . . . 0.0 110.433 179.524 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 12' ' ' ASP . 0.9 OUTLIER -85.19 147.85 26.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.167 -0.958 . . . . 0.0 110.311 179.779 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 92.93 -7.29 76.77 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.43 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 4.1 p -109.83 169.58 8.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.228 -1.16 . . . . 0.0 110.308 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.691 HG22 ' O ' ' A' ' 27' ' ' SER . 15.4 t -125.83 151.1 47.26 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.228 -0.92 . . . . 0.0 110.359 -179.777 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.464 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 1.1 m -66.56 148.76 51.44 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.336 -0.852 . . . . 0.0 110.525 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.515 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 0.2 OUTLIER -170.31 137.26 1.45 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.35 -0.844 . . . . 0.0 110.223 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.466 ' HG ' ' CE3' ' A' ' 24' ' ' TRP . 0.3 OUTLIER -96.46 141.11 30.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 110.277 -179.982 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.544 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.6 OUTLIER -78.78 169.86 18.77 Favored Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.324 -0.86 . . . . 0.0 110.244 -179.918 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.573 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.7 Cg_endo -69.46 -16.5 38.84 Favored 'Trans proline' 0 C--N 1.301 -1.97 0 O-C-N 124.075 1.566 . . . . 0.0 109.939 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.573 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 2.9 m-85 -98.74 1.99 46.59 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.516 -0.74 . . . . 0.0 109.593 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.95 23.22 33.32 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.544 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 23.8 t -92.3 112.77 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.284 -1.127 . . . . 0.0 110.304 -179.757 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.466 ' CE3' ' HG ' ' A' ' 18' ' ' LEU . 1.6 m95 -65.98 126.43 28.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.274 -0.891 . . . . 0.0 110.271 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.515 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 6.3 p90 -157.19 177.37 11.55 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.079 -1.013 . . . . 0.0 110.388 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 15' ' ' THR . 1.9 m -126.5 138.61 53.52 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.425 -0.797 . . . . 0.0 110.098 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.691 ' O ' HG22 ' A' ' 15' ' ' THR . 0.0 OUTLIER -111.41 139.25 21.81 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.202 -0.936 . . . . 0.0 110.576 -179.474 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -74.62 118.49 5.34 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.076 1.566 . . . . 0.0 110.331 179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' A' ' 29' ' ' PHE . 40.2 p90 . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.204 -0.935 . . . . 0.0 110.303 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.567 ' O ' HG23 ' A' ' 1' ' ' VAL . 3.4 m . . . . . 0 N--CA 1.494 1.741 0 CA-C-O 121.295 0.569 . . . . 0.0 110.417 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.513 ' HA ' HD13 ' A' ' 2' ' ' ILE . 5.2 mm -58.71 161.73 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.265 -0.897 . . . . 0.0 110.061 179.464 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.571 ' NE2' HG23 ' A' ' 9' ' ' ILE . 1.9 m-70 -149.01 125.92 11.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.257 -0.902 . . . . 0.0 110.507 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 28.3 p -126.44 21.52 7.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.336 -0.853 . . . . 0.0 110.111 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.461 ' N ' ' OD1' ' A' ' 5' ' ' ASP . 23.3 p-10 -167.65 -128.95 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.369 -0.832 . . . . 0.0 110.008 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.1 11.54 2.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.065 -1.022 . . . . 0.0 110.284 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.444 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -139.93 -85.1 0.23 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.227 -0.921 . . . . 0.0 110.459 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.444 ' C ' ' O ' ' A' ' 7' ' ' ALA . 55.9 m -40.81 141.6 0.56 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.23 -0.919 . . . . 0.0 110.524 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.571 HG23 ' NE2' ' A' ' 3' ' ' HIS . 7.8 mt -128.47 146.74 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.23 -0.919 . . . . 0.0 110.008 179.529 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.508 ' O ' ' HA ' ' A' ' 1' ' ' VAL . 46.0 m -122.26 145.38 44.13 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.199 -0.938 . . . . 0.0 110.408 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.32 -173.53 1.32 Allowed 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 124.097 1.577 . . . . 0.0 110.258 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.498 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 2.5 m-20 -86.64 151.16 23.67 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.231 -0.918 . . . . 0.0 110.422 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.81 8.4 73.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 5.4 p -133.58 167.88 19.68 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.267 -1.137 . . . . 0.0 110.313 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.658 HG22 ' O ' ' A' ' 27' ' ' SER . 10.4 t -128.49 141.41 51.39 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 0.0 110.203 179.686 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.75 138.16 57.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.226 -0.921 . . . . 0.0 110.139 -179.883 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.532 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 2.4 t -148.64 138.33 22.08 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.214 -0.929 . . . . 0.0 110.289 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.522 ' HA ' HD23 ' A' ' 18' ' ' LEU . 0.0 OUTLIER -95.94 131.06 42.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.384 -0.823 . . . . 0.0 110.037 179.692 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.573 ' OG ' ' HB ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -78.41 169.79 19.18 Favored Pre-proline 0 C--N 1.3 -1.561 0 O-C-N 121.346 -0.846 . . . . 0.0 110.52 -179.817 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.625 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 37.6 Cg_endo -69.07 -13.62 36.74 Favored 'Trans proline' 0 C--N 1.301 -1.959 0 O-C-N 124.208 1.636 . . . . 0.0 109.996 179.588 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.625 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 2.1 m-85 -92.03 -11.44 35.94 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.444 -0.785 . . . . 0.0 109.445 178.67 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.48 24.04 14.98 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.573 ' HB ' ' OG ' ' A' ' 19' ' ' SER . 39.9 t -102.04 125.47 56.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.17 -1.194 . . . . 0.0 110.2 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.454 ' CH2' ' HB2' ' A' ' 18' ' ' LEU . 1.7 m95 -81.09 119.09 23.12 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.284 -0.885 . . . . 0.0 110.27 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.532 ' CE1' ' HB3' ' A' ' 17' ' ' SER . 30.8 p90 -140.14 168.1 20.59 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.067 -1.021 . . . . 0.0 110.503 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 10.2 m -94.82 111.32 23.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.302 -0.874 . . . . 0.0 110.271 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.658 ' O ' HG22 ' A' ' 15' ' ' THR . 0.2 OUTLIER -96.05 147.47 33.02 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.348 -0.845 . . . . 0.0 110.396 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -77.39 125.26 7.59 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 124.059 1.557 . . . . 0.0 110.455 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' A' ' 29' ' ' PHE . 36.6 p90 . . . . . 0 N--CA 1.492 1.647 0 O-C-N 121.186 -0.946 . . . . 0.0 110.207 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 20.5 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.279 0.561 . . . . 0.0 110.261 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.507 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 26.5 mm -55.9 148.21 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.918 . . . . 0.0 110.143 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.511 ' CE1' HD13 ' A' ' 9' ' ' ILE . 0.8 OUTLIER -130.85 129.45 42.34 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.228 -0.92 . . . . 0.0 110.455 -179.795 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.474 ' O ' ' N ' ' A' ' 6' ' ' ALA . 58.0 m -142.01 -175.2 4.32 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.285 -0.885 . . . . 0.0 110.036 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.487 ' HB2' ' CE2' ' A' ' 24' ' ' TRP . 4.5 t70 54.75 -88.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.168 -0.958 . . . . 0.0 110.218 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.474 ' N ' ' O ' ' A' ' 4' ' ' CYS . . . -171.9 -40.2 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.254 -0.904 . . . . 0.0 110.326 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.406 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -119.82 -59.22 1.83 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.2 -0.937 . . . . 0.0 110.308 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.406 ' C ' ' O ' ' A' ' 7' ' ' ALA . 6.9 m -43.77 151.81 0.19 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.195 -0.941 . . . . 0.0 110.318 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.511 HD13 ' CE1' ' A' ' 3' ' ' HIS . 12.8 mt -131.23 167.37 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.209 -0.932 . . . . 0.0 110.279 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.507 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 55.7 m -133.87 147.5 64.49 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.2 -0.938 . . . . 0.0 110.205 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.55 -177.02 3.07 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.055 1.555 . . . . 0.0 110.607 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -84.72 151.94 24.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.268 -0.895 . . . . 0.0 110.237 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.45 28.47 57.6 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.547 ' C ' ' CE2' ' A' ' 29' ' ' PHE . 5.3 p -149.41 166.89 27.73 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.28 -1.13 . . . . 0.0 110.38 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.621 ' HB ' ' CE1' ' A' ' 29' ' ' PHE . 13.1 t -121.92 155.47 35.41 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.337 -0.852 . . . . 0.0 110.295 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 74.0 m -82.22 144.6 30.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.924 . . . . 0.0 110.124 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.49 ' HB2' ' CZ ' ' A' ' 25' ' ' TYR . 62.6 m -154.37 160.75 41.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 110.416 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.591 ' HG ' ' CZ3' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -114.81 134.13 55.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.875 . . . . 0.0 110.179 179.585 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.533 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -74.07 172.56 8.25 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.304 -0.872 . . . . 0.0 110.382 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.614 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.5 Cg_endo -69.87 -11.48 30.79 Favored 'Trans proline' 0 C--N 1.302 -1.879 0 O-C-N 123.976 1.514 . . . . 0.0 110.023 -179.749 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.614 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.4 m-85 -103.51 0.82 31.52 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.433 -0.792 . . . . 0.0 109.643 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 90.17 27.84 19.57 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.564 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.533 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 34.2 t -94.96 123.71 47.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.309 -1.112 . . . . 0.0 110.304 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.591 ' CZ3' ' HG ' ' A' ' 18' ' ' LEU . 2.7 m95 -78.6 114.92 17.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.205 -0.934 . . . . 0.0 110.202 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.49 ' CZ ' ' HB2' ' A' ' 17' ' ' SER . 29.1 p90 -136.08 172.53 12.88 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.189 -0.945 . . . . 0.0 110.161 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 8.0 m -114.98 117.38 30.44 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.273 -0.892 . . . . 0.0 110.276 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.4 p -96.47 161.63 26.17 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.308 -0.87 . . . . 0.0 110.162 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -74.79 170.59 20.02 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.889 1.468 . . . . 0.0 110.527 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.621 ' CE1' ' HB ' ' A' ' 15' ' ' THR . 17.4 m-85 . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.281 -0.887 . . . . 0.0 110.169 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.538 ' HB ' HG22 ' A' ' 9' ' ' ILE . 21.1 m . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 121.157 0.504 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.548 HG21 ' SG ' ' A' ' 16' ' ' CYS . 18.5 mm -54.28 164.84 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.231 -0.918 . . . . 0.0 109.996 179.776 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.514 ' O ' ' N ' ' A' ' 5' ' ' ASP . 5.5 m-70 -126.03 -19.47 4.78 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.121 -0.987 . . . . 0.0 110.734 -179.477 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.492 ' HB2' ' O ' ' A' ' 3' ' ' HIS . 9.3 m 66.07 -61.28 0.28 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.232 -0.917 . . . . 0.0 110.289 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.575 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 23.0 t0 -126.32 -56.44 1.42 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.218 -0.926 . . . . 0.0 110.279 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.575 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 176.34 -32.48 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.304 -0.872 . . . . 0.0 110.22 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.42 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -100.07 -77.97 0.52 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.227 -0.921 . . . . 0.0 110.244 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.42 ' C ' ' O ' ' A' ' 7' ' ' ALA . 3.1 m -43.36 116.35 0.91 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.218 -0.926 . . . . 0.0 110.213 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.538 HG22 ' HB ' ' A' ' 1' ' ' VAL . 9.7 mt -97.28 145.4 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.227 -0.921 . . . . 0.0 110.206 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.52 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 7.4 m -124.51 149.89 63.08 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.238 -0.914 . . . . 0.0 110.108 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.473 ' O ' ' OG1' ' A' ' 14' ' ' THR . 43.4 Cg_endo -73.0 176.62 8.83 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 123.977 1.514 . . . . 0.0 110.493 -179.845 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -84.35 165.71 18.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.252 -0.905 . . . . 0.0 110.315 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.59 11.8 65.97 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.473 ' OG1' ' O ' ' A' ' 11' ' ' PRO . 9.1 p -127.47 172.59 10.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.28 -1.129 . . . . 0.0 110.265 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.51 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 12.4 t -125.94 152.79 45.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.275 -0.891 . . . . 0.0 110.283 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.548 ' SG ' HG21 ' A' ' 2' ' ' ILE . 98.0 m -82.11 136.0 35.23 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.303 -0.873 . . . . 0.0 110.24 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.568 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 1.0 OUTLIER -142.45 148.51 37.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -0.93 . . . . 0.0 110.27 179.996 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.524 ' HG ' ' CE2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -104.41 140.78 37.43 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.351 -0.843 . . . . 0.0 110.431 -179.864 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.426 ' HB2' ' HD2' ' A' ' 20' ' ' PRO . 1.0 OUTLIER -86.38 171.98 9.25 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.325 -0.859 . . . . 0.0 110.454 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.577 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.5 Cg_endo -69.57 -14.67 37.04 Favored 'Trans proline' 0 C--N 1.3 -1.975 0 O-C-N 124.05 1.553 . . . . 0.0 109.905 179.444 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.577 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.1 m-85 -98.59 0.12 44.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.352 -0.842 . . . . 0.0 109.774 179.056 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.74 30.8 17.11 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.405 ' O ' HD23 ' A' ' 18' ' ' LEU . 68.4 t -100.65 123.99 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.227 -1.16 . . . . 0.0 110.223 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.524 ' CE2' ' HG ' ' A' ' 18' ' ' LEU . 3.5 m95 -83.36 114.07 21.17 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.28 -0.887 . . . . 0.0 110.036 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.568 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 42.1 p90 -132.65 172.01 13.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 110.337 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.4 m -102.47 132.7 48.33 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.349 -0.845 . . . . 0.0 110.112 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.471 ' O ' HG22 ' A' ' 15' ' ' THR . 0.3 OUTLIER -109.75 137.63 20.46 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.13 -0.981 . . . . 0.0 110.097 179.802 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -72.92 109.39 2.8 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 124.009 1.531 . . . . 0.0 110.555 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.567 ' CG ' ' O ' ' A' ' 29' ' ' PHE . 2.9 p90 . . . . . 0 N--CA 1.491 1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 110.371 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.589 ' O ' HG23 ' A' ' 1' ' ' VAL . 34.9 m . . . . . 0 N--CA 1.496 1.832 0 CA-C-O 121.246 0.546 . . . . 0.0 110.346 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.441 HD13 ' HA ' ' A' ' 2' ' ' ILE . 13.1 mm -50.53 158.13 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.146 -0.972 . . . . 0.0 109.75 179.296 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.545 ' O ' ' N ' ' A' ' 5' ' ' ASP . 1.1 m-70 -136.7 -48.03 0.62 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.09 -1.006 . . . . 0.0 110.536 -179.446 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.485 ' HB2' ' O ' ' A' ' 3' ' ' HIS . 81.0 m 59.0 -77.11 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.304 -0.872 . . . . 0.0 110.1 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 3' ' ' HIS . 3.0 t70 -78.74 -135.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.231 -0.918 . . . . 0.0 110.013 179.468 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.14 8.37 4.37 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.127 -0.983 . . . . 0.0 110.367 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.432 ' O ' HG13 ' A' ' 9' ' ' ILE . . . -139.91 -84.72 0.23 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.225 -0.922 . . . . 0.0 110.49 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.59 HG21 ' HB3' ' A' ' 24' ' ' TRP . 7.1 m -40.89 100.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.336 -0.852 . . . . 0.0 110.511 -179.573 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.535 HG23 ' CD2' ' A' ' 3' ' ' HIS . 6.9 mt -89.42 169.56 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.343 -0.848 . . . . 0.0 110.211 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.469 ' O ' ' HB ' ' A' ' 1' ' ' VAL . 3.0 m -143.15 162.64 41.99 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.213 -0.929 . . . . 0.0 110.399 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -80.0 -159.59 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.037 1.546 . . . . 0.0 110.464 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.467 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 5.6 m-20 -107.13 150.1 26.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.204 -0.935 . . . . 0.0 110.286 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 86.12 29.12 26.32 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.498 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 0.9 OUTLIER -144.12 170.53 15.77 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -1.164 . . . . 0.0 110.312 179.871 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.532 HG22 ' O ' ' A' ' 27' ' ' SER . 9.5 t -125.61 142.48 51.49 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.209 -0.932 . . . . 0.0 110.367 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.401 ' C ' ' HG ' ' A' ' 17' ' ' SER . 3.3 m -65.26 142.62 58.22 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.325 -0.859 . . . . 0.0 110.271 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.401 ' HG ' ' C ' ' A' ' 16' ' ' CYS . 14.3 m -158.84 130.43 6.45 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.275 -0.891 . . . . 0.0 110.056 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.535 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -94.45 136.78 34.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 110.45 -179.796 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.1 p -79.81 169.54 19.67 Favored Pre-proline 0 N--CA 1.487 1.412 0 O-C-N 121.275 -0.891 . . . . 0.0 110.256 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.584 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 40.3 Cg_endo -69.67 -6.76 19.33 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 O-C-N 124.056 1.556 . . . . 0.0 110.183 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.584 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.7 m-85 -106.2 -3.0 21.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.331 -0.856 . . . . 0.0 109.965 179.295 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.18 13.74 47.87 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.2 113.82 24.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.137 -1.213 . . . . 0.0 110.012 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.59 ' HB3' HG21 ' A' ' 8' ' ' THR . 0.0 OUTLIER -76.98 116.92 18.07 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.336 -0.853 . . . . 0.0 110.324 -179.726 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 8.1 p90 -143.39 176.11 9.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.274 -0.891 . . . . 0.0 110.241 179.737 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.498 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 58.0 m -124.47 138.11 54.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 110.193 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.532 ' O ' HG22 ' A' ' 15' ' ' THR . 1.2 t -107.89 150.39 40.25 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.24 -0.913 . . . . 0.0 110.705 -179.107 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -77.29 121.03 5.52 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 124.13 1.595 . . . . 0.0 110.405 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 42.3 p90 . . . . . 0 N--CA 1.493 1.697 0 O-C-N 121.157 -0.964 . . . . 0.0 110.314 179.843 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.566 HG21 HG21 ' A' ' 9' ' ' ILE . 19.5 m . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.317 0.58 . . . . 0.0 110.249 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.538 ' N ' ' O ' ' A' ' 10' ' ' CYS . 37.4 mm -85.22 156.98 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.25 -0.907 . . . . 0.0 110.134 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.625 ' NE2' HG23 ' A' ' 9' ' ' ILE . 4.0 m-70 -139.48 118.94 12.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.281 -0.887 . . . . 0.0 110.24 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.411 ' HB2' ' HB3' ' A' ' 16' ' ' CYS . 13.5 m -133.86 10.64 3.95 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.259 -0.901 . . . . 0.0 110.385 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.461 ' OD1' ' N ' ' A' ' 6' ' ' ALA . 0.7 OUTLIER -130.96 -101.12 0.3 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.184 -0.948 . . . . 0.0 110.191 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.461 ' N ' ' OD1' ' A' ' 5' ' ' ASP . . . -162.8 -43.15 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.061 -1.024 . . . . 0.0 110.065 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.72 -51.51 2.83 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 110.088 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.423 HG22 ' N ' ' A' ' 9' ' ' ILE . 52.5 m -57.59 161.77 3.39 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.333 -0.854 . . . . 0.0 110.223 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.625 HG23 ' NE2' ' A' ' 3' ' ' HIS . 12.7 mt -140.7 172.71 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.259 -0.901 . . . . 0.0 110.055 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.538 ' O ' ' N ' ' A' ' 2' ' ' ILE . 56.8 m -143.22 137.87 15.13 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.182 -0.949 . . . . 0.0 110.521 -179.706 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.28 -166.08 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.939 1.494 . . . . 0.0 110.267 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 52.2 m-20 -90.08 147.93 23.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.198 -0.939 . . . . 0.0 110.199 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.45 18.63 60.05 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.443 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 0.6 OUTLIER -136.06 171.26 14.74 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.245 -1.15 . . . . 0.0 110.306 179.967 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.737 HG22 ' O ' ' A' ' 27' ' ' SER . 15.3 t -132.55 140.88 48.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.236 -0.915 . . . . 0.0 110.261 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.411 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 29.3 m -65.26 131.72 47.23 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.267 -0.895 . . . . 0.0 110.136 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -156.54 138.2 14.15 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.098 -1.001 . . . . 0.0 110.46 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.449 HD23 ' O ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -88.72 143.49 26.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.324 -0.86 . . . . 0.0 110.287 179.726 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.464 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -82.24 169.54 17.99 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.318 -0.864 . . . . 0.0 110.478 -179.699 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.578 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.3 Cg_endo -69.02 -14.43 38.43 Favored 'Trans proline' 0 C--N 1.302 -1.909 0 O-C-N 124.135 1.597 . . . . 0.0 110.166 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.578 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 2.5 m-85 -100.19 1.62 42.15 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.379 -0.826 . . . . 0.0 109.614 178.884 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.77 29.45 15.84 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.464 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 76.5 t -103.75 123.49 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.246 -1.149 . . . . 0.0 110.445 -179.667 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.472 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.9 OUTLIER -76.86 118.74 19.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.249 -0.907 . . . . 0.0 110.312 179.906 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.524 ' CE2' ' OG ' ' A' ' 27' ' ' SER . 40.7 p90 -144.28 168.6 19.69 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.084 -1.01 . . . . 0.0 110.681 179.574 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.443 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 3.4 m -106.09 117.93 35.31 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.446 -0.784 . . . . 0.0 109.649 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.737 ' O ' HG22 ' A' ' 15' ' ' THR . 0.7 OUTLIER -93.81 142.65 25.36 Favored Pre-proline 0 C--N 1.303 -1.455 0 O-C-N 121.174 -0.954 . . . . 0.0 110.716 -178.943 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -75.69 126.19 9.36 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 124.135 1.597 . . . . 0.0 110.46 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.542 ' CG ' ' O ' ' A' ' 29' ' ' PHE . 34.6 p90 . . . . . 0 N--CA 1.493 1.688 0 O-C-N 121.242 -0.911 . . . . 0.0 110.268 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 29.1 m . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 121.266 0.555 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.508 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 32.7 mm -77.67 146.49 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.213 -0.929 . . . . 0.0 110.312 -179.849 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.605 ' CD2' HG23 ' A' ' 9' ' ' ILE . 3.9 m-70 -138.04 83.29 1.97 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.315 -0.866 . . . . 0.0 110.089 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -72.32 -32.01 66.17 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.301 -0.874 . . . . 0.0 110.441 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.488 ' OD2' ' NE1' ' A' ' 24' ' ' TRP . 0.6 OUTLIER -116.34 -89.64 0.57 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.18 -0.95 . . . . 0.0 110.357 -179.849 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -171.89 -32.84 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.162 -0.962 . . . . 0.0 110.354 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -99.31 -83.63 0.42 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 110.234 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.452 HG21 ' O ' ' A' ' 24' ' ' TRP . 62.9 m -52.17 106.55 0.15 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.225 -0.922 . . . . 0.0 110.158 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.605 HG23 ' CD2' ' A' ' 3' ' ' HIS . 6.2 mt -90.65 165.02 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.191 -0.943 . . . . 0.0 110.335 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.508 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 99.4 m -133.73 140.74 37.57 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.267 -0.896 . . . . 0.0 110.057 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.0 173.81 13.43 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.901 1.474 . . . . 0.0 110.424 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.474 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 1.1 m-20 -77.12 152.5 34.91 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.281 -0.887 . . . . 0.0 110.472 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' A' ' 29' ' ' PHE . . . 90.55 -8.27 80.07 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.519 HG22 ' HA ' ' A' ' 28' ' ' PRO . 2.0 p -116.95 166.52 12.07 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.183 -1.186 . . . . 0.0 110.151 179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.674 ' O ' HG23 ' A' ' 15' ' ' THR . 14.8 t -123.54 119.36 29.7 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.333 -0.854 . . . . 0.0 110.375 179.683 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' CYS . . . . . 0.453 ' O ' ' OG ' ' A' ' 17' ' ' SER . 20.6 p -50.34 158.36 0.59 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.214 -0.929 . . . . 0.0 110.18 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.601 ' HB2' ' CZ ' ' A' ' 25' ' ' TYR . 42.4 m -167.44 146.64 5.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.198 -0.938 . . . . 0.0 110.022 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.57 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -108.6 134.73 50.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 110.485 -179.654 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.483 ' HB3' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -78.53 167.79 32.45 Favored Pre-proline 0 C--N 1.304 -1.399 0 O-C-N 121.34 -0.85 . . . . 0.0 109.989 179.543 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.593 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 37.9 Cg_endo -69.56 -11.92 32.15 Favored 'Trans proline' 0 C--N 1.3 -2.009 0 O-C-N 124.022 1.538 . . . . 0.0 109.942 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.593 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.2 m-85 -97.79 -2.31 41.32 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.399 -0.813 . . . . 0.0 109.75 178.919 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.85 21.17 29.07 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.483 ' HB ' ' HB3' ' A' ' 19' ' ' SER . 75.6 t -91.54 119.58 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.273 -1.133 . . . . 0.0 110.38 -179.744 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.57 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 0.6 OUTLIER -84.01 126.66 33.26 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.266 -0.896 . . . . 0.0 110.181 179.765 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.601 ' CZ ' ' HB2' ' A' ' 17' ' ' SER . 32.6 p90 -147.75 174.82 11.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.215 -0.928 . . . . 0.0 110.246 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 4.0 m -114.18 107.65 15.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.261 -0.9 . . . . 0.0 110.223 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.484 ' HB3' HG23 ' A' ' 15' ' ' THR . 9.8 t -70.59 144.01 90.78 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.192 -0.943 . . . . 0.0 109.897 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.519 ' HA ' HG22 ' A' ' 14' ' ' THR . 47.6 Cg_endo -76.17 170.61 19.7 Favored 'Trans proline' 0 C--N 1.299 -2.053 0 O-C-N 123.817 1.43 . . . . 0.0 110.918 -179.363 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 13' ' ' GLY . 2.4 m-85 . . . . . 0 N--CA 1.494 1.774 0 O-C-N 121.459 -0.776 . . . . 0.0 110.201 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' VAL . . . . . 0.727 HG23 HG21 ' A' ' 9' ' ' ILE . 5.9 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.233 0.539 . . . . 0.0 110.331 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.462 ' O ' ' N ' ' A' ' 10' ' ' CYS . 30.1 mm -44.1 152.87 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.273 -0.892 . . . . 0.0 110.223 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.597 ' CE1' HG23 ' A' ' 9' ' ' ILE . 1.0 OUTLIER -120.38 -64.69 1.22 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.184 -0.947 . . . . 0.0 110.336 -179.921 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 4' ' ' CYS . . . . . 0.517 ' HB3' ' O ' ' A' ' 3' ' ' HIS . 1.7 t 59.65 -72.29 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.511 -0.743 . . . . 0.0 110.386 179.753 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.565 ' N ' ' O ' ' A' ' 3' ' ' HIS . 81.1 m-20 -54.75 -163.67 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.178 -0.951 . . . . 0.0 110.297 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -103.92 -19.93 14.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.12 -0.988 . . . . 0.0 110.547 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.426 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -135.72 -79.69 0.42 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.257 -0.902 . . . . 0.0 110.557 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 7' ' ' ALA . 97.5 m -41.24 132.13 2.61 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.344 -0.847 . . . . 0.0 110.387 -179.636 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ILE . . . . . 0.727 HG21 HG23 ' A' ' 1' ' ' VAL . 0.9 OUTLIER -98.46 175.78 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.265 -0.897 . . . . 0.0 110.048 179.972 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 10' ' ' CYS . . . . . 0.462 ' N ' ' O ' ' A' ' 2' ' ' ILE . 1.5 m -130.0 132.9 24.42 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 110.329 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' PRO . . . . . 0.495 ' O ' ' O ' ' A' ' 12' ' ' ASP . 48.5 Cg_endo -77.78 154.42 30.3 Favored 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.009 1.531 . . . . 0.0 110.02 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.495 ' O ' ' O ' ' A' ' 11' ' ' PRO . 7.3 m-20 48.66 179.22 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.164 -0.96 . . . . 0.0 110.139 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' A' ' 14' ' ' THR . . . -55.42 -64.19 4.6 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 179.699 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.52 ' O ' ' O ' ' A' ' 13' ' ' GLY . 0.8 OUTLIER 44.39 -179.24 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.545 -0.973 . . . . 0.0 110.963 179.294 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 15' ' ' THR . . . . . 1.057 HG22 ' O ' ' A' ' 27' ' ' SER . 9.9 t -136.41 155.58 49.82 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.292 -0.88 . . . . 0.0 110.195 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -69.8 127.85 34.35 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.269 -0.894 . . . . 0.0 110.225 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.584 ' O ' ' CD1' ' A' ' 25' ' ' TYR . 8.2 m -142.61 125.09 15.69 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.213 -0.929 . . . . 0.0 110.19 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.573 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -101.66 137.59 39.77 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.199 -0.938 . . . . 0.0 110.192 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.5 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.2 p -79.18 167.13 37.01 Favored Pre-proline 0 C--N 1.303 -1.454 0 O-C-N 121.315 -0.866 . . . . 0.0 110.423 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.587 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.0 Cg_endo -69.61 -7.93 22.29 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 O-C-N 124.041 1.548 . . . . 0.0 110.118 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' TYR . . . . . 0.587 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -103.89 -2.54 26.06 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.476 -0.765 . . . . 0.0 109.639 178.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.9 24.97 15.77 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.5 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 72.2 t -95.29 114.85 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.263 -1.139 . . . . 0.0 110.402 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' TRP . . . . . 0.573 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -76.62 123.46 26.14 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.327 -0.858 . . . . 0.0 110.379 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 25' ' ' TYR . . . . . 0.584 ' CD1' ' O ' ' A' ' 17' ' ' SER . 22.9 p90 -147.58 173.35 12.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.143 -0.973 . . . . 0.0 110.29 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' CYS . . . . . 0.47 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 3.4 m -106.11 147.05 29.42 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.374 -0.829 . . . . 0.0 110.221 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' SER . . . . . 1.057 ' O ' HG22 ' A' ' 15' ' ' THR . 0.9 OUTLIER -130.71 149.26 73.08 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.9 . . . . 0.0 110.346 179.951 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -74.06 127.67 11.58 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 O-C-N 124.098 1.578 . . . . 0.0 110.312 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 14.4 p90 . . . . . 0 N--CA 1.492 1.648 0 O-C-N 121.2 -0.938 . . . . 0.0 110.324 -179.781 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.521 ' HB ' HG22 ' A' ' 9' ' ' ILE . 26.9 m . . . . . 0 N--CA 1.493 1.713 0 CA-C-O 121.278 0.561 . . . . 0.0 110.264 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.504 HG22 ' N ' ' A' ' 3' ' ' HIS . 2.0 mp -87.54 166.32 1.94 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.212 -0.93 . . . . 0.0 110.276 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.504 ' N ' HG22 ' A' ' 2' ' ' ILE . 9.5 m-70 -141.75 161.01 39.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.221 -0.924 . . . . 0.0 110.3 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 26.8 p -161.05 -36.74 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.206 -0.934 . . . . 0.0 110.254 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.653 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 13.5 m-20 -93.91 -78.93 0.42 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.225 -0.922 . . . . 0.0 110.19 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.653 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 171.72 -31.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.282 -0.886 . . . . 0.0 110.144 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.65 -61.49 1.7 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.311 -0.868 . . . . 0.0 110.175 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.8 m -55.22 150.45 11.0 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.246 -0.909 . . . . 0.0 110.14 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.521 HG22 ' HB ' ' A' ' 1' ' ' VAL . 8.4 mt -119.84 172.3 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -0.927 . . . . 0.0 110.245 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.467 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 19.3 t -131.51 136.64 28.89 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.248 -0.907 . . . . 0.0 110.18 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -72.46 -161.1 0.1 OUTLIER 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.978 1.514 . . . . 0.0 110.569 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.412 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 0.9 OUTLIER -96.0 150.17 20.77 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.23 -0.919 . . . . 0.0 110.414 -179.745 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.658 ' O ' HG23 ' A' ' 14' ' ' THR . . . 64.81 53.29 35.42 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.658 HG23 ' O ' ' A' ' 13' ' ' GLY . 0.9 OUTLIER -159.39 170.67 21.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.203 -1.175 . . . . 0.0 110.378 179.931 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.481 ' O ' HG23 ' A' ' 15' ' ' THR . 12.2 t -130.88 131.9 44.82 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.346 -0.846 . . . . 0.0 110.235 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.2 132.76 43.97 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.292 -0.88 . . . . 0.0 110.302 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -152.12 157.88 42.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 110.245 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.465 ' HA ' HD23 ' A' ' 18' ' ' LEU . 0.2 OUTLIER -105.87 136.22 45.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.313 -0.867 . . . . 0.0 110.288 -179.944 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.508 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.9 OUTLIER -78.31 165.37 50.67 Favored Pre-proline 0 N--CA 1.488 1.446 0 O-C-N 121.24 -0.912 . . . . 0.0 110.213 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.589 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.9 Cg_endo -69.39 -11.61 31.72 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 O-C-N 124.038 1.546 . . . . 0.0 110.04 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.589 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.7 m-85 -101.54 5.2 41.69 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.476 -0.765 . . . . 0.0 109.553 178.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.74 21.16 51.82 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.508 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 60.6 t -93.9 123.08 45.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.32 -1.106 . . . . 0.0 110.281 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.559 ' CE2' ' OD1' ' A' ' 5' ' ' ASP . 1.3 m95 -81.09 130.71 35.14 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.243 -0.911 . . . . 0.0 110.21 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.1 p90 -165.42 173.08 11.45 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.207 -0.933 . . . . 0.0 110.331 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.409 ' SG ' ' C ' ' A' ' 15' ' ' THR . 0.1 OUTLIER -109.19 137.22 47.41 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -0.924 . . . . 0.0 110.24 179.705 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.9 t -108.4 147.44 35.67 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.263 -0.898 . . . . 0.0 110.338 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.6 114.14 3.96 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.029 1.541 . . . . 0.0 110.476 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.48 ' CD1' ' C ' ' A' ' 29' ' ' PHE . 20.9 p90 -102.51 169.25 8.78 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.253 -0.905 . . . . 0.0 110.295 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.1 t . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.325 -179.995 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.596 ' HB ' HG22 ' A' ' 9' ' ' ILE . 30.5 m . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 121.138 0.494 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.422 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 31.9 mm -105.3 157.17 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.251 -0.906 . . . . 0.0 110.572 -179.694 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.486 ' NE2' HG23 ' A' ' 9' ' ' ILE . 12.4 m-70 -134.53 125.75 27.95 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.277 -0.889 . . . . 0.0 110.061 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -113.41 -50.65 2.85 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 0.0 110.501 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.605 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 12.8 t70 -90.86 -70.01 0.7 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.261 -0.899 . . . . 0.0 110.479 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.605 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 175.17 -46.55 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.195 -0.941 . . . . 0.0 110.36 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -100.14 -20.07 16.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.204 -0.935 . . . . 0.0 110.342 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.7 m -82.84 140.72 32.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.303 -0.873 . . . . 0.0 110.266 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.596 HG22 ' HB ' ' A' ' 1' ' ' VAL . 4.3 mt -125.91 166.38 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.193 -0.942 . . . . 0.0 110.293 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 1' ' ' VAL . 10.0 m -147.3 155.6 46.32 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.265 -0.897 . . . . 0.0 109.958 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.96 -166.29 0.28 Allowed 'Trans proline' 0 C--N 1.303 -1.817 0 O-C-N 123.942 1.496 . . . . 0.0 110.373 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -95.56 152.26 18.59 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.266 -0.896 . . . . 0.0 110.313 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.2 12.07 84.95 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -124.3 170.14 11.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -1.141 . . . . 0.0 110.396 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 27' ' ' SER . 11.8 t -129.86 139.09 51.25 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.879 . . . . 0.0 110.249 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.3 p -62.69 134.61 56.56 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.275 -0.891 . . . . 0.0 110.353 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.401 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 4.7 m -153.91 133.71 13.03 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.299 -0.875 . . . . 0.0 110.21 179.76 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.476 ' HA ' HD23 ' A' ' 18' ' ' LEU . 0.4 OUTLIER -91.97 143.8 26.11 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -0.927 . . . . 0.0 110.301 -179.796 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.525 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -79.41 172.71 9.17 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.278 -0.888 . . . . 0.0 110.332 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.615 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.9 Cg_endo -69.87 -7.17 20.43 Favored 'Trans proline' 0 C--N 1.302 -1.885 0 O-C-N 124.167 1.614 . . . . 0.0 110.174 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.615 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 4.2 m-85 -109.51 -0.17 18.96 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.393 -0.817 . . . . 0.0 109.623 178.816 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.56 17.86 37.52 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.525 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 48.0 t -87.53 108.9 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.27 -1.135 . . . . 0.0 110.438 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.552 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -65.25 124.34 21.92 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.229 -0.919 . . . . 0.0 110.416 179.982 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.49 ' C ' ' CD1' ' A' ' 25' ' ' TYR . 15.5 p90 -148.25 171.66 15.6 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.165 -0.959 . . . . 0.0 110.162 179.397 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 4.3 m -106.35 118.02 35.55 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.177 -0.952 . . . . 0.0 110.257 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.772 ' O ' HG22 ' A' ' 15' ' ' THR . 23.3 t -84.82 139.22 37.42 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.265 -0.897 . . . . 0.0 110.318 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -77.17 120.68 5.45 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 124.063 1.56 . . . . 0.0 110.397 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.489 ' CD1' ' C ' ' A' ' 29' ' ' PHE . 14.4 p90 -119.38 158.33 26.39 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.183 -0.948 . . . . 0.0 110.223 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 28.7 t . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.321 179.912 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.501 HG21 HG21 ' A' ' 9' ' ' ILE . 29.8 m . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 121.202 0.525 . . . . 0.0 110.348 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.505 ' N ' ' O ' ' A' ' 10' ' ' CYS . 45.4 mm -93.17 143.13 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 110.2 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -122.81 109.63 14.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 110.119 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -149.17 22.9 0.95 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.362 -0.836 . . . . 0.0 110.215 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.495 ' OD1' ' CH2' ' A' ' 24' ' ' TRP . 75.0 m-20 -137.32 -166.18 1.89 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.206 -0.934 . . . . 0.0 110.173 179.742 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.51 -59.38 2.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 110.276 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -136.33 -46.33 0.63 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 110.26 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.462 ' CB ' ' HB3' ' A' ' 24' ' ' TRP . 19.1 m -45.27 112.05 0.4 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.172 -0.955 . . . . 0.0 110.1 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.501 HG21 HG21 ' A' ' 1' ' ' VAL . 12.3 mt -85.82 167.53 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.292 -0.88 . . . . 0.0 110.235 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.505 ' O ' ' N ' ' A' ' 2' ' ' ILE . 31.0 m -129.84 141.83 43.23 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.249 -0.907 . . . . 0.0 110.324 -179.754 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.51 -166.6 0.34 Allowed 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.957 1.504 . . . . 0.0 110.267 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.9 148.69 22.03 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.237 -0.914 . . . . 0.0 110.348 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.98 0.94 89.81 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.2 p -117.58 170.24 8.91 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.137 -1.213 . . . . 0.0 110.399 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.802 HG22 ' O ' ' A' ' 27' ' ' SER . 14.8 t -134.32 144.69 48.44 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.159 -0.963 . . . . 0.0 110.503 -179.697 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -52.4 140.62 21.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.308 -0.87 . . . . 0.0 110.402 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.533 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 9.0 t -160.23 124.39 3.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.262 -0.899 . . . . 0.0 110.235 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.462 HD23 ' O ' ' A' ' 23' ' ' VAL . 0.1 OUTLIER -100.85 117.95 35.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.224 -0.922 . . . . 0.0 110.425 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.483 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -56.07 162.13 3.16 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.246 -0.909 . . . . 0.0 110.139 179.637 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.607 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.2 Cg_endo -69.35 -6.82 19.32 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 124.009 1.531 . . . . 0.0 110.116 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.607 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.4 m-85 -100.31 -5.97 26.61 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.423 -0.798 . . . . 0.0 109.688 179.001 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 99.21 17.44 27.13 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.483 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 67.4 t -89.97 115.36 29.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.266 -1.138 . . . . 0.0 110.298 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.534 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -74.08 125.79 29.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.357 -0.84 . . . . 0.0 110.37 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.533 ' CE1' ' HB3' ' A' ' 17' ' ' SER . 8.8 p90 -154.47 174.52 14.79 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 110.282 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.9 m -115.54 116.68 28.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.262 -0.899 . . . . 0.0 110.132 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.802 ' O ' HG22 ' A' ' 15' ' ' THR . 3.3 t -84.86 134.59 41.32 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.274 -0.891 . . . . 0.0 110.402 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -74.48 118.08 5.21 Favored 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.003 1.528 . . . . 0.0 110.423 179.724 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.404 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 24.5 p90 -121.25 158.13 28.79 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.186 -0.946 . . . . 0.0 110.24 179.844 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.295 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.533 ' O ' HG23 ' A' ' 1' ' ' VAL . 30.1 m . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.29 0.567 . . . . 0.0 110.259 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.528 ' N ' ' O ' ' A' ' 10' ' ' CYS . 40.5 mm -45.38 155.69 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.203 -0.936 . . . . 0.0 110.054 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.466 ' O ' ' N ' ' A' ' 5' ' ' ASP . 1.8 m-70 -130.64 -60.59 0.98 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.115 -0.991 . . . . 0.0 110.575 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.464 ' CB ' ' O ' ' A' ' 3' ' ' HIS . 0.5 OUTLIER 66.75 -67.97 0.15 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.234 -0.916 . . . . 0.0 110.268 -179.776 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.502 ' OD2' ' N ' ' A' ' 8' ' ' THR . 9.9 p-10 -80.88 -138.83 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 0.0 110.1 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -128.56 -6.21 5.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.953 . . . . 0.0 110.392 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -137.13 -65.54 0.54 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.213 -0.929 . . . . 0.0 110.203 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.502 ' N ' ' OD2' ' A' ' 5' ' ' ASP . 5.1 m -48.7 111.95 0.54 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.234 -0.917 . . . . 0.0 110.272 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.495 HG22 ' HB ' ' A' ' 1' ' ' VAL . 6.0 mt -90.83 151.74 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.21 -0.931 . . . . 0.0 110.128 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.528 ' O ' ' N ' ' A' ' 2' ' ' ILE . 23.7 m -127.13 139.68 35.77 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.17 -0.956 . . . . 0.0 110.298 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -74.91 -161.18 0.12 Allowed 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 124.02 1.537 . . . . 0.0 110.362 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -95.5 150.61 20.12 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.284 -0.885 . . . . 0.0 110.304 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.1 12.95 80.17 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 1.2 p -121.63 169.39 10.75 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.199 -1.177 . . . . 0.0 110.447 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.695 HG22 ' O ' ' A' ' 27' ' ' SER . 12.6 t -131.93 157.09 44.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.28 -0.888 . . . . 0.0 110.288 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.4 m -58.3 127.82 34.05 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.287 -0.883 . . . . 0.0 109.861 179.469 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.573 ' HB3' ' CE2' ' A' ' 25' ' ' TYR . 1.3 t -141.72 124.26 15.85 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.939 . . . . 0.0 110.684 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.586 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.1 OUTLIER -109.03 126.99 53.72 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.385 -0.822 . . . . 0.0 110.051 179.201 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.518 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -67.9 163.33 50.99 Favored Pre-proline 0 C--N 1.301 -1.513 0 O-C-N 121.217 -0.927 . . . . 0.0 110.284 180.0 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.603 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.0 Cg_endo -69.08 -8.59 24.01 Favored 'Trans proline' 0 C--N 1.302 -1.879 0 O-C-N 124.111 1.585 . . . . 0.0 110.126 179.712 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.603 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.6 m-85 -100.68 -1.04 36.23 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.372 -0.83 . . . . 0.0 109.746 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.3 17.44 39.77 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.518 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 94.0 t -91.03 112.47 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.408 -1.054 . . . . 0.0 110.172 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.586 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 2.7 m95 -71.46 142.31 50.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.259 -0.901 . . . . 0.0 110.273 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.573 ' CE2' ' HB3' ' A' ' 17' ' ' SER . 24.6 p90 -170.23 174.12 5.49 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.277 -0.889 . . . . 0.0 110.267 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.497 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 2.6 m -106.81 141.81 37.45 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.247 -0.908 . . . . 0.0 110.285 -179.132 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.695 ' O ' HG22 ' A' ' 15' ' ' THR . 0.9 OUTLIER -118.91 141.95 31.03 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.217 -0.927 . . . . 0.0 110.208 179.784 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -74.61 104.3 1.85 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 124.081 1.569 . . . . 0.0 110.531 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.59 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 8.2 p90 -111.51 150.58 29.73 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.212 -0.93 . . . . 0.0 110.294 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.263 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.653 ' HB ' HG22 ' A' ' 9' ' ' ILE . 30.8 m . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.323 0.582 . . . . 0.0 110.216 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.526 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 36.4 mm -83.55 148.18 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.219 -0.925 . . . . 0.0 110.307 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.9 m80 -118.79 126.41 51.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.175 -0.953 . . . . 0.0 110.398 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 26.9 m -80.28 -68.94 0.63 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.297 -0.877 . . . . 0.0 110.275 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -104.63 -90.27 0.4 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.278 -0.889 . . . . 0.0 110.163 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -146.66 10.28 1.06 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.289 -0.882 . . . . 0.0 110.393 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.435 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -140.11 -76.27 0.33 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.206 -0.934 . . . . 0.0 110.318 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.689 HG21 ' HB3' ' A' ' 24' ' ' TRP . 8.6 m -41.63 147.84 0.17 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.31 -0.869 . . . . 0.0 110.364 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.653 HG22 ' HB ' ' A' ' 1' ' ' VAL . 15.2 mt -131.71 169.61 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.279 -0.888 . . . . 0.0 110.129 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.526 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 63.2 m -145.67 146.27 28.69 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.156 -0.965 . . . . 0.0 110.327 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -73.02 -175.02 1.74 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.012 1.532 . . . . 0.0 110.472 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -84.83 156.87 21.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.239 -0.913 . . . . 0.0 110.226 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.15 3.52 90.54 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.0 p -127.1 170.27 12.53 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.238 -1.154 . . . . 0.0 110.213 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 27' ' ' SER . 9.0 t -128.2 156.0 43.62 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.218 -0.926 . . . . 0.0 110.349 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.3 m -73.29 128.83 36.6 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.278 -0.888 . . . . 0.0 110.176 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.414 ' OG ' ' CZ ' ' A' ' 25' ' ' TYR . 32.9 t -137.19 130.2 30.69 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.28 -0.887 . . . . 0.0 110.243 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.595 ' HG ' ' CE2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -105.19 106.38 16.85 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.186 -0.946 . . . . 0.0 110.294 179.815 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.508 ' HB3' ' HB ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -46.18 157.81 0.4 Allowed Pre-proline 0 C--N 1.301 -1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 110.218 179.718 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.606 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.0 Cg_endo -68.69 -11.66 32.49 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 124.041 1.548 . . . . 0.0 110.026 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.606 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.0 m-85 -93.24 -8.71 41.49 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.456 -0.777 . . . . 0.0 109.641 178.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 100.8 19.9 16.14 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.508 ' HB ' ' HB3' ' A' ' 19' ' ' SER . 61.2 t -94.97 115.91 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.236 -1.155 . . . . 0.0 110.123 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.689 ' HB3' HG21 ' A' ' 8' ' ' THR . 0.2 OUTLIER -77.84 126.78 31.37 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.335 -0.853 . . . . 0.0 110.503 -179.525 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.414 ' CZ ' ' OG ' ' A' ' 17' ' ' SER . 28.0 p90 -154.72 171.69 19.14 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.917 . . . . 0.0 110.125 179.304 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.3 m -106.45 135.6 47.67 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.216 -0.927 . . . . 0.0 110.068 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.772 ' O ' HG22 ' A' ' 15' ' ' THR . 12.0 t -115.4 143.71 30.97 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.204 -0.935 . . . . 0.0 110.324 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.73 125.02 9.68 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 124.034 1.544 . . . . 0.0 110.4 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.508 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 14.8 p90 -135.01 172.05 13.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.305 -0.872 . . . . 0.0 110.219 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.227 179.769 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.618 ' HB ' HG22 ' A' ' 9' ' ' ILE . 23.6 m . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.252 0.549 . . . . 0.0 110.308 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.502 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 34.2 mm -88.46 143.17 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.166 -0.959 . . . . 0.0 110.114 179.552 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.593 ' NE2' HG23 ' A' ' 9' ' ' ILE . 7.3 m-70 -129.17 119.51 24.21 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.193 -0.942 . . . . 0.0 110.598 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 87.1 m -124.3 11.76 8.76 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.986 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -150.29 -90.23 0.07 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.392 -0.818 . . . . 0.0 110.207 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -176.09 -32.39 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.16 -0.963 . . . . 0.0 110.244 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.482 ' O ' ' CG1' ' A' ' 9' ' ' ILE . . . -105.38 -75.5 0.63 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.2 -0.938 . . . . 0.0 110.258 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 42.8 m -43.47 139.74 1.95 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.24 -0.913 . . . . 0.0 110.394 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.618 HG22 ' HB ' ' A' ' 1' ' ' VAL . 4.4 mt -135.85 147.69 28.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 0.0 110.217 179.788 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.528 ' O ' ' CB ' ' A' ' 1' ' ' VAL . 98.1 m -111.34 148.69 39.29 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.305 -0.872 . . . . 0.0 109.982 179.726 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.43 ' O ' ' CG ' ' A' ' 12' ' ' ASP . 45.4 Cg_endo -74.7 -90.34 0.01 OUTLIER 'Trans proline' 0 C--N 1.302 -1.869 0 O-C-N 123.846 1.445 . . . . 0.0 110.335 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.43 ' CG ' ' O ' ' A' ' 11' ' ' PRO . 21.1 m-20 -158.86 164.28 35.86 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.371 -0.831 . . . . 0.0 110.181 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.32 13.26 48.92 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.472 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 1.3 p -124.07 169.74 11.37 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.217 -1.166 . . . . 0.0 110.308 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.642 HG22 ' O ' ' A' ' 27' ' ' SER . 8.9 t -129.59 153.81 47.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.141 -0.974 . . . . 0.0 110.494 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 60.2 m -63.86 127.47 31.52 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.262 -0.899 . . . . 0.0 110.147 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.514 ' HB3' ' CE2' ' A' ' 25' ' ' TYR . 10.7 t -138.9 133.99 32.63 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 110.265 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.449 HD23 ' HA ' ' A' ' 18' ' ' LEU . 0.2 OUTLIER -99.34 135.89 40.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.169 -0.957 . . . . 0.0 110.316 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.509 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.4 OUTLIER -79.06 166.13 44.16 Favored Pre-proline 0 C--N 1.303 -1.415 0 O-C-N 121.325 -0.859 . . . . 0.0 110.243 -179.992 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.585 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.9 Cg_endo -69.39 -10.73 29.63 Favored 'Trans proline' 0 C--N 1.301 -1.951 0 O-C-N 124.057 1.556 . . . . 0.0 110.022 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.585 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -104.06 -0.51 28.65 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.429 -0.794 . . . . 0.0 109.667 179.007 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.11 15.32 48.72 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.509 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 92.3 t -87.0 119.15 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.292 -1.122 . . . . 0.0 110.191 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.498 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.6 OUTLIER -77.75 128.16 33.59 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 110.458 -179.747 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.514 ' CE2' ' HB3' ' A' ' 17' ' ' SER . 37.1 p90 -152.74 172.52 16.56 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.27 -0.894 . . . . 0.0 110.086 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.472 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 4.0 m -101.92 141.42 34.79 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.209 -0.932 . . . . 0.0 110.193 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.642 ' O ' HG22 ' A' ' 15' ' ' THR . 3.4 t -116.16 141.7 28.17 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.173 -0.954 . . . . 0.0 110.389 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -75.38 129.27 11.86 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.061 1.558 . . . . 0.0 110.488 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.449 ' O ' ' HB3' ' A' ' 30' ' ' SER . 43.6 p90 -133.14 154.15 50.87 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.223 -0.923 . . . . 0.0 110.214 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.449 ' HB3' ' O ' ' A' ' 29' ' ' PHE . 21.8 t . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.271 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.696 ' HB ' HG22 ' A' ' 9' ' ' ILE . 28.6 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.224 0.535 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.459 ' H ' HD12 ' A' ' 2' ' ' ILE . 2.5 mp -50.89 160.6 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.242 -0.911 . . . . 0.0 110.147 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.409 ' N ' HG22 ' A' ' 2' ' ' ILE . 4.4 m-70 -148.12 89.43 1.73 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.195 -0.941 . . . . 0.0 110.354 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 63.9 m -92.59 -41.39 10.25 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.265 -0.897 . . . . 0.0 110.091 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.708 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 8.3 t70 -85.14 -86.57 0.13 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.269 -0.894 . . . . 0.0 110.217 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.708 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 170.31 -27.66 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.188 -0.945 . . . . 0.0 110.354 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.439 ' O ' ' CG1' ' A' ' 9' ' ' ILE . . . -105.01 -81.51 0.53 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.174 -0.954 . . . . 0.0 110.335 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.485 ' C ' ' CG1' ' A' ' 9' ' ' ILE . 89.5 m -41.18 155.4 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.292 -0.88 . . . . 0.0 110.458 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.696 HG22 ' HB ' ' A' ' 1' ' ' VAL . 6.1 mt -150.11 145.78 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.212 -0.93 . . . . 0.0 110.181 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.675 ' O ' HG12 ' A' ' 1' ' ' VAL . 0.0 OUTLIER -130.08 -170.2 0.21 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 110.22 179.591 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.583 ' CD ' ' CB ' ' A' ' 10' ' ' CYS . 45.8 Cg_endo -87.27 175.4 4.77 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.822 1.433 . . . . 0.0 110.75 -178.802 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -91.63 151.37 20.72 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.296 -0.878 . . . . 0.0 110.3 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.85 -6.09 51.42 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 4.6 p -114.39 171.68 7.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.192 -1.181 . . . . 0.0 110.25 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.519 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 14.7 t -115.94 134.33 55.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.312 -0.867 . . . . 0.0 110.311 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.2 m -45.05 147.02 0.74 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.244 -0.91 . . . . 0.0 110.367 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.569 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 29.0 m -161.69 135.02 6.34 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.306 -0.871 . . . . 0.0 110.337 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.539 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -106.64 142.39 36.36 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.225 -0.922 . . . . 0.0 110.211 179.996 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.503 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -84.14 168.02 24.11 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.168 -0.957 . . . . 0.0 110.291 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.585 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.5 Cg_endo -69.61 -8.83 24.62 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 124.098 1.578 . . . . 0.0 110.176 -179.726 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.585 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -103.63 0.95 31.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.432 -0.792 . . . . 0.0 109.627 179.173 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.98 16.88 49.74 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.254 -1.538 . . . . 0.0 109.254 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.506 ' O ' HD23 ' A' ' 18' ' ' LEU . 97.2 t -86.59 115.52 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.359 -1.083 . . . . 0.0 110.295 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.539 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 1.0 OUTLIER -75.61 135.41 40.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.294 -0.879 . . . . 0.0 110.325 179.973 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.569 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 24.8 p90 -163.8 176.56 9.4 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.252 -0.905 . . . . 0.0 110.35 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.497 ' SG ' ' HD2' ' A' ' 11' ' ' PRO . 11.1 p -114.38 130.06 56.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.344 -0.847 . . . . 0.0 110.26 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.401 ' O ' HG22 ' A' ' 15' ' ' THR . 1.1 p -99.94 146.03 31.2 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 0.0 110.253 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -73.13 104.43 1.78 Allowed 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 123.999 1.526 . . . . 0.0 110.411 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.519 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 0.5 OUTLIER -120.54 160.63 22.79 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.314 -0.866 . . . . 0.0 110.406 -179.848 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.9 t . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.232 179.844 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.7 ' HB ' HG22 ' A' ' 9' ' ' ILE . 6.5 m . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 121.281 0.562 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.476 ' O ' ' HB2' ' A' ' 10' ' ' CYS . 2.6 mp -90.06 154.8 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.279 -0.888 . . . . 0.0 110.274 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.49 ' NE2' HG23 ' A' ' 9' ' ' ILE . 15.0 m-70 -129.42 114.86 16.68 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.188 -0.945 . . . . 0.0 110.198 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 30.0 m -71.51 -39.6 70.68 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 110.318 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.698 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 23.7 t0 -125.18 -59.75 1.38 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.221 -0.924 . . . . 0.0 110.406 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.698 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 170.6 -25.37 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.174 -0.954 . . . . 0.0 110.43 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -100.05 -51.31 3.72 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 44.5 m -70.09 128.15 35.28 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.308 -0.87 . . . . 0.0 110.397 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.7 HG22 ' HB ' ' A' ' 1' ' ' VAL . 4.1 mt -97.64 176.7 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.209 -0.932 . . . . 0.0 110.07 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.488 ' O ' ' HA ' ' A' ' 1' ' ' VAL . 30.3 m -152.85 139.41 12.42 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.288 -0.882 . . . . 0.0 110.637 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.37 177.82 8.3 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 O-C-N 124.126 1.593 . . . . 0.0 110.433 179.524 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 12' ' ' ASP . 0.9 OUTLIER -85.19 147.85 26.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.167 -0.958 . . . . 0.0 110.311 179.779 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 92.93 -7.29 76.77 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.43 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 4.1 p -109.83 169.58 8.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.228 -1.16 . . . . 0.0 110.308 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.691 HG22 ' O ' ' A' ' 27' ' ' SER . 15.4 t -125.83 151.1 47.26 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.228 -0.92 . . . . 0.0 110.359 -179.777 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.464 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 1.1 m -66.56 148.76 51.44 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.336 -0.852 . . . . 0.0 110.525 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.515 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 0.2 OUTLIER -170.31 137.26 1.45 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.35 -0.844 . . . . 0.0 110.223 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.466 ' HG ' ' CE3' ' A' ' 24' ' ' TRP . 0.3 OUTLIER -96.46 141.11 30.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 110.277 -179.982 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.544 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.6 OUTLIER -78.78 169.86 18.77 Favored Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.324 -0.86 . . . . 0.0 110.244 -179.918 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.573 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.7 Cg_endo -69.46 -16.5 38.84 Favored 'Trans proline' 0 C--N 1.301 -1.97 0 O-C-N 124.075 1.566 . . . . 0.0 109.939 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.573 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 2.9 m-85 -98.74 1.99 46.59 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.516 -0.74 . . . . 0.0 109.593 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.95 23.22 33.32 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.544 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 23.8 t -92.3 112.77 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.284 -1.127 . . . . 0.0 110.304 -179.757 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.466 ' CE3' ' HG ' ' A' ' 18' ' ' LEU . 1.6 m95 -65.98 126.43 28.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.274 -0.891 . . . . 0.0 110.271 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.515 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 6.3 p90 -157.19 177.37 11.55 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.079 -1.013 . . . . 0.0 110.388 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 15' ' ' THR . 1.9 m -126.5 138.61 53.52 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.425 -0.797 . . . . 0.0 110.098 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.691 ' O ' HG22 ' A' ' 15' ' ' THR . 0.0 OUTLIER -111.41 139.25 21.81 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.202 -0.936 . . . . 0.0 110.576 -179.474 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -74.62 118.49 5.34 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.076 1.566 . . . . 0.0 110.331 179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' A' ' 29' ' ' PHE . 40.2 p90 -101.0 142.38 32.56 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.204 -0.935 . . . . 0.0 110.303 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 29' ' ' PHE . 75.4 m . . . . . 0 N--CA 1.491 1.576 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.265 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.567 ' O ' HG23 ' A' ' 1' ' ' VAL . 3.4 m . . . . . 0 N--CA 1.494 1.741 0 CA-C-O 121.295 0.569 . . . . 0.0 110.417 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.513 ' HA ' HD13 ' A' ' 2' ' ' ILE . 5.2 mm -58.71 161.73 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.265 -0.897 . . . . 0.0 110.061 179.464 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.571 ' NE2' HG23 ' A' ' 9' ' ' ILE . 1.9 m-70 -149.01 125.92 11.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.257 -0.902 . . . . 0.0 110.507 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 28.3 p -126.44 21.52 7.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.336 -0.853 . . . . 0.0 110.111 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.461 ' N ' ' OD1' ' A' ' 5' ' ' ASP . 23.3 p-10 -167.65 -128.95 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.369 -0.832 . . . . 0.0 110.008 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.1 11.54 2.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.065 -1.022 . . . . 0.0 110.284 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.444 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -139.93 -85.1 0.23 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.227 -0.921 . . . . 0.0 110.459 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.444 ' C ' ' O ' ' A' ' 7' ' ' ALA . 55.9 m -40.81 141.6 0.56 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.23 -0.919 . . . . 0.0 110.524 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.571 HG23 ' NE2' ' A' ' 3' ' ' HIS . 7.8 mt -128.47 146.74 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.23 -0.919 . . . . 0.0 110.008 179.529 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.508 ' O ' ' HA ' ' A' ' 1' ' ' VAL . 46.0 m -122.26 145.38 44.13 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.199 -0.938 . . . . 0.0 110.408 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.32 -173.53 1.32 Allowed 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 124.097 1.577 . . . . 0.0 110.258 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.498 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 2.5 m-20 -86.64 151.16 23.67 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.231 -0.918 . . . . 0.0 110.422 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.81 8.4 73.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 5.4 p -133.58 167.88 19.68 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.267 -1.137 . . . . 0.0 110.313 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.658 HG22 ' O ' ' A' ' 27' ' ' SER . 10.4 t -128.49 141.41 51.39 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 0.0 110.203 179.686 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.75 138.16 57.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.226 -0.921 . . . . 0.0 110.139 -179.883 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.532 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 2.4 t -148.64 138.33 22.08 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.214 -0.929 . . . . 0.0 110.289 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.522 ' HA ' HD23 ' A' ' 18' ' ' LEU . 0.0 OUTLIER -95.94 131.06 42.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.384 -0.823 . . . . 0.0 110.037 179.692 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.573 ' OG ' ' HB ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -78.41 169.79 19.18 Favored Pre-proline 0 C--N 1.3 -1.561 0 O-C-N 121.346 -0.846 . . . . 0.0 110.52 -179.817 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.625 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 37.6 Cg_endo -69.07 -13.62 36.74 Favored 'Trans proline' 0 C--N 1.301 -1.959 0 O-C-N 124.208 1.636 . . . . 0.0 109.996 179.588 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.625 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 2.1 m-85 -92.03 -11.44 35.94 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.444 -0.785 . . . . 0.0 109.445 178.67 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.48 24.04 14.98 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.573 ' HB ' ' OG ' ' A' ' 19' ' ' SER . 39.9 t -102.04 125.47 56.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.17 -1.194 . . . . 0.0 110.2 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.454 ' CH2' ' HB2' ' A' ' 18' ' ' LEU . 1.7 m95 -81.09 119.09 23.12 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.284 -0.885 . . . . 0.0 110.27 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.532 ' CE1' ' HB3' ' A' ' 17' ' ' SER . 30.8 p90 -140.14 168.1 20.59 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.067 -1.021 . . . . 0.0 110.503 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 10.2 m -94.82 111.32 23.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.302 -0.874 . . . . 0.0 110.271 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.658 ' O ' HG22 ' A' ' 15' ' ' THR . 0.2 OUTLIER -96.05 147.47 33.02 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.348 -0.845 . . . . 0.0 110.396 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -77.39 125.26 7.59 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 124.059 1.557 . . . . 0.0 110.455 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.429 ' O ' ' O ' ' A' ' 30' ' ' SER . 36.6 p90 -104.82 154.38 20.12 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.186 -0.946 . . . . 0.0 110.207 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 29' ' ' PHE . 75.0 m . . . . . 0 N--CA 1.492 1.629 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.305 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 20.5 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.279 0.561 . . . . 0.0 110.261 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.507 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 26.5 mm -55.9 148.21 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.918 . . . . 0.0 110.143 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.511 ' CE1' HD13 ' A' ' 9' ' ' ILE . 0.8 OUTLIER -130.85 129.45 42.34 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.228 -0.92 . . . . 0.0 110.455 -179.795 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.474 ' O ' ' N ' ' A' ' 6' ' ' ALA . 58.0 m -142.01 -175.2 4.32 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.285 -0.885 . . . . 0.0 110.036 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.487 ' HB2' ' CE2' ' A' ' 24' ' ' TRP . 4.5 t70 54.75 -88.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.168 -0.958 . . . . 0.0 110.218 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.474 ' N ' ' O ' ' A' ' 4' ' ' CYS . . . -171.9 -40.2 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.254 -0.904 . . . . 0.0 110.326 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.406 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -119.82 -59.22 1.83 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.2 -0.937 . . . . 0.0 110.308 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.406 ' C ' ' O ' ' A' ' 7' ' ' ALA . 6.9 m -43.77 151.81 0.19 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.195 -0.941 . . . . 0.0 110.318 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.511 HD13 ' CE1' ' A' ' 3' ' ' HIS . 12.8 mt -131.23 167.37 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.209 -0.932 . . . . 0.0 110.279 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.507 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 55.7 m -133.87 147.5 64.49 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.2 -0.938 . . . . 0.0 110.205 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.55 -177.02 3.07 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.055 1.555 . . . . 0.0 110.607 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -84.72 151.94 24.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.268 -0.895 . . . . 0.0 110.237 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.45 28.47 57.6 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.547 ' C ' ' CE2' ' A' ' 29' ' ' PHE . 5.3 p -149.41 166.89 27.73 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.28 -1.13 . . . . 0.0 110.38 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.621 ' HB ' ' CE1' ' A' ' 29' ' ' PHE . 13.1 t -121.92 155.47 35.41 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.337 -0.852 . . . . 0.0 110.295 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 74.0 m -82.22 144.6 30.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.924 . . . . 0.0 110.124 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.49 ' HB2' ' CZ ' ' A' ' 25' ' ' TYR . 62.6 m -154.37 160.75 41.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 110.416 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.591 ' HG ' ' CZ3' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -114.81 134.13 55.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.875 . . . . 0.0 110.179 179.585 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.533 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -74.07 172.56 8.25 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.304 -0.872 . . . . 0.0 110.382 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.614 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.5 Cg_endo -69.87 -11.48 30.79 Favored 'Trans proline' 0 C--N 1.302 -1.879 0 O-C-N 123.976 1.514 . . . . 0.0 110.023 -179.749 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.614 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.4 m-85 -103.51 0.82 31.52 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.433 -0.792 . . . . 0.0 109.643 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 90.17 27.84 19.57 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.564 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.533 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 34.2 t -94.96 123.71 47.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.309 -1.112 . . . . 0.0 110.304 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.591 ' CZ3' ' HG ' ' A' ' 18' ' ' LEU . 2.7 m95 -78.6 114.92 17.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.205 -0.934 . . . . 0.0 110.202 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.49 ' CZ ' ' HB2' ' A' ' 17' ' ' SER . 29.1 p90 -136.08 172.53 12.88 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.189 -0.945 . . . . 0.0 110.161 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 8.0 m -114.98 117.38 30.44 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.273 -0.892 . . . . 0.0 110.276 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.4 p -96.47 161.63 26.17 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.308 -0.87 . . . . 0.0 110.162 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -74.79 170.59 20.02 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.889 1.468 . . . . 0.0 110.527 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.621 ' CE1' ' HB ' ' A' ' 15' ' ' THR . 17.4 m-85 -98.47 87.45 3.85 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.281 -0.887 . . . . 0.0 110.169 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.2 p . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.185 179.994 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.538 ' HB ' HG22 ' A' ' 9' ' ' ILE . 21.1 m . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 121.157 0.504 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.548 HG21 ' SG ' ' A' ' 16' ' ' CYS . 18.5 mm -54.28 164.84 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.231 -0.918 . . . . 0.0 109.996 179.776 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.514 ' O ' ' N ' ' A' ' 5' ' ' ASP . 5.5 m-70 -126.03 -19.47 4.78 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.121 -0.987 . . . . 0.0 110.734 -179.477 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.492 ' HB2' ' O ' ' A' ' 3' ' ' HIS . 9.3 m 66.07 -61.28 0.28 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.232 -0.917 . . . . 0.0 110.289 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.575 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 23.0 t0 -126.32 -56.44 1.42 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.218 -0.926 . . . . 0.0 110.279 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.575 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 176.34 -32.48 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.304 -0.872 . . . . 0.0 110.22 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.42 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -100.07 -77.97 0.52 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.227 -0.921 . . . . 0.0 110.244 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.42 ' C ' ' O ' ' A' ' 7' ' ' ALA . 3.1 m -43.36 116.35 0.91 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.218 -0.926 . . . . 0.0 110.213 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.538 HG22 ' HB ' ' A' ' 1' ' ' VAL . 9.7 mt -97.28 145.4 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.227 -0.921 . . . . 0.0 110.206 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.52 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 7.4 m -124.51 149.89 63.08 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.238 -0.914 . . . . 0.0 110.108 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.473 ' O ' ' OG1' ' A' ' 14' ' ' THR . 43.4 Cg_endo -73.0 176.62 8.83 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 123.977 1.514 . . . . 0.0 110.493 -179.845 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -84.35 165.71 18.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.252 -0.905 . . . . 0.0 110.315 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.59 11.8 65.97 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.473 ' OG1' ' O ' ' A' ' 11' ' ' PRO . 9.1 p -127.47 172.59 10.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.28 -1.129 . . . . 0.0 110.265 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.51 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 12.4 t -125.94 152.79 45.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.275 -0.891 . . . . 0.0 110.283 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.548 ' SG ' HG21 ' A' ' 2' ' ' ILE . 98.0 m -82.11 136.0 35.23 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.303 -0.873 . . . . 0.0 110.24 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.568 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 1.0 OUTLIER -142.45 148.51 37.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -0.93 . . . . 0.0 110.27 179.996 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.524 ' HG ' ' CE2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -104.41 140.78 37.43 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.351 -0.843 . . . . 0.0 110.431 -179.864 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.426 ' HB2' ' HD2' ' A' ' 20' ' ' PRO . 1.0 OUTLIER -86.38 171.98 9.25 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.325 -0.859 . . . . 0.0 110.454 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.577 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.5 Cg_endo -69.57 -14.67 37.04 Favored 'Trans proline' 0 C--N 1.3 -1.975 0 O-C-N 124.05 1.553 . . . . 0.0 109.905 179.444 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.577 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.1 m-85 -98.59 0.12 44.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.352 -0.842 . . . . 0.0 109.774 179.056 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.74 30.8 17.11 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.405 ' O ' HD23 ' A' ' 18' ' ' LEU . 68.4 t -100.65 123.99 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.227 -1.16 . . . . 0.0 110.223 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.524 ' CE2' ' HG ' ' A' ' 18' ' ' LEU . 3.5 m95 -83.36 114.07 21.17 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.28 -0.887 . . . . 0.0 110.036 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.568 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 42.1 p90 -132.65 172.01 13.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 110.337 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.4 m -102.47 132.7 48.33 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.349 -0.845 . . . . 0.0 110.112 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.471 ' O ' HG22 ' A' ' 15' ' ' THR . 0.3 OUTLIER -109.75 137.63 20.46 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.13 -0.981 . . . . 0.0 110.097 179.802 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -72.92 109.39 2.8 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 124.009 1.531 . . . . 0.0 110.555 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.567 ' CG ' ' O ' ' A' ' 29' ' ' PHE . 2.9 p90 -129.31 125.28 36.39 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 110.371 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.259 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.589 ' O ' HG23 ' A' ' 1' ' ' VAL . 34.9 m . . . . . 0 N--CA 1.496 1.832 0 CA-C-O 121.246 0.546 . . . . 0.0 110.346 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.441 HD13 ' HA ' ' A' ' 2' ' ' ILE . 13.1 mm -50.53 158.13 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.146 -0.972 . . . . 0.0 109.75 179.296 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.545 ' O ' ' N ' ' A' ' 5' ' ' ASP . 1.1 m-70 -136.7 -48.03 0.62 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.09 -1.006 . . . . 0.0 110.536 -179.446 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.485 ' HB2' ' O ' ' A' ' 3' ' ' HIS . 81.0 m 59.0 -77.11 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.304 -0.872 . . . . 0.0 110.1 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 3' ' ' HIS . 3.0 t70 -78.74 -135.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.231 -0.918 . . . . 0.0 110.013 179.468 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.14 8.37 4.37 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.127 -0.983 . . . . 0.0 110.367 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.432 ' O ' HG13 ' A' ' 9' ' ' ILE . . . -139.91 -84.72 0.23 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.225 -0.922 . . . . 0.0 110.49 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.59 HG21 ' HB3' ' A' ' 24' ' ' TRP . 7.1 m -40.89 100.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.336 -0.852 . . . . 0.0 110.511 -179.573 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.535 HG23 ' CD2' ' A' ' 3' ' ' HIS . 6.9 mt -89.42 169.56 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.343 -0.848 . . . . 0.0 110.211 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.469 ' O ' ' HB ' ' A' ' 1' ' ' VAL . 3.0 m -143.15 162.64 41.99 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.213 -0.929 . . . . 0.0 110.399 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -80.0 -159.59 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.037 1.546 . . . . 0.0 110.464 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.467 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 5.6 m-20 -107.13 150.1 26.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.204 -0.935 . . . . 0.0 110.286 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 86.12 29.12 26.32 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.498 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 0.9 OUTLIER -144.12 170.53 15.77 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -1.164 . . . . 0.0 110.312 179.871 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.532 HG22 ' O ' ' A' ' 27' ' ' SER . 9.5 t -125.61 142.48 51.49 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.209 -0.932 . . . . 0.0 110.367 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.401 ' C ' ' HG ' ' A' ' 17' ' ' SER . 3.3 m -65.26 142.62 58.22 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.325 -0.859 . . . . 0.0 110.271 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.401 ' HG ' ' C ' ' A' ' 16' ' ' CYS . 14.3 m -158.84 130.43 6.45 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.275 -0.891 . . . . 0.0 110.056 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.535 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -94.45 136.78 34.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 110.45 -179.796 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.1 p -79.81 169.54 19.67 Favored Pre-proline 0 N--CA 1.487 1.412 0 O-C-N 121.275 -0.891 . . . . 0.0 110.256 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.584 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 40.3 Cg_endo -69.67 -6.76 19.33 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 O-C-N 124.056 1.556 . . . . 0.0 110.183 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.584 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.7 m-85 -106.2 -3.0 21.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.331 -0.856 . . . . 0.0 109.965 179.295 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.18 13.74 47.87 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.2 113.82 24.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.137 -1.213 . . . . 0.0 110.012 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.59 ' HB3' HG21 ' A' ' 8' ' ' THR . 0.0 OUTLIER -76.98 116.92 18.07 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.336 -0.853 . . . . 0.0 110.324 -179.726 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 8.1 p90 -143.39 176.11 9.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.274 -0.891 . . . . 0.0 110.241 179.737 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.498 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 58.0 m -124.47 138.11 54.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 110.193 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.532 ' O ' HG22 ' A' ' 15' ' ' THR . 1.2 t -107.89 150.39 40.25 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.24 -0.913 . . . . 0.0 110.705 -179.107 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -77.29 121.03 5.52 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 124.13 1.595 . . . . 0.0 110.405 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.45 ' CD1' ' HB2' ' A' ' 30' ' ' SER . 42.3 p90 -111.95 163.93 13.68 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.157 -0.964 . . . . 0.0 110.314 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' SER . . . . . 0.45 ' HB2' ' CD1' ' A' ' 29' ' ' PHE . 5.0 m . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 118.007 -0.996 . . . . 0.0 110.286 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.566 HG21 HG21 ' A' ' 9' ' ' ILE . 19.5 m . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.317 0.58 . . . . 0.0 110.249 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.538 ' N ' ' O ' ' A' ' 10' ' ' CYS . 37.4 mm -85.22 156.98 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.25 -0.907 . . . . 0.0 110.134 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.625 ' NE2' HG23 ' A' ' 9' ' ' ILE . 4.0 m-70 -139.48 118.94 12.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.281 -0.887 . . . . 0.0 110.24 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.411 ' HB2' ' HB3' ' A' ' 16' ' ' CYS . 13.5 m -133.86 10.64 3.95 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.259 -0.901 . . . . 0.0 110.385 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.461 ' OD1' ' N ' ' A' ' 6' ' ' ALA . 0.7 OUTLIER -130.96 -101.12 0.3 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.184 -0.948 . . . . 0.0 110.191 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.461 ' N ' ' OD1' ' A' ' 5' ' ' ASP . . . -162.8 -43.15 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.061 -1.024 . . . . 0.0 110.065 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.72 -51.51 2.83 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 110.088 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.423 HG22 ' N ' ' A' ' 9' ' ' ILE . 52.5 m -57.59 161.77 3.39 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.333 -0.854 . . . . 0.0 110.223 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.625 HG23 ' NE2' ' A' ' 3' ' ' HIS . 12.7 mt -140.7 172.71 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.259 -0.901 . . . . 0.0 110.055 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.538 ' O ' ' N ' ' A' ' 2' ' ' ILE . 56.8 m -143.22 137.87 15.13 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.182 -0.949 . . . . 0.0 110.521 -179.706 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.28 -166.08 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.939 1.494 . . . . 0.0 110.267 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 52.2 m-20 -90.08 147.93 23.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.198 -0.939 . . . . 0.0 110.199 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.45 18.63 60.05 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.443 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 0.6 OUTLIER -136.06 171.26 14.74 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.245 -1.15 . . . . 0.0 110.306 179.967 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.737 HG22 ' O ' ' A' ' 27' ' ' SER . 15.3 t -132.55 140.88 48.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.236 -0.915 . . . . 0.0 110.261 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.411 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 29.3 m -65.26 131.72 47.23 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.267 -0.895 . . . . 0.0 110.136 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -156.54 138.2 14.15 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.098 -1.001 . . . . 0.0 110.46 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.449 HD23 ' O ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -88.72 143.49 26.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.324 -0.86 . . . . 0.0 110.287 179.726 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.464 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -82.24 169.54 17.99 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.318 -0.864 . . . . 0.0 110.478 -179.699 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.578 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.3 Cg_endo -69.02 -14.43 38.43 Favored 'Trans proline' 0 C--N 1.302 -1.909 0 O-C-N 124.135 1.597 . . . . 0.0 110.166 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.578 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 2.5 m-85 -100.19 1.62 42.15 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.379 -0.826 . . . . 0.0 109.614 178.884 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.77 29.45 15.84 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.464 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 76.5 t -103.75 123.49 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.246 -1.149 . . . . 0.0 110.445 -179.667 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.472 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.9 OUTLIER -76.86 118.74 19.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.249 -0.907 . . . . 0.0 110.312 179.906 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.524 ' CE2' ' OG ' ' A' ' 27' ' ' SER . 40.7 p90 -144.28 168.6 19.69 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.084 -1.01 . . . . 0.0 110.681 179.574 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.443 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 3.4 m -106.09 117.93 35.31 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.446 -0.784 . . . . 0.0 109.649 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.737 ' O ' HG22 ' A' ' 15' ' ' THR . 0.7 OUTLIER -93.81 142.65 25.36 Favored Pre-proline 0 C--N 1.303 -1.455 0 O-C-N 121.174 -0.954 . . . . 0.0 110.716 -178.943 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -75.69 126.19 9.36 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 124.135 1.597 . . . . 0.0 110.46 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.542 ' CG ' ' O ' ' A' ' 29' ' ' PHE . 34.6 p90 -123.67 118.33 27.01 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.242 -0.911 . . . . 0.0 110.268 179.846 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.331 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 29.1 m . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 121.266 0.555 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.508 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 32.7 mm -77.67 146.49 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.213 -0.929 . . . . 0.0 110.312 -179.849 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.605 ' CD2' HG23 ' A' ' 9' ' ' ILE . 3.9 m-70 -138.04 83.29 1.97 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.315 -0.866 . . . . 0.0 110.089 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -72.32 -32.01 66.17 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.301 -0.874 . . . . 0.0 110.441 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.488 ' OD2' ' NE1' ' A' ' 24' ' ' TRP . 0.6 OUTLIER -116.34 -89.64 0.57 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.18 -0.95 . . . . 0.0 110.357 -179.849 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -171.89 -32.84 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.162 -0.962 . . . . 0.0 110.354 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -99.31 -83.63 0.42 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 110.234 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.452 HG21 ' O ' ' A' ' 24' ' ' TRP . 62.9 m -52.17 106.55 0.15 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.225 -0.922 . . . . 0.0 110.158 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.605 HG23 ' CD2' ' A' ' 3' ' ' HIS . 6.2 mt -90.65 165.02 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.191 -0.943 . . . . 0.0 110.335 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.508 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 99.4 m -133.73 140.74 37.57 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.267 -0.896 . . . . 0.0 110.057 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.0 173.81 13.43 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.901 1.474 . . . . 0.0 110.424 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.474 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 1.1 m-20 -77.12 152.5 34.91 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.281 -0.887 . . . . 0.0 110.472 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' A' ' 29' ' ' PHE . . . 90.55 -8.27 80.07 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.519 HG22 ' HA ' ' A' ' 28' ' ' PRO . 2.0 p -116.95 166.52 12.07 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.183 -1.186 . . . . 0.0 110.151 179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.674 ' O ' HG23 ' A' ' 15' ' ' THR . 14.8 t -123.54 119.36 29.7 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.333 -0.854 . . . . 0.0 110.375 179.683 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' CYS . . . . . 0.453 ' O ' ' OG ' ' A' ' 17' ' ' SER . 20.6 p -50.34 158.36 0.59 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.214 -0.929 . . . . 0.0 110.18 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.601 ' HB2' ' CZ ' ' A' ' 25' ' ' TYR . 42.4 m -167.44 146.64 5.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.198 -0.938 . . . . 0.0 110.022 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.57 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -108.6 134.73 50.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 110.485 -179.654 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.483 ' HB3' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -78.53 167.79 32.45 Favored Pre-proline 0 C--N 1.304 -1.399 0 O-C-N 121.34 -0.85 . . . . 0.0 109.989 179.543 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.593 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 37.9 Cg_endo -69.56 -11.92 32.15 Favored 'Trans proline' 0 C--N 1.3 -2.009 0 O-C-N 124.022 1.538 . . . . 0.0 109.942 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.593 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.2 m-85 -97.79 -2.31 41.32 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.399 -0.813 . . . . 0.0 109.75 178.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.85 21.17 29.07 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.483 ' HB ' ' HB3' ' A' ' 19' ' ' SER . 75.6 t -91.54 119.58 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.273 -1.133 . . . . 0.0 110.38 -179.744 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.57 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 0.6 OUTLIER -84.01 126.66 33.26 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.266 -0.896 . . . . 0.0 110.181 179.765 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.601 ' CZ ' ' HB2' ' A' ' 17' ' ' SER . 32.6 p90 -147.75 174.82 11.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.215 -0.928 . . . . 0.0 110.246 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 4.0 m -114.18 107.65 15.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.261 -0.9 . . . . 0.0 110.223 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.484 ' HB3' HG23 ' A' ' 15' ' ' THR . 9.8 t -70.59 144.01 90.78 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.192 -0.943 . . . . 0.0 109.897 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.519 ' HA ' HG22 ' A' ' 14' ' ' THR . 47.6 Cg_endo -76.17 170.61 19.7 Favored 'Trans proline' 0 C--N 1.299 -2.053 0 O-C-N 123.817 1.43 . . . . 0.0 110.918 -179.363 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 13' ' ' GLY . 2.4 m-85 -97.32 83.59 3.32 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.459 -0.776 . . . . 0.0 110.201 179.804 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.708 0 CA-C-O 117.999 -1.0 . . . . 0.0 110.248 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' VAL . . . . . 0.727 HG23 HG21 ' A' ' 9' ' ' ILE . 5.9 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.233 0.539 . . . . 0.0 110.331 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.462 ' O ' ' N ' ' A' ' 10' ' ' CYS . 30.1 mm -44.1 152.87 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.273 -0.892 . . . . 0.0 110.223 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.597 ' CE1' HG23 ' A' ' 9' ' ' ILE . 1.0 OUTLIER -120.38 -64.69 1.22 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.184 -0.947 . . . . 0.0 110.336 -179.921 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 4' ' ' CYS . . . . . 0.517 ' HB3' ' O ' ' A' ' 3' ' ' HIS . 1.7 t 59.65 -72.29 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.511 -0.743 . . . . 0.0 110.386 179.753 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.565 ' N ' ' O ' ' A' ' 3' ' ' HIS . 81.1 m-20 -54.75 -163.67 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.178 -0.951 . . . . 0.0 110.297 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -103.92 -19.93 14.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.12 -0.988 . . . . 0.0 110.547 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.426 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -135.72 -79.69 0.42 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.257 -0.902 . . . . 0.0 110.557 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 7' ' ' ALA . 97.5 m -41.24 132.13 2.61 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.344 -0.847 . . . . 0.0 110.387 -179.636 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.727 HG21 HG23 ' A' ' 1' ' ' VAL . 0.9 OUTLIER -98.46 175.78 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.265 -0.897 . . . . 0.0 110.048 179.972 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 10' ' ' CYS . . . . . 0.462 ' N ' ' O ' ' A' ' 2' ' ' ILE . 1.5 m -130.0 132.9 24.42 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 110.329 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' PRO . . . . . 0.495 ' O ' ' O ' ' A' ' 12' ' ' ASP . 48.5 Cg_endo -77.78 154.42 30.3 Favored 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.009 1.531 . . . . 0.0 110.02 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.495 ' O ' ' O ' ' A' ' 11' ' ' PRO . 7.3 m-20 48.66 179.22 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.164 -0.96 . . . . 0.0 110.139 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' A' ' 14' ' ' THR . . . -55.42 -64.19 4.6 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 179.699 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.52 ' O ' ' O ' ' A' ' 13' ' ' GLY . 0.8 OUTLIER 44.39 -179.24 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.545 -0.973 . . . . 0.0 110.963 179.294 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 15' ' ' THR . . . . . 1.057 HG22 ' O ' ' A' ' 27' ' ' SER . 9.9 t -136.41 155.58 49.82 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.292 -0.88 . . . . 0.0 110.195 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -69.8 127.85 34.35 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.269 -0.894 . . . . 0.0 110.225 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.584 ' O ' ' CD1' ' A' ' 25' ' ' TYR . 8.2 m -142.61 125.09 15.69 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.213 -0.929 . . . . 0.0 110.19 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.573 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -101.66 137.59 39.77 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.199 -0.938 . . . . 0.0 110.192 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.5 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.2 p -79.18 167.13 37.01 Favored Pre-proline 0 C--N 1.303 -1.454 0 O-C-N 121.315 -0.866 . . . . 0.0 110.423 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.587 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.0 Cg_endo -69.61 -7.93 22.29 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 O-C-N 124.041 1.548 . . . . 0.0 110.118 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' TYR . . . . . 0.587 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -103.89 -2.54 26.06 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.476 -0.765 . . . . 0.0 109.639 178.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.9 24.97 15.77 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.5 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 72.2 t -95.29 114.85 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.263 -1.139 . . . . 0.0 110.402 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' TRP . . . . . 0.573 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -76.62 123.46 26.14 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.327 -0.858 . . . . 0.0 110.379 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 25' ' ' TYR . . . . . 0.584 ' CD1' ' O ' ' A' ' 17' ' ' SER . 22.9 p90 -147.58 173.35 12.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.143 -0.973 . . . . 0.0 110.29 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' CYS . . . . . 0.47 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 3.4 m -106.11 147.05 29.42 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.374 -0.829 . . . . 0.0 110.221 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' SER . . . . . 1.057 ' O ' HG22 ' A' ' 15' ' ' THR . 0.9 OUTLIER -130.71 149.26 73.08 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.9 . . . . 0.0 110.346 179.951 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -74.06 127.67 11.58 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 O-C-N 124.098 1.578 . . . . 0.0 110.312 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -107.45 171.79 7.19 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.2 -0.938 . . . . 0.0 110.324 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.7 t . . . . . 0 N--CA 1.491 1.576 0 CA-C-O 118.045 -0.978 . . . . 0.0 110.264 -179.88 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.521 ' HB ' HG22 ' A' ' 9' ' ' ILE . 26.9 m . . . . . 0 N--CA 1.493 1.713 0 CA-C-O 121.278 0.561 . . . . 0.0 110.264 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.504 HG22 ' N ' ' A' ' 3' ' ' HIS . 2.0 mp -87.54 166.32 1.94 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.212 -0.93 . . . . 0.0 110.276 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.504 ' N ' HG22 ' A' ' 2' ' ' ILE . 9.5 m-70 -141.75 161.01 39.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.221 -0.924 . . . . 0.0 110.3 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 26.8 p -161.05 -36.74 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.206 -0.934 . . . . 0.0 110.254 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.653 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 13.5 m-20 -93.91 -78.93 0.42 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.225 -0.922 . . . . 0.0 110.19 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.653 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 171.72 -31.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.282 -0.886 . . . . 0.0 110.144 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.65 -61.49 1.7 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.311 -0.868 . . . . 0.0 110.175 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.8 m -55.22 150.45 11.0 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.246 -0.909 . . . . 0.0 110.14 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.521 HG22 ' HB ' ' A' ' 1' ' ' VAL . 8.4 mt -119.84 172.3 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -0.927 . . . . 0.0 110.245 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.467 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 19.3 t -131.51 136.64 28.89 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.248 -0.907 . . . . 0.0 110.18 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -72.46 -161.1 0.1 OUTLIER 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.978 1.514 . . . . 0.0 110.569 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.412 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 0.9 OUTLIER -96.0 150.17 20.77 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.23 -0.919 . . . . 0.0 110.414 -179.745 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.658 ' O ' HG23 ' A' ' 14' ' ' THR . . . 64.81 53.29 35.42 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.658 HG23 ' O ' ' A' ' 13' ' ' GLY . 0.9 OUTLIER -159.39 170.67 21.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.203 -1.175 . . . . 0.0 110.378 179.931 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.481 ' O ' HG23 ' A' ' 15' ' ' THR . 12.2 t -130.88 131.9 44.82 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.346 -0.846 . . . . 0.0 110.235 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.2 132.76 43.97 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.292 -0.88 . . . . 0.0 110.302 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -152.12 157.88 42.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 110.245 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.465 ' HA ' HD23 ' A' ' 18' ' ' LEU . 0.2 OUTLIER -105.87 136.22 45.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.313 -0.867 . . . . 0.0 110.288 -179.944 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.508 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.9 OUTLIER -78.31 165.37 50.67 Favored Pre-proline 0 N--CA 1.488 1.446 0 O-C-N 121.24 -0.912 . . . . 0.0 110.213 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.589 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.9 Cg_endo -69.39 -11.61 31.72 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 O-C-N 124.038 1.546 . . . . 0.0 110.04 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.589 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.7 m-85 -101.54 5.2 41.69 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.476 -0.765 . . . . 0.0 109.553 178.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.74 21.16 51.82 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.508 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 60.6 t -93.9 123.08 45.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.32 -1.106 . . . . 0.0 110.281 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.559 ' CE2' ' OD1' ' A' ' 5' ' ' ASP . 1.3 m95 -81.09 130.71 35.14 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.243 -0.911 . . . . 0.0 110.21 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.1 p90 -165.42 173.08 11.45 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.207 -0.933 . . . . 0.0 110.331 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.409 ' SG ' ' C ' ' A' ' 15' ' ' THR . 0.1 OUTLIER -109.19 137.22 47.41 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -0.924 . . . . 0.0 110.24 179.705 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.9 t -108.4 147.44 35.67 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.263 -0.898 . . . . 0.0 110.338 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.6 114.14 3.96 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.029 1.541 . . . . 0.0 110.476 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.48 ' CD1' ' C ' ' A' ' 29' ' ' PHE . 20.9 p90 . . . . . 0 N--CA 1.492 1.657 0 O-C-N 121.253 -0.905 . . . . 0.0 110.295 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.596 ' HB ' HG22 ' A' ' 9' ' ' ILE . 30.5 m . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 121.138 0.494 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.422 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 31.9 mm -105.3 157.17 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.251 -0.906 . . . . 0.0 110.572 -179.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.486 ' NE2' HG23 ' A' ' 9' ' ' ILE . 12.4 m-70 -134.53 125.75 27.95 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.277 -0.889 . . . . 0.0 110.061 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -113.41 -50.65 2.85 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 0.0 110.501 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.605 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 12.8 t70 -90.86 -70.01 0.7 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.261 -0.899 . . . . 0.0 110.479 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.605 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 175.17 -46.55 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.195 -0.941 . . . . 0.0 110.36 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -100.14 -20.07 16.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.204 -0.935 . . . . 0.0 110.342 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.7 m -82.84 140.72 32.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.303 -0.873 . . . . 0.0 110.266 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.596 HG22 ' HB ' ' A' ' 1' ' ' VAL . 4.3 mt -125.91 166.38 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.193 -0.942 . . . . 0.0 110.293 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 1' ' ' VAL . 10.0 m -147.3 155.6 46.32 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.265 -0.897 . . . . 0.0 109.958 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.96 -166.29 0.28 Allowed 'Trans proline' 0 C--N 1.303 -1.817 0 O-C-N 123.942 1.496 . . . . 0.0 110.373 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -95.56 152.26 18.59 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.266 -0.896 . . . . 0.0 110.313 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.2 12.07 84.95 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -124.3 170.14 11.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -1.141 . . . . 0.0 110.396 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 27' ' ' SER . 11.8 t -129.86 139.09 51.25 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.879 . . . . 0.0 110.249 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.3 p -62.69 134.61 56.56 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.275 -0.891 . . . . 0.0 110.353 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.401 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 4.7 m -153.91 133.71 13.03 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.299 -0.875 . . . . 0.0 110.21 179.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.476 ' HA ' HD23 ' A' ' 18' ' ' LEU . 0.4 OUTLIER -91.97 143.8 26.11 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -0.927 . . . . 0.0 110.301 -179.796 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.525 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -79.41 172.71 9.17 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.278 -0.888 . . . . 0.0 110.332 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.615 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.9 Cg_endo -69.87 -7.17 20.43 Favored 'Trans proline' 0 C--N 1.302 -1.885 0 O-C-N 124.167 1.614 . . . . 0.0 110.174 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.615 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 4.2 m-85 -109.51 -0.17 18.96 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.393 -0.817 . . . . 0.0 109.623 178.816 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.56 17.86 37.52 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.525 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 48.0 t -87.53 108.9 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.27 -1.135 . . . . 0.0 110.438 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.552 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -65.25 124.34 21.92 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.229 -0.919 . . . . 0.0 110.416 179.982 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.49 ' C ' ' CD1' ' A' ' 25' ' ' TYR . 15.5 p90 -148.25 171.66 15.6 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.165 -0.959 . . . . 0.0 110.162 179.397 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 4.3 m -106.35 118.02 35.55 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.177 -0.952 . . . . 0.0 110.257 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.772 ' O ' HG22 ' A' ' 15' ' ' THR . 23.3 t -84.82 139.22 37.42 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.265 -0.897 . . . . 0.0 110.318 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -77.17 120.68 5.45 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 124.063 1.56 . . . . 0.0 110.397 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.489 ' CD1' ' C ' ' A' ' 29' ' ' PHE . 14.4 p90 . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.183 -0.948 . . . . 0.0 110.223 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.501 HG21 HG21 ' A' ' 9' ' ' ILE . 29.8 m . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 121.202 0.525 . . . . 0.0 110.348 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.505 ' N ' ' O ' ' A' ' 10' ' ' CYS . 45.4 mm -93.17 143.13 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 110.2 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -122.81 109.63 14.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 110.119 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -149.17 22.9 0.95 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.362 -0.836 . . . . 0.0 110.215 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.495 ' OD1' ' CH2' ' A' ' 24' ' ' TRP . 75.0 m-20 -137.32 -166.18 1.89 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.206 -0.934 . . . . 0.0 110.173 179.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.51 -59.38 2.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 110.276 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -136.33 -46.33 0.63 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 110.26 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.462 ' CB ' ' HB3' ' A' ' 24' ' ' TRP . 19.1 m -45.27 112.05 0.4 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.172 -0.955 . . . . 0.0 110.1 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.501 HG21 HG21 ' A' ' 1' ' ' VAL . 12.3 mt -85.82 167.53 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.292 -0.88 . . . . 0.0 110.235 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.505 ' O ' ' N ' ' A' ' 2' ' ' ILE . 31.0 m -129.84 141.83 43.23 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.249 -0.907 . . . . 0.0 110.324 -179.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.51 -166.6 0.34 Allowed 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.957 1.504 . . . . 0.0 110.267 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.9 148.69 22.03 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.237 -0.914 . . . . 0.0 110.348 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.98 0.94 89.81 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.2 p -117.58 170.24 8.91 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.137 -1.213 . . . . 0.0 110.399 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.802 HG22 ' O ' ' A' ' 27' ' ' SER . 14.8 t -134.32 144.69 48.44 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.159 -0.963 . . . . 0.0 110.503 -179.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -52.4 140.62 21.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.308 -0.87 . . . . 0.0 110.402 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.533 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 9.0 t -160.23 124.39 3.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.262 -0.899 . . . . 0.0 110.235 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.462 HD23 ' O ' ' A' ' 23' ' ' VAL . 0.1 OUTLIER -100.85 117.95 35.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.224 -0.922 . . . . 0.0 110.425 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.483 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -56.07 162.13 3.16 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.246 -0.909 . . . . 0.0 110.139 179.637 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.607 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.2 Cg_endo -69.35 -6.82 19.32 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 124.009 1.531 . . . . 0.0 110.116 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.607 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.4 m-85 -100.31 -5.97 26.61 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.423 -0.798 . . . . 0.0 109.688 179.001 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 99.21 17.44 27.13 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.483 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 67.4 t -89.97 115.36 29.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.266 -1.138 . . . . 0.0 110.298 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.534 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -74.08 125.79 29.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.357 -0.84 . . . . 0.0 110.37 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.533 ' CE1' ' HB3' ' A' ' 17' ' ' SER . 8.8 p90 -154.47 174.52 14.79 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 110.282 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.9 m -115.54 116.68 28.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.262 -0.899 . . . . 0.0 110.132 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.802 ' O ' HG22 ' A' ' 15' ' ' THR . 3.3 t -84.86 134.59 41.32 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.274 -0.891 . . . . 0.0 110.402 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -74.48 118.08 5.21 Favored 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.003 1.528 . . . . 0.0 110.423 179.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.404 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 24.5 p90 . . . . . 0 N--CA 1.492 1.654 0 O-C-N 121.186 -0.946 . . . . 0.0 110.24 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.533 ' O ' HG23 ' A' ' 1' ' ' VAL . 30.1 m . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.29 0.567 . . . . 0.0 110.259 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.528 ' N ' ' O ' ' A' ' 10' ' ' CYS . 40.5 mm -45.38 155.69 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.203 -0.936 . . . . 0.0 110.054 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.466 ' O ' ' N ' ' A' ' 5' ' ' ASP . 1.8 m-70 -130.64 -60.59 0.98 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.115 -0.991 . . . . 0.0 110.575 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.464 ' CB ' ' O ' ' A' ' 3' ' ' HIS . 0.5 OUTLIER 66.75 -67.97 0.15 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.234 -0.916 . . . . 0.0 110.268 -179.776 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.502 ' OD2' ' N ' ' A' ' 8' ' ' THR . 9.9 p-10 -80.88 -138.83 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 0.0 110.1 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -128.56 -6.21 5.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.953 . . . . 0.0 110.392 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -137.13 -65.54 0.54 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.213 -0.929 . . . . 0.0 110.203 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.502 ' N ' ' OD2' ' A' ' 5' ' ' ASP . 5.1 m -48.7 111.95 0.54 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.234 -0.917 . . . . 0.0 110.272 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.495 HG22 ' HB ' ' A' ' 1' ' ' VAL . 6.0 mt -90.83 151.74 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.21 -0.931 . . . . 0.0 110.128 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.528 ' O ' ' N ' ' A' ' 2' ' ' ILE . 23.7 m -127.13 139.68 35.77 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.17 -0.956 . . . . 0.0 110.298 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -74.91 -161.18 0.12 Allowed 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 124.02 1.537 . . . . 0.0 110.362 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -95.5 150.61 20.12 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.284 -0.885 . . . . 0.0 110.304 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.1 12.95 80.17 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 1.2 p -121.63 169.39 10.75 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.199 -1.177 . . . . 0.0 110.447 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.695 HG22 ' O ' ' A' ' 27' ' ' SER . 12.6 t -131.93 157.09 44.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.28 -0.888 . . . . 0.0 110.288 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.4 m -58.3 127.82 34.05 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.287 -0.883 . . . . 0.0 109.861 179.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.573 ' HB3' ' CE2' ' A' ' 25' ' ' TYR . 1.3 t -141.72 124.26 15.85 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.939 . . . . 0.0 110.684 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.586 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.1 OUTLIER -109.03 126.99 53.72 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.385 -0.822 . . . . 0.0 110.051 179.201 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.518 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -67.9 163.33 50.99 Favored Pre-proline 0 C--N 1.301 -1.513 0 O-C-N 121.217 -0.927 . . . . 0.0 110.284 180.0 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.603 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.0 Cg_endo -69.08 -8.59 24.01 Favored 'Trans proline' 0 C--N 1.302 -1.879 0 O-C-N 124.111 1.585 . . . . 0.0 110.126 179.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.603 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.6 m-85 -100.68 -1.04 36.23 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.372 -0.83 . . . . 0.0 109.746 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.3 17.44 39.77 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.518 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 94.0 t -91.03 112.47 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.408 -1.054 . . . . 0.0 110.172 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.586 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 2.7 m95 -71.46 142.31 50.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.259 -0.901 . . . . 0.0 110.273 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.573 ' CE2' ' HB3' ' A' ' 17' ' ' SER . 24.6 p90 -170.23 174.12 5.49 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.277 -0.889 . . . . 0.0 110.267 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.497 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 2.6 m -106.81 141.81 37.45 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.247 -0.908 . . . . 0.0 110.285 -179.132 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.695 ' O ' HG22 ' A' ' 15' ' ' THR . 0.9 OUTLIER -118.91 141.95 31.03 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.217 -0.927 . . . . 0.0 110.208 179.784 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -74.61 104.3 1.85 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 124.081 1.569 . . . . 0.0 110.531 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.59 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 8.2 p90 . . . . . 0 N--CA 1.491 1.596 0 O-C-N 121.212 -0.93 . . . . 0.0 110.294 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.653 ' HB ' HG22 ' A' ' 9' ' ' ILE . 30.8 m . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.323 0.582 . . . . 0.0 110.216 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.526 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 36.4 mm -83.55 148.18 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.219 -0.925 . . . . 0.0 110.307 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.407 ' CE1' HG12 ' A' ' 9' ' ' ILE . 9.9 m-70 -118.79 126.41 51.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.175 -0.953 . . . . 0.0 110.398 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 26.9 m -80.28 -68.94 0.63 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.297 -0.877 . . . . 0.0 110.275 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -104.63 -90.27 0.4 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.278 -0.889 . . . . 0.0 110.163 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -146.66 10.28 1.06 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.289 -0.882 . . . . 0.0 110.393 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.435 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -140.11 -76.27 0.33 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.206 -0.934 . . . . 0.0 110.318 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.689 HG21 ' HB3' ' A' ' 24' ' ' TRP . 8.6 m -41.63 147.84 0.17 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.31 -0.869 . . . . 0.0 110.364 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.653 HG22 ' HB ' ' A' ' 1' ' ' VAL . 15.2 mt -131.71 169.61 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.279 -0.888 . . . . 0.0 110.129 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.526 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 63.2 m -145.67 146.27 28.69 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.156 -0.965 . . . . 0.0 110.327 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -73.02 -175.02 1.74 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.012 1.532 . . . . 0.0 110.472 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -84.83 156.87 21.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.239 -0.913 . . . . 0.0 110.226 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.15 3.52 90.54 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.0 p -127.1 170.27 12.53 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.238 -1.154 . . . . 0.0 110.213 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 27' ' ' SER . 9.0 t -128.2 156.0 43.62 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.218 -0.926 . . . . 0.0 110.349 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.3 m -73.29 128.83 36.6 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.278 -0.888 . . . . 0.0 110.176 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.414 ' OG ' ' CZ ' ' A' ' 25' ' ' TYR . 32.9 t -137.19 130.2 30.69 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.28 -0.887 . . . . 0.0 110.243 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.595 ' HG ' ' CE2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -105.19 106.38 16.85 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.186 -0.946 . . . . 0.0 110.294 179.815 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.508 ' HB3' ' HB ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -46.18 157.81 0.4 Allowed Pre-proline 0 C--N 1.301 -1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 110.218 179.718 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.606 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.0 Cg_endo -68.69 -11.66 32.49 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 124.041 1.548 . . . . 0.0 110.026 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.606 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.0 m-85 -93.24 -8.71 41.49 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.456 -0.777 . . . . 0.0 109.641 178.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 100.8 19.9 16.14 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.508 ' HB ' ' HB3' ' A' ' 19' ' ' SER . 61.2 t -94.97 115.91 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.236 -1.155 . . . . 0.0 110.123 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.689 ' HB3' HG21 ' A' ' 8' ' ' THR . 0.2 OUTLIER -77.84 126.78 31.37 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.335 -0.853 . . . . 0.0 110.503 -179.525 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.414 ' CZ ' ' OG ' ' A' ' 17' ' ' SER . 28.0 p90 -154.72 171.69 19.14 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.917 . . . . 0.0 110.125 179.304 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.3 m -106.45 135.6 47.67 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.216 -0.927 . . . . 0.0 110.068 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.772 ' O ' HG22 ' A' ' 15' ' ' THR . 12.0 t -115.4 143.71 30.97 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.204 -0.935 . . . . 0.0 110.324 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.73 125.02 9.68 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 124.034 1.544 . . . . 0.0 110.4 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.508 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 14.8 p90 . . . . . 0 N--CA 1.49 1.566 0 O-C-N 121.305 -0.872 . . . . 0.0 110.219 179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.618 ' HB ' HG22 ' A' ' 9' ' ' ILE . 23.6 m . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.252 0.549 . . . . 0.0 110.308 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.502 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 34.2 mm -88.46 143.17 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.166 -0.959 . . . . 0.0 110.114 179.552 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.593 ' NE2' HG23 ' A' ' 9' ' ' ILE . 7.3 m-70 -129.17 119.51 24.21 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.193 -0.942 . . . . 0.0 110.598 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 87.1 m -124.3 11.76 8.76 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.986 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -150.29 -90.23 0.07 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.392 -0.818 . . . . 0.0 110.207 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -176.09 -32.39 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.16 -0.963 . . . . 0.0 110.244 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.482 ' O ' ' CG1' ' A' ' 9' ' ' ILE . . . -105.38 -75.5 0.63 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.2 -0.938 . . . . 0.0 110.258 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 42.8 m -43.47 139.74 1.95 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.24 -0.913 . . . . 0.0 110.394 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.618 HG22 ' HB ' ' A' ' 1' ' ' VAL . 4.4 mt -135.85 147.69 28.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 0.0 110.217 179.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.528 ' O ' ' CB ' ' A' ' 1' ' ' VAL . 98.1 m -111.34 148.69 39.29 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.305 -0.872 . . . . 0.0 109.982 179.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.43 ' O ' ' CG ' ' A' ' 12' ' ' ASP . 45.4 Cg_endo -74.7 -90.34 0.01 OUTLIER 'Trans proline' 0 C--N 1.302 -1.869 0 O-C-N 123.846 1.445 . . . . 0.0 110.335 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.43 ' CG ' ' O ' ' A' ' 11' ' ' PRO . 21.1 m-20 -158.86 164.28 35.86 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.371 -0.831 . . . . 0.0 110.181 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.32 13.26 48.92 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.472 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 1.3 p -124.07 169.74 11.37 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.217 -1.166 . . . . 0.0 110.308 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.642 HG22 ' O ' ' A' ' 27' ' ' SER . 8.9 t -129.59 153.81 47.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.141 -0.974 . . . . 0.0 110.494 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 60.2 m -63.86 127.47 31.52 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.262 -0.899 . . . . 0.0 110.147 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.514 ' HB3' ' CE2' ' A' ' 25' ' ' TYR . 10.7 t -138.9 133.99 32.63 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 110.265 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.449 HD23 ' HA ' ' A' ' 18' ' ' LEU . 0.2 OUTLIER -99.34 135.89 40.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.169 -0.957 . . . . 0.0 110.316 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.509 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.4 OUTLIER -79.06 166.13 44.16 Favored Pre-proline 0 C--N 1.303 -1.415 0 O-C-N 121.325 -0.859 . . . . 0.0 110.243 -179.992 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.585 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.9 Cg_endo -69.39 -10.73 29.63 Favored 'Trans proline' 0 C--N 1.301 -1.951 0 O-C-N 124.057 1.556 . . . . 0.0 110.022 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.585 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -104.06 -0.51 28.65 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.429 -0.794 . . . . 0.0 109.667 179.007 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.11 15.32 48.72 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.509 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 92.3 t -87.0 119.15 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.292 -1.122 . . . . 0.0 110.191 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.498 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.6 OUTLIER -77.75 128.16 33.59 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 110.458 -179.747 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.514 ' CE2' ' HB3' ' A' ' 17' ' ' SER . 37.1 p90 -152.74 172.52 16.56 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.27 -0.894 . . . . 0.0 110.086 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.472 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 4.0 m -101.92 141.42 34.79 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.209 -0.932 . . . . 0.0 110.193 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.642 ' O ' HG22 ' A' ' 15' ' ' THR . 3.4 t -116.16 141.7 28.17 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.173 -0.954 . . . . 0.0 110.389 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -75.38 129.27 11.86 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.061 1.558 . . . . 0.0 110.488 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 43.6 p90 . . . . . 0 N--CA 1.492 1.65 0 O-C-N 121.223 -0.923 . . . . 0.0 110.214 -179.886 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.696 ' HB ' HG22 ' A' ' 9' ' ' ILE . 28.6 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.224 0.535 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.459 ' H ' HD12 ' A' ' 2' ' ' ILE . 2.5 mp -50.89 160.6 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.242 -0.911 . . . . 0.0 110.147 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.409 ' N ' HG22 ' A' ' 2' ' ' ILE . 4.4 m-70 -148.12 89.43 1.73 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.195 -0.941 . . . . 0.0 110.354 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 63.9 m -92.59 -41.39 10.25 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.265 -0.897 . . . . 0.0 110.091 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.708 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 8.3 t70 -85.14 -86.57 0.13 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.269 -0.894 . . . . 0.0 110.217 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.708 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 170.31 -27.66 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.188 -0.945 . . . . 0.0 110.354 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.439 ' O ' ' CG1' ' A' ' 9' ' ' ILE . . . -105.01 -81.51 0.53 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.174 -0.954 . . . . 0.0 110.335 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.485 ' C ' ' CG1' ' A' ' 9' ' ' ILE . 89.5 m -41.18 155.4 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.292 -0.88 . . . . 0.0 110.458 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.696 HG22 ' HB ' ' A' ' 1' ' ' VAL . 6.1 mt -150.11 145.78 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.212 -0.93 . . . . 0.0 110.181 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.675 ' O ' HG12 ' A' ' 1' ' ' VAL . 0.0 OUTLIER -130.08 -170.2 0.21 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 110.22 179.591 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.583 ' CD ' ' CB ' ' A' ' 10' ' ' CYS . 45.8 Cg_endo -87.27 175.4 4.77 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.822 1.433 . . . . 0.0 110.75 -178.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -91.63 151.37 20.72 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.296 -0.878 . . . . 0.0 110.3 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.85 -6.09 51.42 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 4.6 p -114.39 171.68 7.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.192 -1.181 . . . . 0.0 110.25 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.519 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 14.7 t -115.94 134.33 55.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.312 -0.867 . . . . 0.0 110.311 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.2 m -45.05 147.02 0.74 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.244 -0.91 . . . . 0.0 110.367 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.569 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 29.0 m -161.69 135.02 6.34 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.306 -0.871 . . . . 0.0 110.337 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.539 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -106.64 142.39 36.36 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.225 -0.922 . . . . 0.0 110.211 179.996 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.503 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -84.14 168.02 24.11 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.168 -0.957 . . . . 0.0 110.291 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.585 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.5 Cg_endo -69.61 -8.83 24.62 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 124.098 1.578 . . . . 0.0 110.176 -179.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.585 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -103.63 0.95 31.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.432 -0.792 . . . . 0.0 109.627 179.173 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.98 16.88 49.74 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.254 -1.538 . . . . 0.0 109.254 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.506 ' O ' HD23 ' A' ' 18' ' ' LEU . 97.2 t -86.59 115.52 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.359 -1.083 . . . . 0.0 110.295 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.539 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 1.0 OUTLIER -75.61 135.41 40.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.294 -0.879 . . . . 0.0 110.325 179.973 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.569 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 24.8 p90 -163.8 176.56 9.4 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.252 -0.905 . . . . 0.0 110.35 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.497 ' SG ' ' HD2' ' A' ' 11' ' ' PRO . 11.1 p -114.38 130.06 56.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.344 -0.847 . . . . 0.0 110.26 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.401 ' O ' HG22 ' A' ' 15' ' ' THR . 1.1 p -99.94 146.03 31.2 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 0.0 110.253 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -73.13 104.43 1.78 Allowed 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 123.999 1.526 . . . . 0.0 110.411 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.519 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 0.5 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 O-C-N 121.314 -0.866 . . . . 0.0 110.406 -179.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.7 ' HB ' HG22 ' A' ' 9' ' ' ILE . 6.5 m . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 121.281 0.562 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.476 ' O ' ' HB2' ' A' ' 10' ' ' CYS . 2.6 mp -90.06 154.8 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.279 -0.888 . . . . 0.0 110.274 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.49 ' NE2' HG23 ' A' ' 9' ' ' ILE . 15.0 m-70 -129.42 114.86 16.68 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.188 -0.945 . . . . 0.0 110.198 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 30.0 m -71.51 -39.6 70.68 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 110.318 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.698 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 23.7 t0 -125.18 -59.75 1.38 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.221 -0.924 . . . . 0.0 110.406 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.698 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 170.6 -25.37 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.174 -0.954 . . . . 0.0 110.43 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -100.05 -51.31 3.72 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 44.5 m -70.09 128.15 35.28 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.308 -0.87 . . . . 0.0 110.397 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.7 HG22 ' HB ' ' A' ' 1' ' ' VAL . 4.1 mt -97.64 176.7 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.209 -0.932 . . . . 0.0 110.07 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.488 ' O ' ' HA ' ' A' ' 1' ' ' VAL . 30.3 m -152.85 139.41 12.42 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.288 -0.882 . . . . 0.0 110.637 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.37 177.82 8.3 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 O-C-N 124.126 1.593 . . . . 0.0 110.433 179.524 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 12' ' ' ASP . 0.9 OUTLIER -85.19 147.85 26.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.167 -0.958 . . . . 0.0 110.311 179.779 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 92.93 -7.29 76.77 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.43 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 4.1 p -109.83 169.58 8.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.228 -1.16 . . . . 0.0 110.308 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.691 HG22 ' O ' ' A' ' 27' ' ' SER . 15.4 t -125.83 151.1 47.26 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.228 -0.92 . . . . 0.0 110.359 -179.777 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.464 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 1.1 m -66.56 148.76 51.44 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.336 -0.852 . . . . 0.0 110.525 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.515 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 0.2 OUTLIER -170.31 137.26 1.45 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.35 -0.844 . . . . 0.0 110.223 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.466 ' HG ' ' CE3' ' A' ' 24' ' ' TRP . 0.3 OUTLIER -96.46 141.11 30.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 110.277 -179.982 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.544 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.6 OUTLIER -78.78 169.86 18.77 Favored Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.324 -0.86 . . . . 0.0 110.244 -179.918 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.573 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.7 Cg_endo -69.46 -16.5 38.84 Favored 'Trans proline' 0 C--N 1.301 -1.97 0 O-C-N 124.075 1.566 . . . . 0.0 109.939 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.573 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 2.9 m-85 -98.74 1.99 46.59 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.516 -0.74 . . . . 0.0 109.593 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.95 23.22 33.32 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.544 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 23.8 t -92.3 112.77 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.284 -1.127 . . . . 0.0 110.304 -179.757 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.466 ' CE3' ' HG ' ' A' ' 18' ' ' LEU . 1.6 m95 -65.98 126.43 28.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.274 -0.891 . . . . 0.0 110.271 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.515 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 6.3 p90 -157.19 177.37 11.55 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.079 -1.013 . . . . 0.0 110.388 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 15' ' ' THR . 1.9 m -126.5 138.61 53.52 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.425 -0.797 . . . . 0.0 110.098 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.691 ' O ' HG22 ' A' ' 15' ' ' THR . 0.0 OUTLIER -111.41 139.25 21.81 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.202 -0.936 . . . . 0.0 110.576 -179.474 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -74.62 118.49 5.34 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.076 1.566 . . . . 0.0 110.331 179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' A' ' 29' ' ' PHE . 40.2 p90 . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.204 -0.935 . . . . 0.0 110.303 -179.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.567 ' O ' HG23 ' A' ' 1' ' ' VAL . 3.4 m . . . . . 0 N--CA 1.494 1.741 0 CA-C-O 121.295 0.569 . . . . 0.0 110.417 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.513 ' HA ' HD13 ' A' ' 2' ' ' ILE . 5.2 mm -58.71 161.73 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.265 -0.897 . . . . 0.0 110.061 179.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.571 ' NE2' HG23 ' A' ' 9' ' ' ILE . 1.9 m-70 -149.01 125.92 11.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.257 -0.902 . . . . 0.0 110.507 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 28.3 p -126.44 21.52 7.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.336 -0.853 . . . . 0.0 110.111 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.461 ' N ' ' OD1' ' A' ' 5' ' ' ASP . 23.3 p-10 -167.65 -128.95 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.369 -0.832 . . . . 0.0 110.008 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.1 11.54 2.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.065 -1.022 . . . . 0.0 110.284 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.444 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -139.93 -85.1 0.23 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.227 -0.921 . . . . 0.0 110.459 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.444 ' C ' ' O ' ' A' ' 7' ' ' ALA . 55.9 m -40.81 141.6 0.56 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.23 -0.919 . . . . 0.0 110.524 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.571 HG23 ' NE2' ' A' ' 3' ' ' HIS . 7.8 mt -128.47 146.74 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.23 -0.919 . . . . 0.0 110.008 179.529 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.508 ' O ' ' HA ' ' A' ' 1' ' ' VAL . 46.0 m -122.26 145.38 44.13 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.199 -0.938 . . . . 0.0 110.408 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.32 -173.53 1.32 Allowed 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 124.097 1.577 . . . . 0.0 110.258 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.498 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 2.5 m-20 -86.64 151.16 23.67 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.231 -0.918 . . . . 0.0 110.422 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.81 8.4 73.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 5.4 p -133.58 167.88 19.68 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.267 -1.137 . . . . 0.0 110.313 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.658 HG22 ' O ' ' A' ' 27' ' ' SER . 10.4 t -128.49 141.41 51.39 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 0.0 110.203 179.686 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.75 138.16 57.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.226 -0.921 . . . . 0.0 110.139 -179.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.532 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 2.4 t -148.64 138.33 22.08 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.214 -0.929 . . . . 0.0 110.289 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.522 ' HA ' HD23 ' A' ' 18' ' ' LEU . 0.0 OUTLIER -95.94 131.06 42.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.384 -0.823 . . . . 0.0 110.037 179.692 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.573 ' OG ' ' HB ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -78.41 169.79 19.18 Favored Pre-proline 0 C--N 1.3 -1.561 0 O-C-N 121.346 -0.846 . . . . 0.0 110.52 -179.817 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.625 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 37.6 Cg_endo -69.07 -13.62 36.74 Favored 'Trans proline' 0 C--N 1.301 -1.959 0 O-C-N 124.208 1.636 . . . . 0.0 109.996 179.588 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.625 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 2.1 m-85 -92.03 -11.44 35.94 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.444 -0.785 . . . . 0.0 109.445 178.67 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.48 24.04 14.98 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.573 ' HB ' ' OG ' ' A' ' 19' ' ' SER . 39.9 t -102.04 125.47 56.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.17 -1.194 . . . . 0.0 110.2 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.454 ' CH2' ' HB2' ' A' ' 18' ' ' LEU . 1.7 m95 -81.09 119.09 23.12 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.284 -0.885 . . . . 0.0 110.27 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.532 ' CE1' ' HB3' ' A' ' 17' ' ' SER . 30.8 p90 -140.14 168.1 20.59 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.067 -1.021 . . . . 0.0 110.503 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 10.2 m -94.82 111.32 23.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.302 -0.874 . . . . 0.0 110.271 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.658 ' O ' HG22 ' A' ' 15' ' ' THR . 0.2 OUTLIER -96.05 147.47 33.02 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.348 -0.845 . . . . 0.0 110.396 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -77.39 125.26 7.59 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 124.059 1.557 . . . . 0.0 110.455 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' A' ' 29' ' ' PHE . 36.6 p90 . . . . . 0 N--CA 1.492 1.647 0 O-C-N 121.186 -0.946 . . . . 0.0 110.207 179.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 20.5 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.279 0.561 . . . . 0.0 110.261 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.507 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 26.5 mm -55.9 148.21 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.918 . . . . 0.0 110.143 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.501 ' CE1' HG12 ' A' ' 9' ' ' ILE . 1.9 m-70 -130.85 129.45 42.34 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.228 -0.92 . . . . 0.0 110.455 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.474 ' O ' ' N ' ' A' ' 6' ' ' ALA . 58.0 m -142.01 -175.2 4.32 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.285 -0.885 . . . . 0.0 110.036 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.487 ' HB2' ' CE2' ' A' ' 24' ' ' TRP . 4.5 t70 54.75 -88.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.168 -0.958 . . . . 0.0 110.218 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.474 ' N ' ' O ' ' A' ' 4' ' ' CYS . . . -171.9 -40.2 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.254 -0.904 . . . . 0.0 110.326 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.406 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -119.82 -59.22 1.83 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.2 -0.937 . . . . 0.0 110.308 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.406 ' C ' ' O ' ' A' ' 7' ' ' ALA . 6.9 m -43.77 151.81 0.19 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.195 -0.941 . . . . 0.0 110.318 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.501 HG12 ' CE1' ' A' ' 3' ' ' HIS . 12.8 mt -131.23 167.37 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.209 -0.932 . . . . 0.0 110.279 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.507 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 55.7 m -133.87 147.5 64.49 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.2 -0.938 . . . . 0.0 110.205 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.55 -177.02 3.07 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.055 1.555 . . . . 0.0 110.607 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -84.72 151.94 24.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.268 -0.895 . . . . 0.0 110.237 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.45 28.47 57.6 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.547 ' C ' ' CE2' ' A' ' 29' ' ' PHE . 5.3 p -149.41 166.89 27.73 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.28 -1.13 . . . . 0.0 110.38 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.621 ' HB ' ' CE1' ' A' ' 29' ' ' PHE . 13.1 t -121.92 155.47 35.41 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.337 -0.852 . . . . 0.0 110.295 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 74.0 m -82.22 144.6 30.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.924 . . . . 0.0 110.124 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.49 ' HB2' ' CZ ' ' A' ' 25' ' ' TYR . 62.6 m -154.37 160.75 41.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 110.416 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.591 ' HG ' ' CZ3' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -114.81 134.13 55.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.875 . . . . 0.0 110.179 179.585 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.533 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -74.07 172.56 8.25 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.304 -0.872 . . . . 0.0 110.382 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.614 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.5 Cg_endo -69.87 -11.48 30.79 Favored 'Trans proline' 0 C--N 1.302 -1.879 0 O-C-N 123.976 1.514 . . . . 0.0 110.023 -179.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.614 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.4 m-85 -103.51 0.82 31.52 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.433 -0.792 . . . . 0.0 109.643 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 90.17 27.84 19.57 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.533 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 34.2 t -94.96 123.71 47.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.309 -1.112 . . . . 0.0 110.304 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.591 ' CZ3' ' HG ' ' A' ' 18' ' ' LEU . 2.7 m95 -78.6 114.92 17.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.205 -0.934 . . . . 0.0 110.202 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.49 ' CZ ' ' HB2' ' A' ' 17' ' ' SER . 29.1 p90 -136.08 172.53 12.88 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.189 -0.945 . . . . 0.0 110.161 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 8.0 m -114.98 117.38 30.44 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.273 -0.892 . . . . 0.0 110.276 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.4 p -96.47 161.63 26.17 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.308 -0.87 . . . . 0.0 110.162 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -74.79 170.59 20.02 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.889 1.468 . . . . 0.0 110.527 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.621 ' CE1' ' HB ' ' A' ' 15' ' ' THR . 17.4 m-85 . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.281 -0.887 . . . . 0.0 110.169 179.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.538 ' HB ' HG22 ' A' ' 9' ' ' ILE . 21.1 m . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 121.157 0.504 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.548 HG21 ' SG ' ' A' ' 16' ' ' CYS . 18.5 mm -54.28 164.84 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.231 -0.918 . . . . 0.0 109.996 179.776 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.514 ' O ' ' N ' ' A' ' 5' ' ' ASP . 5.5 m-70 -126.03 -19.47 4.78 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.121 -0.987 . . . . 0.0 110.734 -179.477 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.492 ' HB2' ' O ' ' A' ' 3' ' ' HIS . 9.3 m 66.07 -61.28 0.28 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.232 -0.917 . . . . 0.0 110.289 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.575 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 23.0 t0 -126.32 -56.44 1.42 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.218 -0.926 . . . . 0.0 110.279 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.575 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 176.34 -32.48 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.304 -0.872 . . . . 0.0 110.22 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.42 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -100.07 -77.97 0.52 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.227 -0.921 . . . . 0.0 110.244 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.42 ' C ' ' O ' ' A' ' 7' ' ' ALA . 3.1 m -43.36 116.35 0.91 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.218 -0.926 . . . . 0.0 110.213 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.538 HG22 ' HB ' ' A' ' 1' ' ' VAL . 9.7 mt -97.28 145.4 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.227 -0.921 . . . . 0.0 110.206 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.52 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 7.4 m -124.51 149.89 63.08 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.238 -0.914 . . . . 0.0 110.108 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.473 ' O ' ' OG1' ' A' ' 14' ' ' THR . 43.4 Cg_endo -73.0 176.62 8.83 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 123.977 1.514 . . . . 0.0 110.493 -179.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -84.35 165.71 18.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.252 -0.905 . . . . 0.0 110.315 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.59 11.8 65.97 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.473 ' OG1' ' O ' ' A' ' 11' ' ' PRO . 9.1 p -127.47 172.59 10.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.28 -1.129 . . . . 0.0 110.265 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.51 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 12.4 t -125.94 152.79 45.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.275 -0.891 . . . . 0.0 110.283 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.548 ' SG ' HG21 ' A' ' 2' ' ' ILE . 98.0 m -82.11 136.0 35.23 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.303 -0.873 . . . . 0.0 110.24 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.568 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 1.0 OUTLIER -142.45 148.51 37.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -0.93 . . . . 0.0 110.27 179.996 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.524 ' HG ' ' CE2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -104.41 140.78 37.43 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.351 -0.843 . . . . 0.0 110.431 -179.864 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.426 ' HB2' ' HD2' ' A' ' 20' ' ' PRO . 1.0 OUTLIER -86.38 171.98 9.25 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.325 -0.859 . . . . 0.0 110.454 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.577 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.5 Cg_endo -69.57 -14.67 37.04 Favored 'Trans proline' 0 C--N 1.3 -1.975 0 O-C-N 124.05 1.553 . . . . 0.0 109.905 179.444 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.577 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.1 m-85 -98.59 0.12 44.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.352 -0.842 . . . . 0.0 109.774 179.056 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.74 30.8 17.11 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.405 ' O ' HD23 ' A' ' 18' ' ' LEU . 68.4 t -100.65 123.99 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.227 -1.16 . . . . 0.0 110.223 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.524 ' CE2' ' HG ' ' A' ' 18' ' ' LEU . 3.5 m95 -83.36 114.07 21.17 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.28 -0.887 . . . . 0.0 110.036 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.568 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 42.1 p90 -132.65 172.01 13.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 110.337 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.4 m -102.47 132.7 48.33 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.349 -0.845 . . . . 0.0 110.112 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.471 ' O ' HG22 ' A' ' 15' ' ' THR . 0.3 OUTLIER -109.75 137.63 20.46 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.13 -0.981 . . . . 0.0 110.097 179.802 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -72.92 109.39 2.8 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 124.009 1.531 . . . . 0.0 110.555 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.567 ' CG ' ' O ' ' A' ' 29' ' ' PHE . 2.9 p90 . . . . . 0 N--CA 1.491 1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 110.371 -179.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.589 ' O ' HG23 ' A' ' 1' ' ' VAL . 34.9 m . . . . . 0 N--CA 1.496 1.832 0 CA-C-O 121.246 0.546 . . . . 0.0 110.346 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.441 HD13 ' HA ' ' A' ' 2' ' ' ILE . 13.1 mm -50.53 158.13 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.146 -0.972 . . . . 0.0 109.75 179.296 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.545 ' O ' ' N ' ' A' ' 5' ' ' ASP . 1.1 m-70 -136.7 -48.03 0.62 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.09 -1.006 . . . . 0.0 110.536 -179.446 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.485 ' HB2' ' O ' ' A' ' 3' ' ' HIS . 81.0 m 59.0 -77.11 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.304 -0.872 . . . . 0.0 110.1 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 3' ' ' HIS . 3.0 t70 -78.74 -135.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.231 -0.918 . . . . 0.0 110.013 179.468 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.14 8.37 4.37 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.127 -0.983 . . . . 0.0 110.367 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.432 ' O ' HG13 ' A' ' 9' ' ' ILE . . . -139.91 -84.72 0.23 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.225 -0.922 . . . . 0.0 110.49 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.59 HG21 ' HB3' ' A' ' 24' ' ' TRP . 7.1 m -40.89 100.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.336 -0.852 . . . . 0.0 110.511 -179.573 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.535 HG23 ' CD2' ' A' ' 3' ' ' HIS . 6.9 mt -89.42 169.56 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.343 -0.848 . . . . 0.0 110.211 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.469 ' O ' ' HB ' ' A' ' 1' ' ' VAL . 3.0 m -143.15 162.64 41.99 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.213 -0.929 . . . . 0.0 110.399 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -80.0 -159.59 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.037 1.546 . . . . 0.0 110.464 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.467 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 5.6 m-20 -107.13 150.1 26.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.204 -0.935 . . . . 0.0 110.286 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 86.12 29.12 26.32 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.498 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 0.9 OUTLIER -144.12 170.53 15.77 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -1.164 . . . . 0.0 110.312 179.871 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.532 HG22 ' O ' ' A' ' 27' ' ' SER . 9.5 t -125.61 142.48 51.49 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.209 -0.932 . . . . 0.0 110.367 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.401 ' C ' ' HG ' ' A' ' 17' ' ' SER . 3.3 m -65.26 142.62 58.22 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.325 -0.859 . . . . 0.0 110.271 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.401 ' HG ' ' C ' ' A' ' 16' ' ' CYS . 14.3 m -158.84 130.43 6.45 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.275 -0.891 . . . . 0.0 110.056 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.535 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -94.45 136.78 34.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 110.45 -179.796 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.1 p -79.81 169.54 19.67 Favored Pre-proline 0 N--CA 1.487 1.412 0 O-C-N 121.275 -0.891 . . . . 0.0 110.256 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.584 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 40.3 Cg_endo -69.67 -6.76 19.33 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 O-C-N 124.056 1.556 . . . . 0.0 110.183 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.584 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.7 m-85 -106.2 -3.0 21.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.331 -0.856 . . . . 0.0 109.965 179.295 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.18 13.74 47.87 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.2 113.82 24.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.137 -1.213 . . . . 0.0 110.012 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.59 ' HB3' HG21 ' A' ' 8' ' ' THR . 0.0 OUTLIER -76.98 116.92 18.07 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.336 -0.853 . . . . 0.0 110.324 -179.726 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 8.1 p90 -143.39 176.11 9.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.274 -0.891 . . . . 0.0 110.241 179.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.498 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 58.0 m -124.47 138.11 54.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 110.193 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.532 ' O ' HG22 ' A' ' 15' ' ' THR . 1.2 t -107.89 150.39 40.25 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.24 -0.913 . . . . 0.0 110.705 -179.107 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -77.29 121.03 5.52 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 124.13 1.595 . . . . 0.0 110.405 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 42.3 p90 . . . . . 0 N--CA 1.493 1.697 0 O-C-N 121.157 -0.964 . . . . 0.0 110.314 179.843 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.566 HG21 HG21 ' A' ' 9' ' ' ILE . 19.5 m . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.317 0.58 . . . . 0.0 110.249 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.538 ' N ' ' O ' ' A' ' 10' ' ' CYS . 37.4 mm -85.22 156.98 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.25 -0.907 . . . . 0.0 110.134 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.625 ' NE2' HG23 ' A' ' 9' ' ' ILE . 4.0 m-70 -139.48 118.94 12.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.281 -0.887 . . . . 0.0 110.24 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.411 ' HB2' ' HB3' ' A' ' 16' ' ' CYS . 13.5 m -133.86 10.64 3.95 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.259 -0.901 . . . . 0.0 110.385 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.461 ' OD1' ' N ' ' A' ' 6' ' ' ALA . 0.7 OUTLIER -130.96 -101.12 0.3 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.184 -0.948 . . . . 0.0 110.191 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.461 ' N ' ' OD1' ' A' ' 5' ' ' ASP . . . -162.8 -43.15 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.061 -1.024 . . . . 0.0 110.065 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.72 -51.51 2.83 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 110.088 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.423 HG22 ' N ' ' A' ' 9' ' ' ILE . 52.5 m -57.59 161.77 3.39 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.333 -0.854 . . . . 0.0 110.223 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.625 HG23 ' NE2' ' A' ' 3' ' ' HIS . 12.7 mt -140.7 172.71 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.259 -0.901 . . . . 0.0 110.055 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.538 ' O ' ' N ' ' A' ' 2' ' ' ILE . 56.8 m -143.22 137.87 15.13 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.182 -0.949 . . . . 0.0 110.521 -179.706 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.28 -166.08 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.939 1.494 . . . . 0.0 110.267 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 52.2 m-20 -90.08 147.93 23.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.198 -0.939 . . . . 0.0 110.199 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.45 18.63 60.05 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.443 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 0.6 OUTLIER -136.06 171.26 14.74 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.245 -1.15 . . . . 0.0 110.306 179.967 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.737 HG22 ' O ' ' A' ' 27' ' ' SER . 15.3 t -132.55 140.88 48.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.236 -0.915 . . . . 0.0 110.261 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.411 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 29.3 m -65.26 131.72 47.23 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.267 -0.895 . . . . 0.0 110.136 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -156.54 138.2 14.15 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.098 -1.001 . . . . 0.0 110.46 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.449 HD23 ' O ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -88.72 143.49 26.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.324 -0.86 . . . . 0.0 110.287 179.726 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.464 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -82.24 169.54 17.99 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.318 -0.864 . . . . 0.0 110.478 -179.699 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.578 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.3 Cg_endo -69.02 -14.43 38.43 Favored 'Trans proline' 0 C--N 1.302 -1.909 0 O-C-N 124.135 1.597 . . . . 0.0 110.166 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.578 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 2.5 m-85 -100.19 1.62 42.15 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.379 -0.826 . . . . 0.0 109.614 178.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.77 29.45 15.84 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.464 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 76.5 t -103.75 123.49 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.246 -1.149 . . . . 0.0 110.445 -179.667 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.472 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.9 OUTLIER -76.86 118.74 19.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.249 -0.907 . . . . 0.0 110.312 179.906 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.524 ' CE2' ' OG ' ' A' ' 27' ' ' SER . 40.7 p90 -144.28 168.6 19.69 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.084 -1.01 . . . . 0.0 110.681 179.574 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.443 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 3.4 m -106.09 117.93 35.31 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.446 -0.784 . . . . 0.0 109.649 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.737 ' O ' HG22 ' A' ' 15' ' ' THR . 0.7 OUTLIER -93.81 142.65 25.36 Favored Pre-proline 0 C--N 1.303 -1.455 0 O-C-N 121.174 -0.954 . . . . 0.0 110.716 -178.943 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -75.69 126.19 9.36 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 124.135 1.597 . . . . 0.0 110.46 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.542 ' CG ' ' O ' ' A' ' 29' ' ' PHE . 34.6 p90 . . . . . 0 N--CA 1.493 1.688 0 O-C-N 121.242 -0.911 . . . . 0.0 110.268 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 29.1 m . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 121.266 0.555 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.508 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 32.7 mm -77.67 146.49 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.213 -0.929 . . . . 0.0 110.312 -179.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.605 ' CD2' HG23 ' A' ' 9' ' ' ILE . 3.9 m-70 -138.04 83.29 1.97 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.315 -0.866 . . . . 0.0 110.089 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -72.32 -32.01 66.17 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.301 -0.874 . . . . 0.0 110.441 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.488 ' OD2' ' NE1' ' A' ' 24' ' ' TRP . 0.6 OUTLIER -116.34 -89.64 0.57 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.18 -0.95 . . . . 0.0 110.357 -179.849 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -171.89 -32.84 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.162 -0.962 . . . . 0.0 110.354 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -99.31 -83.63 0.42 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 110.234 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.452 HG21 ' O ' ' A' ' 24' ' ' TRP . 62.9 m -52.17 106.55 0.15 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.225 -0.922 . . . . 0.0 110.158 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.605 HG23 ' CD2' ' A' ' 3' ' ' HIS . 6.2 mt -90.65 165.02 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.191 -0.943 . . . . 0.0 110.335 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.508 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 99.4 m -133.73 140.74 37.57 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.267 -0.896 . . . . 0.0 110.057 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.0 173.81 13.43 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.901 1.474 . . . . 0.0 110.424 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.474 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 1.1 m-20 -77.12 152.5 34.91 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.281 -0.887 . . . . 0.0 110.472 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' A' ' 29' ' ' PHE . . . 90.55 -8.27 80.07 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.519 HG22 ' HA ' ' A' ' 28' ' ' PRO . 2.0 p -116.95 166.52 12.07 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.183 -1.186 . . . . 0.0 110.151 179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.674 ' O ' HG23 ' A' ' 15' ' ' THR . 14.8 t -123.54 119.36 29.7 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.333 -0.854 . . . . 0.0 110.375 179.683 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . 0.453 ' O ' ' OG ' ' A' ' 17' ' ' SER . 20.6 p -50.34 158.36 0.59 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.214 -0.929 . . . . 0.0 110.18 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.601 ' HB2' ' CZ ' ' A' ' 25' ' ' TYR . 42.4 m -167.44 146.64 5.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.198 -0.938 . . . . 0.0 110.022 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.57 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -108.6 134.73 50.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 110.485 -179.654 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.483 ' HB3' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -78.53 167.79 32.45 Favored Pre-proline 0 C--N 1.304 -1.399 0 O-C-N 121.34 -0.85 . . . . 0.0 109.989 179.543 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.593 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 37.9 Cg_endo -69.56 -11.92 32.15 Favored 'Trans proline' 0 C--N 1.3 -2.009 0 O-C-N 124.022 1.538 . . . . 0.0 109.942 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.593 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.2 m-85 -97.79 -2.31 41.32 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.399 -0.813 . . . . 0.0 109.75 178.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.85 21.17 29.07 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.483 ' HB ' ' HB3' ' A' ' 19' ' ' SER . 75.6 t -91.54 119.58 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.273 -1.133 . . . . 0.0 110.38 -179.744 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.57 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 0.6 OUTLIER -84.01 126.66 33.26 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.266 -0.896 . . . . 0.0 110.181 179.765 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.601 ' CZ ' ' HB2' ' A' ' 17' ' ' SER . 32.6 p90 -147.75 174.82 11.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.215 -0.928 . . . . 0.0 110.246 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 4.0 m -114.18 107.65 15.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.261 -0.9 . . . . 0.0 110.223 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.484 ' HB3' HG23 ' A' ' 15' ' ' THR . 9.8 t -70.59 144.01 90.78 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.192 -0.943 . . . . 0.0 109.897 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.519 ' HA ' HG22 ' A' ' 14' ' ' THR . 47.6 Cg_endo -76.17 170.61 19.7 Favored 'Trans proline' 0 C--N 1.299 -2.053 0 O-C-N 123.817 1.43 . . . . 0.0 110.918 -179.363 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 13' ' ' GLY . 2.4 m-85 . . . . . 0 N--CA 1.494 1.774 0 O-C-N 121.459 -0.776 . . . . 0.0 110.201 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' VAL . . . . . 0.727 HG23 HG21 ' A' ' 9' ' ' ILE . 5.9 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.233 0.539 . . . . 0.0 110.331 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.462 ' O ' ' N ' ' A' ' 10' ' ' CYS . 30.1 mm -44.1 152.87 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.273 -0.892 . . . . 0.0 110.223 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.565 ' O ' ' N ' ' A' ' 5' ' ' ASP . 4.0 m-70 -120.38 -64.69 1.22 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.184 -0.947 . . . . 0.0 110.336 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' CYS . . . . . 0.517 ' HB3' ' O ' ' A' ' 3' ' ' HIS . 1.7 t 59.65 -72.29 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.511 -0.743 . . . . 0.0 110.386 179.753 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.565 ' N ' ' O ' ' A' ' 3' ' ' HIS . 81.1 m-20 -54.75 -163.67 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.178 -0.951 . . . . 0.0 110.297 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -103.92 -19.93 14.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.12 -0.988 . . . . 0.0 110.547 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.426 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -135.72 -79.69 0.42 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.257 -0.902 . . . . 0.0 110.557 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 7' ' ' ALA . 97.5 m -41.24 132.13 2.61 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.344 -0.847 . . . . 0.0 110.387 -179.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ILE . . . . . 0.727 HG21 HG23 ' A' ' 1' ' ' VAL . 0.9 OUTLIER -98.46 175.78 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.265 -0.897 . . . . 0.0 110.048 179.972 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . 0.462 ' N ' ' O ' ' A' ' 2' ' ' ILE . 1.5 m -130.0 132.9 24.42 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 110.329 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . 0.495 ' O ' ' O ' ' A' ' 12' ' ' ASP . 48.5 Cg_endo -77.78 154.42 30.3 Favored 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.009 1.531 . . . . 0.0 110.02 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.495 ' O ' ' O ' ' A' ' 11' ' ' PRO . 7.3 m-20 48.66 179.22 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.164 -0.96 . . . . 0.0 110.139 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' A' ' 14' ' ' THR . . . -55.42 -64.19 4.6 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 179.699 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.52 ' O ' ' O ' ' A' ' 13' ' ' GLY . 0.8 OUTLIER 44.39 -179.24 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.545 -0.973 . . . . 0.0 110.963 179.294 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 1.057 HG22 ' O ' ' A' ' 27' ' ' SER . 9.9 t -136.41 155.58 49.82 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.292 -0.88 . . . . 0.0 110.195 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -69.8 127.85 34.35 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.269 -0.894 . . . . 0.0 110.225 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.584 ' O ' ' CD1' ' A' ' 25' ' ' TYR . 8.2 m -142.61 125.09 15.69 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.213 -0.929 . . . . 0.0 110.19 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.573 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -101.66 137.59 39.77 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.199 -0.938 . . . . 0.0 110.192 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.5 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.2 p -79.18 167.13 37.01 Favored Pre-proline 0 C--N 1.303 -1.454 0 O-C-N 121.315 -0.866 . . . . 0.0 110.423 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.587 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.0 Cg_endo -69.61 -7.93 22.29 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 O-C-N 124.041 1.548 . . . . 0.0 110.118 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' TYR . . . . . 0.587 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -103.89 -2.54 26.06 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.476 -0.765 . . . . 0.0 109.639 178.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.9 24.97 15.77 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.5 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 72.2 t -95.29 114.85 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.263 -1.139 . . . . 0.0 110.402 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' TRP . . . . . 0.573 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -76.62 123.46 26.14 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.327 -0.858 . . . . 0.0 110.379 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' TYR . . . . . 0.584 ' CD1' ' O ' ' A' ' 17' ' ' SER . 22.9 p90 -147.58 173.35 12.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.143 -0.973 . . . . 0.0 110.29 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' CYS . . . . . 0.47 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 3.4 m -106.11 147.05 29.42 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.374 -0.829 . . . . 0.0 110.221 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 1.057 ' O ' HG22 ' A' ' 15' ' ' THR . 0.9 OUTLIER -130.71 149.26 73.08 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.9 . . . . 0.0 110.346 179.951 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -74.06 127.67 11.58 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 O-C-N 124.098 1.578 . . . . 0.0 110.312 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 14.4 p90 . . . . . 0 N--CA 1.492 1.648 0 O-C-N 121.2 -0.938 . . . . 0.0 110.324 -179.781 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.521 ' HB ' HG22 ' A' ' 9' ' ' ILE . 26.9 m . . . . . 0 N--CA 1.493 1.713 0 CA-C-O 121.278 0.561 . . . . 0.0 110.264 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.504 HG22 ' N ' ' A' ' 3' ' ' HIS . 2.0 mp -87.54 166.32 1.94 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.212 -0.93 . . . . 0.0 110.276 179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.504 ' N ' HG22 ' A' ' 2' ' ' ILE . 9.5 m-70 -141.75 161.01 39.0 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.221 -0.924 . . . . 0.0 110.3 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 26.8 p -161.05 -36.74 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.206 -0.934 . . . . 0.0 110.254 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.653 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 13.5 m-20 -93.91 -78.93 0.42 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.225 -0.922 . . . . 0.0 110.19 179.78 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.653 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 171.72 -31.44 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.282 -0.886 . . . . 0.0 110.144 179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -111.65 -61.49 1.7 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.311 -0.868 . . . . 0.0 110.175 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 6.8 m -55.22 150.45 11.0 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.246 -0.909 . . . . 0.0 110.14 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.521 HG22 ' HB ' ' A' ' 1' ' ' VAL . 8.4 mt -119.84 172.3 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -0.927 . . . . 0.0 110.245 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.467 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 19.3 t -131.51 136.64 28.89 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.248 -0.907 . . . . 0.0 110.18 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -72.46 -161.1 0.1 OUTLIER 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.978 1.514 . . . . 0.0 110.569 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.412 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 0.9 OUTLIER -96.0 150.17 20.77 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.23 -0.919 . . . . 0.0 110.414 -179.745 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.658 ' O ' HG23 ' A' ' 14' ' ' THR . . . 64.81 53.29 35.42 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.658 HG23 ' O ' ' A' ' 13' ' ' GLY . 0.9 OUTLIER -159.39 170.67 21.27 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.203 -1.175 . . . . 0.0 110.378 179.931 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.481 ' O ' HG23 ' A' ' 15' ' ' THR . 12.2 t -130.88 131.9 44.82 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.346 -0.846 . . . . 0.0 110.235 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -54.2 132.76 43.97 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.292 -0.88 . . . . 0.0 110.302 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -152.12 157.88 42.2 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.238 -0.914 . . . . 0.0 110.245 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.465 ' HA ' HD23 ' A' ' 18' ' ' LEU . 0.2 OUTLIER -105.87 136.22 45.91 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.313 -0.867 . . . . 0.0 110.288 -179.944 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.508 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.9 OUTLIER -78.31 165.37 50.67 Favored Pre-proline 0 N--CA 1.488 1.446 0 O-C-N 121.24 -0.912 . . . . 0.0 110.213 179.908 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.589 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.9 Cg_endo -69.39 -11.61 31.72 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 O-C-N 124.038 1.546 . . . . 0.0 110.04 -179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.589 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.7 m-85 -101.54 5.2 41.69 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.476 -0.765 . . . . 0.0 109.553 178.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.74 21.16 51.82 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -179.677 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.508 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 60.6 t -93.9 123.08 45.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.32 -1.106 . . . . 0.0 110.281 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.559 ' CE2' ' OD1' ' A' ' 5' ' ' ASP . 1.3 m95 -81.09 130.71 35.14 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.243 -0.911 . . . . 0.0 110.21 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 33.1 p90 -165.42 173.08 11.45 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.207 -0.933 . . . . 0.0 110.331 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.409 ' SG ' ' C ' ' A' ' 15' ' ' THR . 0.1 OUTLIER -109.19 137.22 47.41 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.221 -0.924 . . . . 0.0 110.24 179.705 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 1.9 t -108.4 147.44 35.67 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.263 -0.898 . . . . 0.0 110.338 -179.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -73.6 114.14 3.96 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.029 1.541 . . . . 0.0 110.476 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.48 ' CD1' ' C ' ' A' ' 29' ' ' PHE . 20.9 p90 -102.51 169.25 8.78 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.253 -0.905 . . . . 0.0 110.295 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 12.1 t . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.325 -179.995 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.596 ' HB ' HG22 ' A' ' 9' ' ' ILE . 30.5 m . . . . . 0 N--CA 1.495 1.789 0 CA-C-O 121.138 0.494 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.422 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 31.9 mm -105.3 157.17 6.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.251 -0.906 . . . . 0.0 110.572 -179.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.486 ' NE2' HG23 ' A' ' 9' ' ' ILE . 12.4 m-70 -134.53 125.75 27.95 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.277 -0.889 . . . . 0.0 110.061 179.717 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -113.41 -50.65 2.85 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.345 -0.847 . . . . 0.0 110.501 -179.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.605 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 12.8 t70 -90.86 -70.01 0.7 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.261 -0.899 . . . . 0.0 110.479 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.605 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 175.17 -46.55 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.195 -0.941 . . . . 0.0 110.36 -179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -100.14 -20.07 16.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.204 -0.935 . . . . 0.0 110.342 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 15.7 m -82.84 140.72 32.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.303 -0.873 . . . . 0.0 110.266 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.596 HG22 ' HB ' ' A' ' 1' ' ' VAL . 4.3 mt -125.91 166.38 22.08 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.193 -0.942 . . . . 0.0 110.293 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 1' ' ' VAL . 10.0 m -147.3 155.6 46.32 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.265 -0.897 . . . . 0.0 109.958 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -72.96 -166.29 0.28 Allowed 'Trans proline' 0 C--N 1.303 -1.817 0 O-C-N 123.942 1.496 . . . . 0.0 110.373 179.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 -95.56 152.26 18.59 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.266 -0.896 . . . . 0.0 110.313 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.2 12.07 84.95 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -124.3 170.14 11.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.26 -1.141 . . . . 0.0 110.396 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 27' ' ' SER . 11.8 t -129.86 139.09 51.25 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.293 -0.879 . . . . 0.0 110.249 -179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 9.3 p -62.69 134.61 56.56 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.275 -0.891 . . . . 0.0 110.353 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.401 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 4.7 m -153.91 133.71 13.03 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.299 -0.875 . . . . 0.0 110.21 179.76 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.476 ' HA ' HD23 ' A' ' 18' ' ' LEU . 0.4 OUTLIER -91.97 143.8 26.11 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -0.927 . . . . 0.0 110.301 -179.796 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.525 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -79.41 172.71 9.17 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.278 -0.888 . . . . 0.0 110.332 179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.615 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.9 Cg_endo -69.87 -7.17 20.43 Favored 'Trans proline' 0 C--N 1.302 -1.885 0 O-C-N 124.167 1.614 . . . . 0.0 110.174 -179.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.615 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 4.2 m-85 -109.51 -0.17 18.96 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.393 -0.817 . . . . 0.0 109.623 178.816 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.56 17.86 37.52 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.264 -1.534 . . . . 0.0 109.264 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.525 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 48.0 t -87.53 108.9 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.27 -1.135 . . . . 0.0 110.438 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.552 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -65.25 124.34 21.92 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.229 -0.919 . . . . 0.0 110.416 179.982 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.49 ' C ' ' CD1' ' A' ' 25' ' ' TYR . 15.5 p90 -148.25 171.66 15.6 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.165 -0.959 . . . . 0.0 110.162 179.397 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 4.3 m -106.35 118.02 35.55 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.177 -0.952 . . . . 0.0 110.257 -179.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.772 ' O ' HG22 ' A' ' 15' ' ' THR . 23.3 t -84.82 139.22 37.42 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.265 -0.897 . . . . 0.0 110.318 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -77.17 120.68 5.45 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 124.063 1.56 . . . . 0.0 110.397 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.489 ' CD1' ' C ' ' A' ' 29' ' ' PHE . 14.4 p90 -119.38 158.33 26.39 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.183 -0.948 . . . . 0.0 110.223 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 28.7 t . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.321 179.912 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.501 HG21 HG21 ' A' ' 9' ' ' ILE . 29.8 m . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 121.202 0.525 . . . . 0.0 110.348 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.505 ' N ' ' O ' ' A' ' 10' ' ' CYS . 45.4 mm -93.17 143.13 12.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.281 -0.887 . . . . 0.0 110.2 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 7.8 m-70 -122.81 109.63 14.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.3 -0.875 . . . . 0.0 110.119 179.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -149.17 22.9 0.95 Allowed 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.362 -0.836 . . . . 0.0 110.215 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.495 ' OD1' ' CH2' ' A' ' 24' ' ' TRP . 75.0 m-20 -137.32 -166.18 1.89 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.206 -0.934 . . . . 0.0 110.173 179.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -71.51 -59.38 2.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.227 -0.921 . . . . 0.0 110.276 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -136.33 -46.33 0.63 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.26 -0.9 . . . . 0.0 110.26 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.462 ' CB ' ' HB3' ' A' ' 24' ' ' TRP . 19.1 m -45.27 112.05 0.4 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.172 -0.955 . . . . 0.0 110.1 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.501 HG21 HG21 ' A' ' 1' ' ' VAL . 12.3 mt -85.82 167.53 1.8 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.292 -0.88 . . . . 0.0 110.235 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.505 ' O ' ' N ' ' A' ' 2' ' ' ILE . 31.0 m -129.84 141.83 43.23 Favored Pre-proline 0 N--CA 1.491 1.606 0 O-C-N 121.249 -0.907 . . . . 0.0 110.324 -179.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.51 -166.6 0.34 Allowed 'Trans proline' 0 C--N 1.304 -1.767 0 O-C-N 123.957 1.504 . . . . 0.0 110.267 179.638 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -91.9 148.69 22.03 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.237 -0.914 . . . . 0.0 110.348 -179.964 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 83.98 0.94 89.81 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.2 p -117.58 170.24 8.91 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.137 -1.213 . . . . 0.0 110.399 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.802 HG22 ' O ' ' A' ' 27' ' ' SER . 14.8 t -134.32 144.69 48.44 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.159 -0.963 . . . . 0.0 110.503 -179.697 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -52.4 140.62 21.73 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.308 -0.87 . . . . 0.0 110.402 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.533 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 9.0 t -160.23 124.39 3.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.262 -0.899 . . . . 0.0 110.235 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.462 HD23 ' O ' ' A' ' 23' ' ' VAL . 0.1 OUTLIER -100.85 117.95 35.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.224 -0.922 . . . . 0.0 110.425 -179.938 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.483 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -56.07 162.13 3.16 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.246 -0.909 . . . . 0.0 110.139 179.637 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.607 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.2 Cg_endo -69.35 -6.82 19.32 Favored 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 124.009 1.531 . . . . 0.0 110.116 179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.607 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.4 m-85 -100.31 -5.97 26.61 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.423 -0.798 . . . . 0.0 109.688 179.001 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 99.21 17.44 27.13 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 -179.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.483 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 67.4 t -89.97 115.36 29.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.266 -1.138 . . . . 0.0 110.298 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.534 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -74.08 125.79 29.1 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.357 -0.84 . . . . 0.0 110.37 -179.997 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.533 ' CE1' ' HB3' ' A' ' 17' ' ' SER . 8.8 p90 -154.47 174.52 14.79 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.252 -0.905 . . . . 0.0 110.282 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.9 m -115.54 116.68 28.59 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.262 -0.899 . . . . 0.0 110.132 -179.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.802 ' O ' HG22 ' A' ' 15' ' ' THR . 3.3 t -84.86 134.59 41.32 Favored Pre-proline 0 N--CA 1.493 1.709 0 O-C-N 121.274 -0.891 . . . . 0.0 110.402 -179.572 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -74.48 118.08 5.21 Favored 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.003 1.528 . . . . 0.0 110.423 179.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.404 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 24.5 p90 -121.25 158.13 28.79 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.186 -0.946 . . . . 0.0 110.24 179.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.295 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.533 ' O ' HG23 ' A' ' 1' ' ' VAL . 30.1 m . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 121.29 0.567 . . . . 0.0 110.259 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.528 ' N ' ' O ' ' A' ' 10' ' ' CYS . 40.5 mm -45.38 155.69 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.203 -0.936 . . . . 0.0 110.054 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.466 ' O ' ' N ' ' A' ' 5' ' ' ASP . 1.8 m-70 -130.64 -60.59 0.98 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.115 -0.991 . . . . 0.0 110.575 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.464 ' CB ' ' O ' ' A' ' 3' ' ' HIS . 0.5 OUTLIER 66.75 -67.97 0.15 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.234 -0.916 . . . . 0.0 110.268 -179.776 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.502 ' OD2' ' N ' ' A' ' 8' ' ' THR . 9.9 p-10 -80.88 -138.83 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.231 -0.918 . . . . 0.0 110.1 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -128.56 -6.21 5.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.176 -0.953 . . . . 0.0 110.392 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -137.13 -65.54 0.54 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.213 -0.929 . . . . 0.0 110.203 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.502 ' N ' ' OD2' ' A' ' 5' ' ' ASP . 5.1 m -48.7 111.95 0.54 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.234 -0.917 . . . . 0.0 110.272 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.495 HG22 ' HB ' ' A' ' 1' ' ' VAL . 6.0 mt -90.83 151.74 3.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.21 -0.931 . . . . 0.0 110.128 179.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.528 ' O ' ' N ' ' A' ' 2' ' ' ILE . 23.7 m -127.13 139.68 35.77 Favored Pre-proline 0 N--CA 1.492 1.64 0 O-C-N 121.17 -0.956 . . . . 0.0 110.298 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -74.91 -161.18 0.12 Allowed 'Trans proline' 0 C--N 1.304 -1.766 0 O-C-N 124.02 1.537 . . . . 0.0 110.362 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 23.3 m-20 -95.5 150.61 20.12 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.284 -0.885 . . . . 0.0 110.304 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.1 12.95 80.17 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.704 -1.358 . . . . 0.0 109.704 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 1.2 p -121.63 169.39 10.75 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.199 -1.177 . . . . 0.0 110.447 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.695 HG22 ' O ' ' A' ' 27' ' ' SER . 12.6 t -131.93 157.09 44.91 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.28 -0.888 . . . . 0.0 110.288 179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 36.4 m -58.3 127.82 34.05 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.287 -0.883 . . . . 0.0 109.861 179.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.573 ' HB3' ' CE2' ' A' ' 25' ' ' TYR . 1.3 t -141.72 124.26 15.85 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.197 -0.939 . . . . 0.0 110.684 -179.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.586 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.1 OUTLIER -109.03 126.99 53.72 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.385 -0.822 . . . . 0.0 110.051 179.201 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.518 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -67.9 163.33 50.99 Favored Pre-proline 0 C--N 1.301 -1.513 0 O-C-N 121.217 -0.927 . . . . 0.0 110.284 180.0 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.603 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.0 Cg_endo -69.08 -8.59 24.01 Favored 'Trans proline' 0 C--N 1.302 -1.879 0 O-C-N 124.111 1.585 . . . . 0.0 110.126 179.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.603 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.6 m-85 -100.68 -1.04 36.23 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.372 -0.83 . . . . 0.0 109.746 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.3 17.44 39.77 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.518 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 94.0 t -91.03 112.47 25.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.408 -1.054 . . . . 0.0 110.172 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.586 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 2.7 m95 -71.46 142.31 50.21 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.259 -0.901 . . . . 0.0 110.273 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.573 ' CE2' ' HB3' ' A' ' 17' ' ' SER . 24.6 p90 -170.23 174.12 5.49 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.277 -0.889 . . . . 0.0 110.267 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.497 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 2.6 m -106.81 141.81 37.45 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.247 -0.908 . . . . 0.0 110.285 -179.132 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.695 ' O ' HG22 ' A' ' 15' ' ' THR . 0.9 OUTLIER -118.91 141.95 31.03 Favored Pre-proline 0 N--CA 1.495 1.785 0 O-C-N 121.217 -0.927 . . . . 0.0 110.208 179.784 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -74.61 104.3 1.85 Allowed 'Trans proline' 0 C--N 1.308 -1.59 0 O-C-N 124.081 1.569 . . . . 0.0 110.531 -179.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.59 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 8.2 p90 -111.51 150.58 29.73 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.212 -0.93 . . . . 0.0 110.294 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.263 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.653 ' HB ' HG22 ' A' ' 9' ' ' ILE . 30.8 m . . . . . 0 N--CA 1.491 1.622 0 CA-C-O 121.323 0.582 . . . . 0.0 110.216 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.526 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 36.4 mm -83.55 148.18 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.219 -0.925 . . . . 0.0 110.307 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.407 ' CE1' HG12 ' A' ' 9' ' ' ILE . 9.9 m-70 -118.79 126.41 51.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.175 -0.953 . . . . 0.0 110.398 -179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 26.9 m -80.28 -68.94 0.63 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.297 -0.877 . . . . 0.0 110.275 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -104.63 -90.27 0.4 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.278 -0.889 . . . . 0.0 110.163 179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -146.66 10.28 1.06 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.289 -0.882 . . . . 0.0 110.393 179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.435 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -140.11 -76.27 0.33 Allowed 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.206 -0.934 . . . . 0.0 110.318 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.689 HG21 ' HB3' ' A' ' 24' ' ' TRP . 8.6 m -41.63 147.84 0.17 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.31 -0.869 . . . . 0.0 110.364 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.653 HG22 ' HB ' ' A' ' 1' ' ' VAL . 15.2 mt -131.71 169.61 21.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.279 -0.888 . . . . 0.0 110.129 -179.766 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.526 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 63.2 m -145.67 146.27 28.69 Favored Pre-proline 0 N--CA 1.491 1.619 0 O-C-N 121.156 -0.965 . . . . 0.0 110.327 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -73.02 -175.02 1.74 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.012 1.532 . . . . 0.0 110.472 -179.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 -84.83 156.87 21.13 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.239 -0.913 . . . . 0.0 110.226 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.15 3.52 90.54 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.0 p -127.1 170.27 12.53 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.238 -1.154 . . . . 0.0 110.213 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.772 HG22 ' O ' ' A' ' 27' ' ' SER . 9.0 t -128.2 156.0 43.62 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.218 -0.926 . . . . 0.0 110.349 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 1.3 m -73.29 128.83 36.6 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.278 -0.888 . . . . 0.0 110.176 179.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.414 ' OG ' ' CZ ' ' A' ' 25' ' ' TYR . 32.9 t -137.19 130.2 30.69 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.28 -0.887 . . . . 0.0 110.243 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.595 ' HG ' ' CE2' ' A' ' 24' ' ' TRP . 0.0 OUTLIER -105.19 106.38 16.85 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.186 -0.946 . . . . 0.0 110.294 179.815 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.508 ' HB3' ' HB ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -46.18 157.81 0.4 Allowed Pre-proline 0 C--N 1.301 -1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 110.218 179.718 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.606 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.0 Cg_endo -68.69 -11.66 32.49 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 124.041 1.548 . . . . 0.0 110.026 179.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.606 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.0 m-85 -93.24 -8.71 41.49 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.456 -0.777 . . . . 0.0 109.641 178.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 100.8 19.9 16.14 Favored Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.362 -1.495 . . . . 0.0 109.362 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.508 ' HB ' ' HB3' ' A' ' 19' ' ' SER . 61.2 t -94.97 115.91 34.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.236 -1.155 . . . . 0.0 110.123 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.689 ' HB3' HG21 ' A' ' 8' ' ' THR . 0.2 OUTLIER -77.84 126.78 31.37 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.335 -0.853 . . . . 0.0 110.503 -179.525 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.414 ' CZ ' ' OG ' ' A' ' 17' ' ' SER . 28.0 p90 -154.72 171.69 19.14 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.232 -0.917 . . . . 0.0 110.125 179.304 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.3 m -106.45 135.6 47.67 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.216 -0.927 . . . . 0.0 110.068 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.772 ' O ' HG22 ' A' ' 15' ' ' THR . 12.0 t -115.4 143.71 30.97 Favored Pre-proline 0 N--CA 1.493 1.699 0 O-C-N 121.204 -0.935 . . . . 0.0 110.324 -179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -73.73 125.02 9.68 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 124.034 1.544 . . . . 0.0 110.4 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.508 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 14.8 p90 -135.01 172.05 13.56 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.305 -0.872 . . . . 0.0 110.219 179.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.227 179.769 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.618 ' HB ' HG22 ' A' ' 9' ' ' ILE . 23.6 m . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.252 0.549 . . . . 0.0 110.308 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.502 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 34.2 mm -88.46 143.17 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.166 -0.959 . . . . 0.0 110.114 179.552 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.593 ' NE2' HG23 ' A' ' 9' ' ' ILE . 7.3 m-70 -129.17 119.51 24.21 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.193 -0.942 . . . . 0.0 110.598 -179.646 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 87.1 m -124.3 11.76 8.76 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.297 -0.877 . . . . 0.0 109.986 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -150.29 -90.23 0.07 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.392 -0.818 . . . . 0.0 110.207 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -176.09 -32.39 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.16 -0.963 . . . . 0.0 110.244 179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.482 ' O ' ' CG1' ' A' ' 9' ' ' ILE . . . -105.38 -75.5 0.63 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.2 -0.938 . . . . 0.0 110.258 179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 42.8 m -43.47 139.74 1.95 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.24 -0.913 . . . . 0.0 110.394 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.618 HG22 ' HB ' ' A' ' 1' ' ' VAL . 4.4 mt -135.85 147.69 28.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.222 -0.924 . . . . 0.0 110.217 179.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.528 ' O ' ' CB ' ' A' ' 1' ' ' VAL . 98.1 m -111.34 148.69 39.29 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.305 -0.872 . . . . 0.0 109.982 179.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.43 ' O ' ' CG ' ' A' ' 12' ' ' ASP . 45.4 Cg_endo -74.7 -90.34 0.01 OUTLIER 'Trans proline' 0 C--N 1.302 -1.869 0 O-C-N 123.846 1.445 . . . . 0.0 110.335 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.43 ' CG ' ' O ' ' A' ' 11' ' ' PRO . 21.1 m-20 -158.86 164.28 35.86 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.371 -0.831 . . . . 0.0 110.181 179.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.32 13.26 48.92 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.472 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 1.3 p -124.07 169.74 11.37 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.217 -1.166 . . . . 0.0 110.308 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.642 HG22 ' O ' ' A' ' 27' ' ' SER . 8.9 t -129.59 153.81 47.7 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.141 -0.974 . . . . 0.0 110.494 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 60.2 m -63.86 127.47 31.52 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.262 -0.899 . . . . 0.0 110.147 179.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.514 ' HB3' ' CE2' ' A' ' 25' ' ' TYR . 10.7 t -138.9 133.99 32.63 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.217 -0.927 . . . . 0.0 110.265 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.449 HD23 ' HA ' ' A' ' 18' ' ' LEU . 0.2 OUTLIER -99.34 135.89 40.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.169 -0.957 . . . . 0.0 110.316 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.509 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.4 OUTLIER -79.06 166.13 44.16 Favored Pre-proline 0 C--N 1.303 -1.415 0 O-C-N 121.325 -0.859 . . . . 0.0 110.243 -179.992 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.585 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.9 Cg_endo -69.39 -10.73 29.63 Favored 'Trans proline' 0 C--N 1.301 -1.951 0 O-C-N 124.057 1.556 . . . . 0.0 110.022 -179.844 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.585 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -104.06 -0.51 28.65 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.429 -0.794 . . . . 0.0 109.667 179.007 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.11 15.32 48.72 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 109.397 -1.481 . . . . 0.0 109.397 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.509 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 92.3 t -87.0 119.15 34.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.292 -1.122 . . . . 0.0 110.191 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.498 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.6 OUTLIER -77.75 128.16 33.59 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.252 -0.905 . . . . 0.0 110.458 -179.747 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.514 ' CE2' ' HB3' ' A' ' 17' ' ' SER . 37.1 p90 -152.74 172.52 16.56 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.27 -0.894 . . . . 0.0 110.086 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.472 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 4.0 m -101.92 141.42 34.79 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.209 -0.932 . . . . 0.0 110.193 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.642 ' O ' HG22 ' A' ' 15' ' ' THR . 3.4 t -116.16 141.7 28.17 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 121.173 -0.954 . . . . 0.0 110.389 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -75.38 129.27 11.86 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.061 1.558 . . . . 0.0 110.488 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.449 ' O ' ' HB3' ' A' ' 30' ' ' SER . 43.6 p90 -133.14 154.15 50.87 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.223 -0.923 . . . . 0.0 110.214 -179.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.449 ' HB3' ' O ' ' A' ' 29' ' ' PHE . 21.8 t . . . . . 0 N--CA 1.492 1.669 0 CA-C-O 118.013 -0.994 . . . . 0.0 110.271 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.696 ' HB ' HG22 ' A' ' 9' ' ' ILE . 28.6 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.224 0.535 . . . . 0.0 110.316 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.459 ' H ' HD12 ' A' ' 2' ' ' ILE . 2.5 mp -50.89 160.6 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.242 -0.911 . . . . 0.0 110.147 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.409 ' N ' HG22 ' A' ' 2' ' ' ILE . 4.4 m-70 -148.12 89.43 1.73 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.195 -0.941 . . . . 0.0 110.354 -179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 63.9 m -92.59 -41.39 10.25 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.265 -0.897 . . . . 0.0 110.091 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.708 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 8.3 t70 -85.14 -86.57 0.13 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.269 -0.894 . . . . 0.0 110.217 179.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.708 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 170.31 -27.66 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.188 -0.945 . . . . 0.0 110.354 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.439 ' O ' ' CG1' ' A' ' 9' ' ' ILE . . . -105.01 -81.51 0.53 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.174 -0.954 . . . . 0.0 110.335 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.485 ' C ' ' CG1' ' A' ' 9' ' ' ILE . 89.5 m -41.18 155.4 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.292 -0.88 . . . . 0.0 110.458 -179.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.696 HG22 ' HB ' ' A' ' 1' ' ' VAL . 6.1 mt -150.11 145.78 17.04 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.212 -0.93 . . . . 0.0 110.181 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.675 ' O ' HG12 ' A' ' 1' ' ' VAL . 0.0 OUTLIER -130.08 -170.2 0.21 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.26 -0.9 . . . . 0.0 110.22 179.591 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.583 ' CD ' ' CB ' ' A' ' 10' ' ' CYS . 45.8 Cg_endo -87.27 175.4 4.77 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.822 1.433 . . . . 0.0 110.75 -178.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -91.63 151.37 20.72 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.296 -0.878 . . . . 0.0 110.3 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 102.85 -6.09 51.42 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 4.6 p -114.39 171.68 7.47 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.192 -1.181 . . . . 0.0 110.25 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.519 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 14.7 t -115.94 134.33 55.09 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.312 -0.867 . . . . 0.0 110.311 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 5.2 m -45.05 147.02 0.74 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.244 -0.91 . . . . 0.0 110.367 179.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.569 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 29.0 m -161.69 135.02 6.34 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.306 -0.871 . . . . 0.0 110.337 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.539 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -106.64 142.39 36.36 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.225 -0.922 . . . . 0.0 110.211 179.996 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.503 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -84.14 168.02 24.11 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.168 -0.957 . . . . 0.0 110.291 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.585 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.5 Cg_endo -69.61 -8.83 24.62 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 124.098 1.578 . . . . 0.0 110.176 -179.726 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.585 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -103.63 0.95 31.4 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.432 -0.792 . . . . 0.0 109.627 179.173 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.98 16.88 49.74 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.254 -1.538 . . . . 0.0 109.254 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.506 ' O ' HD23 ' A' ' 18' ' ' LEU . 97.2 t -86.59 115.52 27.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.359 -1.083 . . . . 0.0 110.295 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.539 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 1.0 OUTLIER -75.61 135.41 40.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.294 -0.879 . . . . 0.0 110.325 179.973 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.569 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 24.8 p90 -163.8 176.56 9.4 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.252 -0.905 . . . . 0.0 110.35 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.497 ' SG ' ' HD2' ' A' ' 11' ' ' PRO . 11.1 p -114.38 130.06 56.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.344 -0.847 . . . . 0.0 110.26 179.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.401 ' O ' HG22 ' A' ' 15' ' ' THR . 1.1 p -99.94 146.03 31.2 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.237 -0.914 . . . . 0.0 110.253 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.4 Cg_endo -73.13 104.43 1.78 Allowed 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 123.999 1.526 . . . . 0.0 110.411 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.519 ' CD1' ' HB ' ' A' ' 15' ' ' THR . 0.5 OUTLIER -120.54 160.63 22.79 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.314 -0.866 . . . . 0.0 110.406 -179.848 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 8.9 t . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.232 179.844 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.7 ' HB ' HG22 ' A' ' 9' ' ' ILE . 6.5 m . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 121.281 0.562 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.476 ' O ' ' HB2' ' A' ' 10' ' ' CYS . 2.6 mp -90.06 154.8 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.279 -0.888 . . . . 0.0 110.274 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.49 ' NE2' HG23 ' A' ' 9' ' ' ILE . 15.0 m-70 -129.42 114.86 16.68 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.188 -0.945 . . . . 0.0 110.198 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 30.0 m -71.51 -39.6 70.68 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.277 -0.889 . . . . 0.0 110.318 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.698 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 23.7 t0 -125.18 -59.75 1.38 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.221 -0.924 . . . . 0.0 110.406 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.698 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 170.6 -25.37 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.174 -0.954 . . . . 0.0 110.43 -179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -100.05 -51.31 3.72 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . . . . . . . . . 44.5 m -70.09 128.15 35.28 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.308 -0.87 . . . . 0.0 110.397 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.7 HG22 ' HB ' ' A' ' 1' ' ' VAL . 4.1 mt -97.64 176.7 0.71 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.725 0 O-C-N 121.209 -0.932 . . . . 0.0 110.07 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.488 ' O ' ' HA ' ' A' ' 1' ' ' VAL . 30.3 m -152.85 139.41 12.42 Favored Pre-proline 0 N--CA 1.492 1.675 0 O-C-N 121.288 -0.882 . . . . 0.0 110.637 -179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.37 177.82 8.3 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 O-C-N 124.126 1.593 . . . . 0.0 110.433 179.524 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 12' ' ' ASP . 0.9 OUTLIER -85.19 147.85 26.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.167 -0.958 . . . . 0.0 110.311 179.779 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 92.93 -7.29 76.77 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.43 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 4.1 p -109.83 169.58 8.63 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.228 -1.16 . . . . 0.0 110.308 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.691 HG22 ' O ' ' A' ' 27' ' ' SER . 15.4 t -125.83 151.1 47.26 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.228 -0.92 . . . . 0.0 110.359 -179.777 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.464 ' HA ' ' SG ' ' A' ' 26' ' ' CYS . 1.1 m -66.56 148.76 51.44 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.336 -0.852 . . . . 0.0 110.525 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.515 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 0.2 OUTLIER -170.31 137.26 1.45 Allowed 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.35 -0.844 . . . . 0.0 110.223 179.972 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.466 ' HG ' ' CE3' ' A' ' 24' ' ' TRP . 0.3 OUTLIER -96.46 141.11 30.14 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.311 -0.868 . . . . 0.0 110.277 -179.982 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.544 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 0.6 OUTLIER -78.78 169.86 18.77 Favored Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.324 -0.86 . . . . 0.0 110.244 -179.918 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.573 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.7 Cg_endo -69.46 -16.5 38.84 Favored 'Trans proline' 0 C--N 1.301 -1.97 0 O-C-N 124.075 1.566 . . . . 0.0 109.939 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.573 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 2.9 m-85 -98.74 1.99 46.59 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.516 -0.74 . . . . 0.0 109.593 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.95 23.22 33.32 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.544 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 23.8 t -92.3 112.77 26.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.284 -1.127 . . . . 0.0 110.304 -179.757 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.466 ' CE3' ' HG ' ' A' ' 18' ' ' LEU . 1.6 m95 -65.98 126.43 28.53 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.274 -0.891 . . . . 0.0 110.271 179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.515 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 6.3 p90 -157.19 177.37 11.55 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.079 -1.013 . . . . 0.0 110.388 179.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.498 ' HA ' ' O ' ' A' ' 15' ' ' THR . 1.9 m -126.5 138.61 53.52 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.425 -0.797 . . . . 0.0 110.098 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.691 ' O ' HG22 ' A' ' 15' ' ' THR . 0.0 OUTLIER -111.41 139.25 21.81 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.202 -0.936 . . . . 0.0 110.576 -179.474 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -74.62 118.49 5.34 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.076 1.566 . . . . 0.0 110.331 179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' A' ' 29' ' ' PHE . 40.2 p90 -101.0 142.38 32.56 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.204 -0.935 . . . . 0.0 110.303 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.406 ' C ' ' O ' ' A' ' 29' ' ' PHE . 75.4 m . . . . . 0 N--CA 1.491 1.576 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.265 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.567 ' O ' HG23 ' A' ' 1' ' ' VAL . 3.4 m . . . . . 0 N--CA 1.494 1.741 0 CA-C-O 121.295 0.569 . . . . 0.0 110.417 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.513 ' HA ' HD13 ' A' ' 2' ' ' ILE . 5.2 mm -58.71 161.73 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 O-C-N 121.265 -0.897 . . . . 0.0 110.061 179.464 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.571 ' NE2' HG23 ' A' ' 9' ' ' ILE . 1.9 m-70 -149.01 125.92 11.24 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.257 -0.902 . . . . 0.0 110.507 -179.663 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 28.3 p -126.44 21.52 7.19 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.336 -0.853 . . . . 0.0 110.111 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.461 ' N ' ' OD1' ' A' ' 5' ' ' ASP . 23.3 p-10 -167.65 -128.95 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.369 -0.832 . . . . 0.0 110.008 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -141.1 11.54 2.18 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.065 -1.022 . . . . 0.0 110.284 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.444 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -139.93 -85.1 0.23 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.227 -0.921 . . . . 0.0 110.459 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.444 ' C ' ' O ' ' A' ' 7' ' ' ALA . 55.9 m -40.81 141.6 0.56 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.23 -0.919 . . . . 0.0 110.524 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.571 HG23 ' NE2' ' A' ' 3' ' ' HIS . 7.8 mt -128.47 146.74 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.23 -0.919 . . . . 0.0 110.008 179.529 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.508 ' O ' ' HA ' ' A' ' 1' ' ' VAL . 46.0 m -122.26 145.38 44.13 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.199 -0.938 . . . . 0.0 110.408 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.32 -173.53 1.32 Allowed 'Trans proline' 0 C--N 1.304 -1.799 0 O-C-N 124.097 1.577 . . . . 0.0 110.258 179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.498 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 2.5 m-20 -86.64 151.16 23.67 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.231 -0.918 . . . . 0.0 110.422 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 87.81 8.4 73.1 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 5.4 p -133.58 167.88 19.68 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.267 -1.137 . . . . 0.0 110.313 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.658 HG22 ' O ' ' A' ' 27' ' ' SER . 10.4 t -128.49 141.41 51.39 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 0.0 110.203 179.686 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -65.75 138.16 57.75 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.226 -0.921 . . . . 0.0 110.139 -179.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.532 ' HB3' ' CE1' ' A' ' 25' ' ' TYR . 2.4 t -148.64 138.33 22.08 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.214 -0.929 . . . . 0.0 110.289 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.522 ' HA ' HD23 ' A' ' 18' ' ' LEU . 0.0 OUTLIER -95.94 131.06 42.69 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.384 -0.823 . . . . 0.0 110.037 179.692 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.573 ' OG ' ' HB ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -78.41 169.79 19.18 Favored Pre-proline 0 C--N 1.3 -1.561 0 O-C-N 121.346 -0.846 . . . . 0.0 110.52 -179.817 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.625 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 37.6 Cg_endo -69.07 -13.62 36.74 Favored 'Trans proline' 0 C--N 1.301 -1.959 0 O-C-N 124.208 1.636 . . . . 0.0 109.996 179.588 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.625 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 2.1 m-85 -92.03 -11.44 35.94 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.444 -0.785 . . . . 0.0 109.445 178.67 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.48 24.04 14.98 Favored Glycine 0 N--CA 1.489 2.194 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 -179.615 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.573 ' HB ' ' OG ' ' A' ' 19' ' ' SER . 39.9 t -102.04 125.47 56.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.17 -1.194 . . . . 0.0 110.2 179.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.454 ' CH2' ' HB2' ' A' ' 18' ' ' LEU . 1.7 m95 -81.09 119.09 23.12 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.284 -0.885 . . . . 0.0 110.27 -179.762 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.532 ' CE1' ' HB3' ' A' ' 17' ' ' SER . 30.8 p90 -140.14 168.1 20.59 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.067 -1.021 . . . . 0.0 110.503 179.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 10.2 m -94.82 111.32 23.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.302 -0.874 . . . . 0.0 110.271 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.658 ' O ' HG22 ' A' ' 15' ' ' THR . 0.2 OUTLIER -96.05 147.47 33.02 Favored Pre-proline 0 N--CA 1.491 1.599 0 O-C-N 121.348 -0.845 . . . . 0.0 110.396 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -77.39 125.26 7.59 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 124.059 1.557 . . . . 0.0 110.455 179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.429 ' O ' ' O ' ' A' ' 30' ' ' SER . 36.6 p90 -104.82 154.38 20.12 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.186 -0.946 . . . . 0.0 110.207 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.429 ' O ' ' O ' ' A' ' 29' ' ' PHE . 75.0 m . . . . . 0 N--CA 1.492 1.629 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.305 -179.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 20.5 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.279 0.561 . . . . 0.0 110.261 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.507 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 26.5 mm -55.9 148.21 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.232 -0.918 . . . . 0.0 110.143 179.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.501 ' CE1' HG12 ' A' ' 9' ' ' ILE . 1.9 m-70 -130.85 129.45 42.34 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.228 -0.92 . . . . 0.0 110.455 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.474 ' O ' ' N ' ' A' ' 6' ' ' ALA . 58.0 m -142.01 -175.2 4.32 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.285 -0.885 . . . . 0.0 110.036 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.487 ' HB2' ' CE2' ' A' ' 24' ' ' TRP . 4.5 t70 54.75 -88.77 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.168 -0.958 . . . . 0.0 110.218 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.474 ' N ' ' O ' ' A' ' 4' ' ' CYS . . . -171.9 -40.2 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.254 -0.904 . . . . 0.0 110.326 -179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.406 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -119.82 -59.22 1.83 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.2 -0.937 . . . . 0.0 110.308 -179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.406 ' C ' ' O ' ' A' ' 7' ' ' ALA . 6.9 m -43.77 151.81 0.19 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.195 -0.941 . . . . 0.0 110.318 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.501 HG12 ' CE1' ' A' ' 3' ' ' HIS . 12.8 mt -131.23 167.37 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.209 -0.932 . . . . 0.0 110.279 -179.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.507 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 55.7 m -133.87 147.5 64.49 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.2 -0.938 . . . . 0.0 110.205 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.55 -177.02 3.07 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 124.055 1.555 . . . . 0.0 110.607 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -84.72 151.94 24.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.268 -0.895 . . . . 0.0 110.237 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.45 28.47 57.6 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.557 -1.417 . . . . 0.0 109.557 179.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.547 ' C ' ' CE2' ' A' ' 29' ' ' PHE . 5.3 p -149.41 166.89 27.73 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.28 -1.13 . . . . 0.0 110.38 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.621 ' HB ' ' CE1' ' A' ' 29' ' ' PHE . 13.1 t -121.92 155.47 35.41 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.337 -0.852 . . . . 0.0 110.295 179.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 74.0 m -82.22 144.6 30.56 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.222 -0.924 . . . . 0.0 110.124 179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.49 ' HB2' ' CZ ' ' A' ' 25' ' ' TYR . 62.6 m -154.37 160.75 41.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 110.416 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.591 ' HG ' ' CZ3' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -114.81 134.13 55.37 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.301 -0.875 . . . . 0.0 110.179 179.585 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.533 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.1 p -74.07 172.56 8.25 Favored Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.304 -0.872 . . . . 0.0 110.382 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.614 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.5 Cg_endo -69.87 -11.48 30.79 Favored 'Trans proline' 0 C--N 1.302 -1.879 0 O-C-N 123.976 1.514 . . . . 0.0 110.023 -179.749 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.614 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.4 m-85 -103.51 0.82 31.52 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.433 -0.792 . . . . 0.0 109.643 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 90.17 27.84 19.57 Favored Glycine 0 N--CA 1.489 2.196 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 -179.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.533 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 34.2 t -94.96 123.71 47.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.309 -1.112 . . . . 0.0 110.304 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.591 ' CZ3' ' HG ' ' A' ' 18' ' ' LEU . 2.7 m95 -78.6 114.92 17.94 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.205 -0.934 . . . . 0.0 110.202 179.835 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.49 ' CZ ' ' HB2' ' A' ' 17' ' ' SER . 29.1 p90 -136.08 172.53 12.88 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.189 -0.945 . . . . 0.0 110.161 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 8.0 m -114.98 117.38 30.44 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.273 -0.892 . . . . 0.0 110.276 -179.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 11.4 p -96.47 161.63 26.17 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.308 -0.87 . . . . 0.0 110.162 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -74.79 170.59 20.02 Favored 'Trans proline' 0 C--N 1.303 -1.846 0 O-C-N 123.889 1.468 . . . . 0.0 110.527 -179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.621 ' CE1' ' HB ' ' A' ' 15' ' ' THR . 17.4 m-85 -98.47 87.45 3.85 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.281 -0.887 . . . . 0.0 110.169 179.723 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 5.2 p . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.185 179.994 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.538 ' HB ' HG22 ' A' ' 9' ' ' ILE . 21.1 m . . . . . 0 N--CA 1.492 1.662 0 CA-C-O 121.157 0.504 . . . . 0.0 110.326 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.548 HG21 ' SG ' ' A' ' 16' ' ' CYS . 18.5 mm -54.28 164.84 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.231 -0.918 . . . . 0.0 109.996 179.776 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.514 ' O ' ' N ' ' A' ' 5' ' ' ASP . 5.5 m-70 -126.03 -19.47 4.78 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.121 -0.987 . . . . 0.0 110.734 -179.477 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.492 ' HB2' ' O ' ' A' ' 3' ' ' HIS . 9.3 m 66.07 -61.28 0.28 Allowed 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.232 -0.917 . . . . 0.0 110.289 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.575 ' O ' ' HB2' ' A' ' 6' ' ' ALA . 23.0 t0 -126.32 -56.44 1.42 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.218 -0.926 . . . . 0.0 110.279 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.575 ' HB2' ' O ' ' A' ' 5' ' ' ASP . . . 176.34 -32.48 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.304 -0.872 . . . . 0.0 110.22 179.829 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.42 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -100.07 -77.97 0.52 Allowed 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.227 -0.921 . . . . 0.0 110.244 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.42 ' C ' ' O ' ' A' ' 7' ' ' ALA . 3.1 m -43.36 116.35 0.91 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.218 -0.926 . . . . 0.0 110.213 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.538 HG22 ' HB ' ' A' ' 1' ' ' VAL . 9.7 mt -97.28 145.4 9.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 121.227 -0.921 . . . . 0.0 110.206 -179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.52 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 7.4 m -124.51 149.89 63.08 Favored Pre-proline 0 N--CA 1.491 1.575 0 O-C-N 121.238 -0.914 . . . . 0.0 110.108 179.801 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.473 ' O ' ' OG1' ' A' ' 14' ' ' THR . 43.4 Cg_endo -73.0 176.62 8.83 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 123.977 1.514 . . . . 0.0 110.493 -179.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 66.3 m-20 -84.35 165.71 18.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.252 -0.905 . . . . 0.0 110.315 -179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.59 11.8 65.97 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.473 ' OG1' ' O ' ' A' ' 11' ' ' PRO . 9.1 p -127.47 172.59 10.55 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.28 -1.129 . . . . 0.0 110.265 179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.51 ' HB ' ' CD1' ' A' ' 29' ' ' PHE . 12.4 t -125.94 152.79 45.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.275 -0.891 . . . . 0.0 110.283 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.548 ' SG ' HG21 ' A' ' 2' ' ' ILE . 98.0 m -82.11 136.0 35.23 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.303 -0.873 . . . . 0.0 110.24 -179.958 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.568 ' HB3' ' CZ ' ' A' ' 25' ' ' TYR . 1.0 OUTLIER -142.45 148.51 37.87 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.212 -0.93 . . . . 0.0 110.27 179.996 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.524 ' HG ' ' CE2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -104.41 140.78 37.43 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.351 -0.843 . . . . 0.0 110.431 -179.864 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.426 ' HB2' ' HD2' ' A' ' 20' ' ' PRO . 1.0 OUTLIER -86.38 171.98 9.25 Favored Pre-proline 0 N--CA 1.488 1.428 0 O-C-N 121.325 -0.859 . . . . 0.0 110.454 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.577 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 38.5 Cg_endo -69.57 -14.67 37.04 Favored 'Trans proline' 0 C--N 1.3 -1.975 0 O-C-N 124.05 1.553 . . . . 0.0 109.905 179.444 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.577 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.1 m-85 -98.59 0.12 44.25 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.352 -0.842 . . . . 0.0 109.774 179.056 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.74 30.8 17.11 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.405 ' O ' HD23 ' A' ' 18' ' ' LEU . 68.4 t -100.65 123.99 53.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.227 -1.16 . . . . 0.0 110.223 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.524 ' CE2' ' HG ' ' A' ' 18' ' ' LEU . 3.5 m95 -83.36 114.07 21.17 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.28 -0.887 . . . . 0.0 110.036 179.476 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.568 ' CZ ' ' HB3' ' A' ' 17' ' ' SER . 42.1 p90 -132.65 172.01 13.09 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.205 -0.934 . . . . 0.0 110.337 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 3.4 m -102.47 132.7 48.33 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.349 -0.845 . . . . 0.0 110.112 -179.6 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.471 ' O ' HG22 ' A' ' 15' ' ' THR . 0.3 OUTLIER -109.75 137.63 20.46 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.13 -0.981 . . . . 0.0 110.097 179.802 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -72.92 109.39 2.8 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 124.009 1.531 . . . . 0.0 110.555 -179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.567 ' CG ' ' O ' ' A' ' 29' ' ' PHE . 2.9 p90 -129.31 125.28 36.39 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 110.371 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.259 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.589 ' O ' HG23 ' A' ' 1' ' ' VAL . 34.9 m . . . . . 0 N--CA 1.496 1.832 0 CA-C-O 121.246 0.546 . . . . 0.0 110.346 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.441 HD13 ' HA ' ' A' ' 2' ' ' ILE . 13.1 mm -50.53 158.13 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.146 -0.972 . . . . 0.0 109.75 179.296 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.545 ' O ' ' N ' ' A' ' 5' ' ' ASP . 1.1 m-70 -136.7 -48.03 0.62 Allowed 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.09 -1.006 . . . . 0.0 110.536 -179.446 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.485 ' HB2' ' O ' ' A' ' 3' ' ' HIS . 81.0 m 59.0 -77.11 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.304 -0.872 . . . . 0.0 110.1 -179.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.545 ' N ' ' O ' ' A' ' 3' ' ' HIS . 3.0 t70 -78.74 -135.67 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.231 -0.918 . . . . 0.0 110.013 179.468 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -132.14 8.37 4.37 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.127 -0.983 . . . . 0.0 110.367 179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.432 ' O ' HG13 ' A' ' 9' ' ' ILE . . . -139.91 -84.72 0.23 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.225 -0.922 . . . . 0.0 110.49 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.59 HG21 ' HB3' ' A' ' 24' ' ' TRP . 7.1 m -40.89 100.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.336 -0.852 . . . . 0.0 110.511 -179.573 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.535 HG23 ' CD2' ' A' ' 3' ' ' HIS . 6.9 mt -89.42 169.56 1.36 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.343 -0.848 . . . . 0.0 110.211 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.469 ' O ' ' HB ' ' A' ' 1' ' ' VAL . 3.0 m -143.15 162.64 41.99 Favored Pre-proline 0 N--CA 1.493 1.708 0 O-C-N 121.213 -0.929 . . . . 0.0 110.399 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -80.0 -159.59 0.11 Allowed 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 124.037 1.546 . . . . 0.0 110.464 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.467 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 5.6 m-20 -107.13 150.1 26.94 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.204 -0.935 . . . . 0.0 110.286 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 86.12 29.12 26.32 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.498 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 0.9 OUTLIER -144.12 170.53 15.77 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -1.164 . . . . 0.0 110.312 179.871 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.532 HG22 ' O ' ' A' ' 27' ' ' SER . 9.5 t -125.61 142.48 51.49 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.209 -0.932 . . . . 0.0 110.367 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.401 ' C ' ' HG ' ' A' ' 17' ' ' SER . 3.3 m -65.26 142.62 58.22 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.325 -0.859 . . . . 0.0 110.271 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.401 ' HG ' ' C ' ' A' ' 16' ' ' CYS . 14.3 m -158.84 130.43 6.45 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.275 -0.891 . . . . 0.0 110.056 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.535 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -94.45 136.78 34.36 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.236 -0.915 . . . . 0.0 110.45 -179.796 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 1.1 p -79.81 169.54 19.67 Favored Pre-proline 0 N--CA 1.487 1.412 0 O-C-N 121.275 -0.891 . . . . 0.0 110.256 179.84 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.584 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 40.3 Cg_endo -69.67 -6.76 19.33 Favored 'Trans proline' 0 C--N 1.299 -2.031 0 O-C-N 124.056 1.556 . . . . 0.0 110.183 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.584 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.7 m-85 -106.2 -3.0 21.85 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.331 -0.856 . . . . 0.0 109.965 179.295 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.18 13.74 47.87 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 56.3 t -85.2 113.82 24.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.137 -1.213 . . . . 0.0 110.012 179.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.59 ' HB3' HG21 ' A' ' 8' ' ' THR . 0.0 OUTLIER -76.98 116.92 18.07 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.336 -0.853 . . . . 0.0 110.324 -179.726 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . . . . . . . . . 8.1 p90 -143.39 176.11 9.41 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.274 -0.891 . . . . 0.0 110.241 179.737 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.498 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 58.0 m -124.47 138.11 54.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.288 -0.882 . . . . 0.0 110.193 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.532 ' O ' HG22 ' A' ' 15' ' ' THR . 1.2 t -107.89 150.39 40.25 Favored Pre-proline 0 N--CA 1.493 1.715 0 O-C-N 121.24 -0.913 . . . . 0.0 110.705 -179.107 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -77.29 121.03 5.52 Favored 'Trans proline' 0 C--N 1.305 -1.747 0 O-C-N 124.13 1.595 . . . . 0.0 110.405 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.45 ' CD1' ' HB2' ' A' ' 30' ' ' SER . 42.3 p90 -111.95 163.93 13.68 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.157 -0.964 . . . . 0.0 110.314 179.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . 0.45 ' HB2' ' CD1' ' A' ' 29' ' ' PHE . 5.0 m . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 118.007 -0.996 . . . . 0.0 110.286 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.566 HG21 HG21 ' A' ' 9' ' ' ILE . 19.5 m . . . . . 0 N--CA 1.495 1.807 0 CA-C-O 121.317 0.58 . . . . 0.0 110.249 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.538 ' N ' ' O ' ' A' ' 10' ' ' CYS . 37.4 mm -85.22 156.98 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.25 -0.907 . . . . 0.0 110.134 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.625 ' NE2' HG23 ' A' ' 9' ' ' ILE . 4.0 m-70 -139.48 118.94 12.93 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.281 -0.887 . . . . 0.0 110.24 179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.411 ' HB2' ' HB3' ' A' ' 16' ' ' CYS . 13.5 m -133.86 10.64 3.95 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.259 -0.901 . . . . 0.0 110.385 -179.758 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.461 ' OD1' ' N ' ' A' ' 6' ' ' ALA . 0.7 OUTLIER -130.96 -101.12 0.3 Allowed 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.184 -0.948 . . . . 0.0 110.191 179.944 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.461 ' N ' ' OD1' ' A' ' 5' ' ' ASP . . . -162.8 -43.15 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.061 -1.024 . . . . 0.0 110.065 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -112.72 -51.51 2.83 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 110.088 179.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.423 HG22 ' N ' ' A' ' 9' ' ' ILE . 52.5 m -57.59 161.77 3.39 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.333 -0.854 . . . . 0.0 110.223 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.625 HG23 ' NE2' ' A' ' 3' ' ' HIS . 12.7 mt -140.7 172.71 10.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.259 -0.901 . . . . 0.0 110.055 179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.538 ' O ' ' N ' ' A' ' 2' ' ' ILE . 56.8 m -143.22 137.87 15.13 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.182 -0.949 . . . . 0.0 110.521 -179.706 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -76.28 -166.08 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 123.939 1.494 . . . . 0.0 110.267 179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 52.2 m-20 -90.08 147.93 23.33 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.198 -0.939 . . . . 0.0 110.199 179.652 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.45 18.63 60.05 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.443 ' HB ' ' HB3' ' A' ' 26' ' ' CYS . 0.6 OUTLIER -136.06 171.26 14.74 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.245 -1.15 . . . . 0.0 110.306 179.967 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.737 HG22 ' O ' ' A' ' 27' ' ' SER . 15.3 t -132.55 140.88 48.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.236 -0.915 . . . . 0.0 110.261 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.411 ' HB3' ' HB2' ' A' ' 4' ' ' CYS . 29.3 m -65.26 131.72 47.23 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.267 -0.895 . . . . 0.0 110.136 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -156.54 138.2 14.15 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.098 -1.001 . . . . 0.0 110.46 179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.449 HD23 ' O ' ' A' ' 23' ' ' VAL . 0.3 OUTLIER -88.72 143.49 26.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.324 -0.86 . . . . 0.0 110.287 179.726 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.464 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -82.24 169.54 17.99 Favored Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.318 -0.864 . . . . 0.0 110.478 -179.699 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.578 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 38.3 Cg_endo -69.02 -14.43 38.43 Favored 'Trans proline' 0 C--N 1.302 -1.909 0 O-C-N 124.135 1.597 . . . . 0.0 110.166 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.578 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 2.5 m-85 -100.19 1.62 42.15 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.379 -0.826 . . . . 0.0 109.614 178.884 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 89.77 29.45 15.84 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -179.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.464 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 76.5 t -103.75 123.49 57.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.246 -1.149 . . . . 0.0 110.445 -179.667 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.472 ' HA ' ' CE3' ' A' ' 24' ' ' TRP . 0.9 OUTLIER -76.86 118.74 19.76 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.249 -0.907 . . . . 0.0 110.312 179.906 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.524 ' CE2' ' OG ' ' A' ' 27' ' ' SER . 40.7 p90 -144.28 168.6 19.69 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.084 -1.01 . . . . 0.0 110.681 179.574 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.443 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 3.4 m -106.09 117.93 35.31 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.446 -0.784 . . . . 0.0 109.649 179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.737 ' O ' HG22 ' A' ' 15' ' ' THR . 0.7 OUTLIER -93.81 142.65 25.36 Favored Pre-proline 0 C--N 1.303 -1.455 0 O-C-N 121.174 -0.954 . . . . 0.0 110.716 -178.943 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -75.69 126.19 9.36 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 124.135 1.597 . . . . 0.0 110.46 179.557 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.542 ' CG ' ' O ' ' A' ' 29' ' ' PHE . 34.6 p90 -123.67 118.33 27.01 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.242 -0.911 . . . . 0.0 110.268 179.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.493 1.691 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.331 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . . . . . . . . . 29.1 m . . . . . 0 N--CA 1.494 1.768 0 CA-C-O 121.266 0.555 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.508 ' HB ' ' HB2' ' A' ' 10' ' ' CYS . 32.7 mm -77.67 146.49 8.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.213 -0.929 . . . . 0.0 110.312 -179.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.605 ' CD2' HG23 ' A' ' 9' ' ' ILE . 3.9 m-70 -138.04 83.29 1.97 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.315 -0.866 . . . . 0.0 110.089 179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -72.32 -32.01 66.17 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.301 -0.874 . . . . 0.0 110.441 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.488 ' OD2' ' NE1' ' A' ' 24' ' ' TRP . 0.6 OUTLIER -116.34 -89.64 0.57 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.18 -0.95 . . . . 0.0 110.357 -179.849 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -171.89 -32.84 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.162 -0.962 . . . . 0.0 110.354 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -99.31 -83.63 0.42 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.169 -0.957 . . . . 0.0 110.234 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.452 HG21 ' O ' ' A' ' 24' ' ' TRP . 62.9 m -52.17 106.55 0.15 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.225 -0.922 . . . . 0.0 110.158 179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.605 HG23 ' CD2' ' A' ' 3' ' ' HIS . 6.2 mt -90.65 165.02 2.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.191 -0.943 . . . . 0.0 110.335 -179.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.508 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 99.4 m -133.73 140.74 37.57 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.267 -0.896 . . . . 0.0 110.057 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -74.0 173.81 13.43 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.901 1.474 . . . . 0.0 110.424 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.474 ' N ' ' OD1' ' A' ' 12' ' ' ASP . 1.1 m-20 -77.12 152.5 34.91 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.281 -0.887 . . . . 0.0 110.472 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.573 ' O ' ' CD1' ' A' ' 29' ' ' PHE . . . 90.55 -8.27 80.07 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 179.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.519 HG22 ' HA ' ' A' ' 28' ' ' PRO . 2.0 p -116.95 166.52 12.07 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.183 -1.186 . . . . 0.0 110.151 179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.674 ' O ' HG23 ' A' ' 15' ' ' THR . 14.8 t -123.54 119.36 29.7 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.333 -0.854 . . . . 0.0 110.375 179.683 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . 0.453 ' O ' ' OG ' ' A' ' 17' ' ' SER . 20.6 p -50.34 158.36 0.59 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.214 -0.929 . . . . 0.0 110.18 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.601 ' HB2' ' CZ ' ' A' ' 25' ' ' TYR . 42.4 m -167.44 146.64 5.03 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.198 -0.938 . . . . 0.0 110.022 179.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.57 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -108.6 134.73 50.95 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.204 -0.935 . . . . 0.0 110.485 -179.654 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.483 ' HB3' ' HB ' ' A' ' 23' ' ' VAL . 1.0 OUTLIER -78.53 167.79 32.45 Favored Pre-proline 0 C--N 1.304 -1.399 0 O-C-N 121.34 -0.85 . . . . 0.0 109.989 179.543 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.593 ' HG2' ' CE1' ' A' ' 21' ' ' TYR . 37.9 Cg_endo -69.56 -11.92 32.15 Favored 'Trans proline' 0 C--N 1.3 -2.009 0 O-C-N 124.022 1.538 . . . . 0.0 109.942 179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.593 ' CE1' ' HG2' ' A' ' 20' ' ' PRO . 3.2 m-85 -97.79 -2.31 41.32 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.399 -0.813 . . . . 0.0 109.75 178.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.85 21.17 29.07 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.483 ' HB ' ' HB3' ' A' ' 19' ' ' SER . 75.6 t -91.54 119.58 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.273 -1.133 . . . . 0.0 110.38 -179.744 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.57 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 0.6 OUTLIER -84.01 126.66 33.26 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.266 -0.896 . . . . 0.0 110.181 179.765 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.601 ' CZ ' ' HB2' ' A' ' 17' ' ' SER . 32.6 p90 -147.75 174.82 11.44 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.215 -0.928 . . . . 0.0 110.246 179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . . . . . . . . . 4.0 m -114.18 107.65 15.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.261 -0.9 . . . . 0.0 110.223 -179.591 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.484 ' HB3' HG23 ' A' ' 15' ' ' THR . 9.8 t -70.59 144.01 90.78 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.192 -0.943 . . . . 0.0 109.897 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.519 ' HA ' HG22 ' A' ' 14' ' ' THR . 47.6 Cg_endo -76.17 170.61 19.7 Favored 'Trans proline' 0 C--N 1.299 -2.053 0 O-C-N 123.817 1.43 . . . . 0.0 110.918 -179.363 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.573 ' CD1' ' O ' ' A' ' 13' ' ' GLY . 2.4 m-85 -97.32 83.59 3.32 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.459 -0.776 . . . . 0.0 110.201 179.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.708 0 CA-C-O 117.999 -1.0 . . . . 0.0 110.248 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' VAL . . . . . 0.727 HG23 HG21 ' A' ' 9' ' ' ILE . 5.9 m . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.233 0.539 . . . . 0.0 110.331 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.462 ' O ' ' N ' ' A' ' 10' ' ' CYS . 30.1 mm -44.1 152.87 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.273 -0.892 . . . . 0.0 110.223 179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.565 ' O ' ' N ' ' A' ' 5' ' ' ASP . 4.0 m-70 -120.38 -64.69 1.22 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.184 -0.947 . . . . 0.0 110.336 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' CYS . . . . . 0.517 ' HB3' ' O ' ' A' ' 3' ' ' HIS . 1.7 t 59.65 -72.29 0.03 OUTLIER 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.511 -0.743 . . . . 0.0 110.386 179.753 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.565 ' N ' ' O ' ' A' ' 3' ' ' HIS . 81.1 m-20 -54.75 -163.67 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.178 -0.951 . . . . 0.0 110.297 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -103.92 -19.93 14.07 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.12 -0.988 . . . . 0.0 110.547 -179.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.426 ' O ' ' C ' ' A' ' 8' ' ' THR . . . -135.72 -79.69 0.42 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.257 -0.902 . . . . 0.0 110.557 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' THR . . . . . 0.426 ' C ' ' O ' ' A' ' 7' ' ' ALA . 97.5 m -41.24 132.13 2.61 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.344 -0.847 . . . . 0.0 110.387 -179.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.727 HG21 HG23 ' A' ' 1' ' ' VAL . 0.9 OUTLIER -98.46 175.78 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.265 -0.897 . . . . 0.0 110.048 179.972 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . 0.462 ' N ' ' O ' ' A' ' 2' ' ' ILE . 1.5 m -130.0 132.9 24.42 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.31 -0.869 . . . . 0.0 110.329 179.718 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . 0.495 ' O ' ' O ' ' A' ' 12' ' ' ASP . 48.5 Cg_endo -77.78 154.42 30.3 Favored 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 124.009 1.531 . . . . 0.0 110.02 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.495 ' O ' ' O ' ' A' ' 11' ' ' PRO . 7.3 m-20 48.66 179.22 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.164 -0.96 . . . . 0.0 110.139 -179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' A' ' 14' ' ' THR . . . -55.42 -64.19 4.6 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 179.699 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.52 ' O ' ' O ' ' A' ' 13' ' ' GLY . 0.8 OUTLIER 44.39 -179.24 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.545 -0.973 . . . . 0.0 110.963 179.294 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 1.057 HG22 ' O ' ' A' ' 27' ' ' SER . 9.9 t -136.41 155.58 49.82 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.292 -0.88 . . . . 0.0 110.195 -179.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -69.8 127.85 34.35 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.269 -0.894 . . . . 0.0 110.225 179.829 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.584 ' O ' ' CD1' ' A' ' 25' ' ' TYR . 8.2 m -142.61 125.09 15.69 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.213 -0.929 . . . . 0.0 110.19 179.501 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.573 ' HG ' ' CD2' ' A' ' 24' ' ' TRP . 0.2 OUTLIER -101.66 137.59 39.77 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.199 -0.938 . . . . 0.0 110.192 -179.952 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.5 ' CB ' ' HB ' ' A' ' 23' ' ' VAL . 1.2 p -79.18 167.13 37.01 Favored Pre-proline 0 C--N 1.303 -1.454 0 O-C-N 121.315 -0.866 . . . . 0.0 110.423 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.587 ' HG2' ' CZ ' ' A' ' 21' ' ' TYR . 39.0 Cg_endo -69.61 -7.93 22.29 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 O-C-N 124.041 1.548 . . . . 0.0 110.118 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' TYR . . . . . 0.587 ' CZ ' ' HG2' ' A' ' 20' ' ' PRO . 3.8 m-85 -103.89 -2.54 26.06 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.476 -0.765 . . . . 0.0 109.639 178.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.9 24.97 15.77 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.5 ' HB ' ' CB ' ' A' ' 19' ' ' SER . 72.2 t -95.29 114.85 32.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.263 -1.139 . . . . 0.0 110.402 -179.908 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' TRP . . . . . 0.573 ' CD2' ' HG ' ' A' ' 18' ' ' LEU . 0.1 OUTLIER -76.62 123.46 26.14 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.327 -0.858 . . . . 0.0 110.379 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' TYR . . . . . 0.584 ' CD1' ' O ' ' A' ' 17' ' ' SER . 22.9 p90 -147.58 173.35 12.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.143 -0.973 . . . . 0.0 110.29 179.429 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' CYS . . . . . 0.47 ' HB3' ' HB ' ' A' ' 14' ' ' THR . 3.4 m -106.11 147.05 29.42 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.374 -0.829 . . . . 0.0 110.221 -179.031 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 1.057 ' O ' HG22 ' A' ' 15' ' ' THR . 0.9 OUTLIER -130.71 149.26 73.08 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.9 . . . . 0.0 110.346 179.951 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -74.06 127.67 11.58 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 O-C-N 124.098 1.578 . . . . 0.0 110.312 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . . . . . . . . . 14.4 p90 -107.45 171.79 7.19 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.2 -0.938 . . . . 0.0 110.324 -179.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' SER . . . . . . . . . . . . . 33.7 t . . . . . 0 N--CA 1.491 1.576 0 CA-C-O 118.045 -0.978 . . . . 0.0 110.264 -179.88 . . . . . . . . 0 0 . 1 stop_ save_